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This paper is the second chronological supplement to the Carcinogenic Potency Database, published
earlier in thisjournal (1,2,4). We report here results ofcarcinogenesis bioassays published in the general
literature between January 1983 and December 1984, and in Technical Reports of the National Cancer
Institute/National Toxicology Program between January 1983 and May 1986. This supplement includes
results of 525 long-term, chronic experiments of 199 test compounds, and reports the same information
about each experiment in the same plot format as the earlier papers: e.g., the species and strain of test
animal, the route and duration ofcompound administration, dose level and other aspects ofexperimental
protocol, histopathology and tumor incidence, TD50 (carcinogenic potency) and its statistical significance,
dose response, author's opinion about carcinogenicity, and literature citation. We refer the reader to the
1984 publications for a description ofthe numerical index of carcinogenic potency (TD50), a guide to the
plot ofthe database, and a discussion ofthe sources ofdata, the rationale for the inclusion of particular
experiments and particular target sites, and the conventions adopted in summarizing the literature. The
three plots ofthe database are to be used together, since results ofexperiments published in earlier plots
are not repeated. Taken together, the three plots include results for more than 3500 experiments on 975
chemicals. Appendix 14 is an index to all chemicals in the database and indicates which plot(s) each
chemical appears in.
Background
This is the third paper in which a portion ofthe Car-
cinogenic Potency Database (CPDB)ispublished inplot
format. We have developed the CPDB in an effort to
improve the use ofanimal bioassay data in the study of
chemical carcinogenesis, and in the assessment of po-
tential health hazards to humans. Together the three
plots quantify and standardize the very diverse litera-
tureoflong-term, chroniccarcinogenesis bioassayspub-
*A computer tape of the plot of the database and appendices can
be obtained from the first author.
tBiology and Medicine Division, Lawrence Berkeley Laboratory,
Berkeley, CA 94720.
tDepartment ofBiochemistry, University ofCalifornia, Berkeley,
CA 94720.
lishedthrough 1984. The CPDB organizes thepublished
literature systematically and applies an index ofcarcin-
ogenic potency, the TD50, to the results ofexperiments
on 975 test compounds. We firstpresentedthe database
in two papers in 1984, Peto et al. (1) and Gold et al. (2).
Peto et al. (1) described our numerical index of carcin-
ogenic potency, the TD50, andthe statisticalprocedures
adopted for estimating it from experimental data.
Briefly, TD50 may be defined as follows: for a given
target site(s), ifthere are no tumors in control animals,
then TD50 is that chronic dose rate in mg/kg body
weight/day which would induce tumors in halfthe test
animals atthe end ofastandardlifespan forthe species.
Sincethetumor(s) ofinterestoftendoes occurincontrol
animals, TD50 is more precisely defined as that chronic
dose rate which will halve the probability ofremainingGOLD ETAL.
tumor-free throughout the standard lifespan ofthe spe-
cies (1,3). The range of TD50 values for carcinogens in
the CPDB is more than 10 million-fold.
Gold et al. (2) presented a guide to the plot of the
database describing the contents, field by field, as well
as a discussion of the sources of data, the criteria for
the inclusion of particular experiments and particular
target sites, and the conventions adopted in summariz-
ing the literature. The second plot (4) covered the lit-
erature published in 1981 and 1982. The present paper
is a chronological supplement for 1983 and 1984. It is
our intention that the three plots be used together, and
thatreaders who are notfamiliar with the database will
read the earlier papers when using the plot. We have
not duplicated earlier results, and thus for complete
data on chemicals in more than one plot, all ofthe pub-
lications are necessary.
Each plot of the database provides the same set of
information about each experiment in the same format,
including the species, strain, and sex of test animal;
features of the experimental protocol such as route of
administration, duration ofdosing, dose level(s) in mg/
kg body weight/day, and duration of experiment; his-
topathology and tumor incidence; carcinogenic potency
and its statistical significance; shape of the dose-re-
sponse curve; author's opinion astocarcinogenicity; and
literature citation. Aword ofcautionisnecessary about
the limitations ofthe database. We have included only
long-term tests ofindividual compounds which fit a set
of criteria compatible with calculating potency; many
animal cancer tests are excluded. Moreover, we have
not attempted to evaluate whether or not a compound
isacarcinogen; rather, wereportthepublishedopinions
of the investigators whose data we present, as well as
the statistical significance of the TD50 calculated from
their results. Further discussion ofthe criteria for the
database and the limitations can be found in Gold et al.
(2).
TheTD50valuesintheCPDB forthe NCI/NTPbioas-
says have been estimated using full lifetable informa-
tion. For the TD50 values from the general literature,
the estimates use the final proportions of animals with
tumors, since only this summary information is con-
sistently published (1,3). In a few cases, no TD50 could
be calculated because all dosed animals had the tumor
ofinterest, andonlysummaryincidencedatawereavail-
able (5). The TD50 values for the compounds in this
supplementary plot fall within the range of values re-
ported earlier (2).
In 1983 the NTP adopted a new set ofcategories for
theirinterpretive conclusions. In the "author's opinion"
column on our plot, we report these evaluations using
the same codes as in our earlier plots with the addition
of"e" to denote "equivocal evidence ofcarcinogenicity."
The "author's opinion" column forthe generalliterature
is the same as in earlier plots. Appendix 11 in this pub-
lication lists the codes and definitions used for the au-
thor's opinion, and full details are given in Gold et al.
(2).
The appendices to each ofthe three plots provide the
same types of information for the data in that publica-
tion, and are given the same appendix numbers. Ap-
pendix 1 lists alphabetically the compounds included in
the plot and their common synonyms; Appendix 2 pro-
vides a list of the compounds sorted by Chemical Ab-
stracts Service (CAS) Registry number. The next sev-
eral appendices provide codes and definitions required
for using the plot: strains of test animal (Appendix 3);
routes of administration (Appendix 4); sites of tumor
induction (Appendix 5); histopathology (Appendix 6);
notecodes (Appendix 7); dose-response curve symbols
(Appendix 8); reference codes (Appendix 9); NCI/NTP
bioassays evaluated as inadequate (Appendix 10); and
author's opinion codes (Appendix 11). Appendices 12
and 13 give full bibliographic information for all exper-
iments reported in this plot: the bibliography for the
general literature (Appendix 12); and a list ofthe NCI/
NTP Technical Reports (Appendix 13). We have added
a new Appendix in this publication, Appendix 14, that
indicates which plot contains results ofexperiments on
each of the 975 chemicals in the database; it is sorted
alphabetically by chemical name or common synonym.
We are continuing to update the Carcinogenic Po-
tency Database with papers published after 1984, and
are alsoattemptingtoaddearlierpaperswhichweover-
looked in our literature search. Therefore, we would
appreciate information aboutanytestswhichthereader
notices are missing.
Plot in This Supplement
The plot ofthe database includes results of525 long-
term, chronic experiments with 199 chemicals. It pre-
sents results for 35 compounds from Technical Reports
of the National Cancer Institute/National Toxicology
Program (NCI/NTP) published between January 1983
and May 1986, as well as results for 167 compounds
published in the general literature between January
1983 and December 1984. Several experiments which
havebeenidentifiedfromearlieryearsarealsoincluded.
Experimentsinrats, mice, andhamstersarereported
here for 199 compounds representing avarietyofchem-
ical classes, (e.g., nitroso compounds and halogenated
hydrocarbons) with a variety of uses. Some are natu-
rally occurring substances which are constituents of
foods (e.g., safrole, quercetin, and estragole); food ad-
ditives (e.g., D,L-monosodium glutamate and butylated
hydroxyanisole); industrial compounds (e.g., ethylene
oxide and 1,2-propylene oxide); and drugs (e.g., pheno-
barbital and primodolol). Ofthe 199 chemicals, 66 were
also included in the first or second plot, and we have
flagged these with atriple asterisk(***) afterthechem-
ical name in the plot. For some substances, only a few
experiments are reported here, but large numbers of
experimentswerepreviouslyreported (2,3), e.g., 2-ace-
tylaminofluorene and DDT.
Analyses of the Database
The three plots ofthe CPDB include more than 3500
experiments on 975 chemicals which meet the inclusion
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Table 1. Correct CAS numbers for eleven chemicals in earlier
CPDB plots.
CAS number Chemical name
520-45-6 3-Acetyl-6-methyl-2,4-pyrandione
1308-38-9 Chromic oxide pigment
75-47-8 Iodoform







1694-09-3 FD&C Violet No. 1
rules ofthe database and are therefore suitable for es-
timatingTD50. There is great diversity in the database.
Most ofthe chemicals have been tested in rats or mice;
however, some have been tested in hamsters, dogs, or
monkeys. Experiments with 95 different mouse strains
and 72 rat strains are included. For a given chemical,
the database may contain only a single experiment, or
agreat many experiments. Forexample, amongthe 706
chemicals tested in rats, 33% have only one rat test and
52% have two tests; however, 11 chemicals have more
than 10 tests. Overall, about half of the 975 chemicals
in the database are positive in at least one experiment
according to the opinion of the published author. This
proportion is similar for rats and mice and for each of
the three plots ofthe database. There is generally good
concordance between authors' opinions as to carcino-
genicity and the statistical significance of the experi-
mental results.
Of the 975 chemicals in the CPDB, 392 have been
tested in both rats and mice. Among these, 130 (33%)
are positive in both species, 166 (43%) are negative in
both, 56 (14%) are positive only in mice, and 40 (10%)
are positive only in rats. We are currently examining
these results and some possible explanations for differ-
ences between the species.
Our group has used the CPDB to address several
issues relevant to interspecies extrapolation and chem-
icalcarcinogenesis. Thegood correlationofcarcinogenic
potencyfoundbetweenratsandmicehasbeendescribed
using the chemicals tested by the NCI/NTP Bioassay
Program and some tautologous aspects ofthis compar-
ison have been examined (5). Two methods for esti-
mating carcinogenic potency (TD50) from animal bioas-
says have been compared, one based on lifetable data
and one based on summary incidence data (6). We have
described the potencies ofcompounds which induce tu-
mors atparticulartarget sites inrats and mice and have
examined other indicators of a chemical's hazard, in-
cluding whether tumors were induced at more than one
sitein asingle sex-speciesgroup oftestanimal, whether
tumors mayhavecaused thedeathofthe animal orwere
found at sacrifice, and whether metastases of induced
tumors occurred (7). Reproducibilityofresults hasbeen
investigated in 70 "near-replicate" comparisons con-
sisting of two or more tests of the same chemical ad-
ministered by the same route and using the same sex
and strain ofrodent. Overall, there wasgoodreproduci-
bility of positivity, target site, and TD50 in rats, mice,
and hamsters (8).
We have proposed a rough index of possible carcin-
ogenic hazards to humans from exposures to chemicals
that are carcinogenic in rodents, the HERP (human
exposure dose/rodent potency dose). The HERP ex-
presses each human exposure (mg/kg/day) as a per-
centage ofthe rodent TD50. We have computed HERP
values for a variety of man-made and naturally occur-
ring substances to which people may be exposed and
have constructed a scale to rank possible hazards, al-
though not to estimate absolute risks directly (9). In a
separate analysis using a similar index, we rank the
potential carcinogenic hazards permitted to U.S. work-
ers from exposures to 41 rodent carcinogens that are
regulated with Permissible Exposure Levels (PELs) by
the U.S. Occupational, Safety, and Health Administra-
tion. Forsome substances, exposures atthePELwould
be close to the dose rate that produces tumors in 50%
of test animals (10-12).
Errata in the Earlier Publication
A few omissions and errors in earlier plots of the
CPDB (2,4) have come to our attention.
Definitions for two codes were omitted from the ap-
pendices: the sitecode"sbg"standsforsebaceousgland,
and the strain code "ssa" stands for S strain, albino.
The strain code "sds" should have been "sss."
The chemicallisted as mercury (II) acetate is actually
phenylmercuric acetate. The CAS number is correct.
For eleven chemicals in the earlier plots, the CAS
numbers were reported incorrectly. The correct num-
bers for these substances, sorted alphabetically, are
listed in Table 1.
We would appreciate hearing about any additional
errors that the reader may discover.
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Plot of the Carcinogenic Potency Database
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
ACETANINOPHEN***
1 M f if. eat liv mix 78w78 a
a M f if, eat Lun tur 78w78 a
2 M m if. eat Liv mix 78w78 a
a M m ifm eat liv hpc 78w78 a
b N m if. eat Lun tur 78w78 a
TD50 2TaiLpvL
DR AuOp
lOOng. .. ..ug : 10. :100.:1mg.:10. :100. : g..:10
+ 4.14gm / P<.0005+
no dre P-1.
+ . 1.01gm / P<.0005+
4.909m / P<.003
no dre P-1.
2-ACETYLAMINOFLUORENE*** lOOng..: ..1ug.:10. :100. 1m :g.:10. :100. I :g. :10
3 N f bat eat Liv tur 52w52 ek .> no dre P-I.
a N f bal eat ubl car 52w52 ek
4 N m bal eat ubt car 52w52 ek
5 M f cd1 eat liv hpc 53w92 a
6 M m cdl eat liv hpc 53w92 e
a M m cdl eat ubl pam 53w92 a
b N m cdl eat ubl tcc 53w92 a
c M m cdl eat kid mix 53w92 e
d N m cdl eat liv hpa 53w92 a
7 R f lev eat liv mix 56w56
a R f lev eat ski mix 56w56
b R f lev eat mgl mix 56w56
8 R m lev eat liv mix 56w56 s
a R m Lev eat ski mix 56w56 s















AFLATOXIN 81*** Ong .. :. .ug..:10. :100. g : . 1g :10. :100.:Ig. :10
9 N f c5v ipj Lmr tur 52w92 . + . 4.02ug
a M f c5v ipj lun ben 52w92 75.3ug
b N f c5v ipj Liv tur 52w92 no dre
c M f c5v ipj tba tur 52w92 4.49ug
10 N m c5v ipj lun ben 52w92 .> .245mg
a N m c5v ipj Liv mal 52w92 no dre
b N m c5v ipj Liv ben 52w92 no dre
c M m c5v ipj tba tur 52w92 no dre
11 R m buf eat Liv hpc 26w52 ekr . + . 5.73ug
a R m buf eat Liv nnd 26w52 ekr 7.95ug
ALLANTOIN O0ng.. : ..lug. :10. :100. g :.1g :10. :100..:g. :10
12 R f f34 eat Liv nnd 25.30 a .> no dre
13 R m f34 eat Liv nnd 25m30 a .> no dre
ALLYL ISOVALERATE
14 M f b6c gav --- MXA 24.25
a M f b6c gav --- mLm 24m25
b N f b6c gav --- mlh 24m25
c N f b6c gav TBA MXB 24.25
d M f b6c gav Liv MXB 24.25
a M f b6c gav Lun MXB 24.25
15 M m b6c gav gam sqp 24.25
a N m b6c gav TBA MXB 24.25
b M m b6c gav Liv MXB 24m25
c M m b6c gav Lun MXB 24.25
16 R f f34 gav TBA MXB 24.25
a R f f34 gav Liv MXB 24m25
17 R m f34 gav --- MXA 24.25
a R m f34 gav pre MXA 24.25
b R m f34 gav - m--le 24m25
c R m f34 gav TBA MXB 24m25
d R m f34 gav Liv MXB 24.25
O0ng .. :. .ug. :10. :100. 1 :mg. : 10. :100. :g. :10
62.8mg * P<.03 c
102.mg * P<.08 c








A + 43.5mg * P<.08 -
no dre P-1.
+ : 123.mg * P<.004 c
136.mg * P<.03
149.mg * P<.02 c
50.5mg * P<.2
264.mg * P<.2
2-AMINO-3-METHYL-9H-PYRIDO-12,3-b1-INDOLE ..lug.:10. :100. : mg.:10..:100.. : . :10
18 M f cdf eat blv hms 84w84 . + . 38.6mg
a N f cdf eat Liv mix 84w84 38.6mg
b N f cdf eat liv hpc 84w84 98.9mg
c N f cdf eat liv hpa 84w84 118.mg
d N f cdf eat lun ads 84w84 1.84gm
e M f cdf eat lun mix 84w84 no dre
19 N m cdf eat bLv hms 73w73 . + . 15.6mg
a N m cdf eat liv mix 73w73 43.5mg
b N m cdf eat Liv hpa 73w73 90.9mg
c N m cdf eat liv hpc 73w73 127.mg
d M m cdf eat lun ade 73w73 1.18gm
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RefNum LoConf UpConf Cntrl lDose lInc 20ose 2Inc
ACETAMINOPHEN*** (TylonoL, paracetamot) 103-90-2
1 1579 1.959m 12.49m 0/51 650.mg 0/58
a 1579 2.77gm n.s.s. 0/51 650.mg 0/58
2 1579 591.mg 1.97gm 1/52 600.mg 1/57
a 1579 1.86gm 28.7gm 0/52 600.mg 0/57















3 1665 .969mg n.s.s. 0/24 1.04mg 0/48 3.12mg 0/48 5.85mg 0/24 7.67mg 0/16 11.2mg 0/8
a 1665 .969mg n.s.s. 0/24
4 1665 4.11mg 26.7mg 0/23
5 1635. 5.10mg 11.9mg 0/60
6 1635m 8.67mg 22.7mg 1/57
a 1635m 19.2mg 71.1mg 0/57
b 1635m 19.2mg 71.1mg 0/57
c 1635m 37.3mg 375.mg 0/57
d 1635m 53.1mg n.s.s. 6/57
7 1635m 1.05mg 2.28mg 0/60
a 1635m 6.60mg 33.3mg 1/60
b 1635m 16.4mg n.s.s. 16/60
8 1635m .796mg 1.76mg 1/60
a 1635m 7.46mg n.s.s. 5/60
b 1635m 16.5mg n.s.s. 0/60
AFLATOXIN B1*** 1162-65-8
9 1636 1.62ug 67.6ug 3/11
a 1636 12.3ug n.s.s. 0/11
b 1636 23.4ug n.s.s. 0/11
c 1636 1.68ug n.s.s. 4/11
10 1636 11.3ug n.s.s. 1/20
a 1636 19.5ug n.s.s. 2/20
b 1636 19.5ug n.s.s. 2/20
c 1636 8.52ug n.s.s. 11/20
11 1664 2.66ug 18.7ug 0/14
a 1664 3.40ug 47.3ug 0/14
ALLANTOIN 97-59-6
12 1654 217.mg n.s.s. 4/24
13 1654 241.mg n.s.s. 5/24
ALLYL ISOVALERATE 2835-39-4
14 c54717 26.6mg n.s.s. 11/50
a c54717 37.7mg n.s.s. 6/50
b c54717 88.9mg n.s.s. 0/50
c c54717 19.8mg n.s.s. 31/50
d c54717 197.mg n.s.a. 3/50
a c54717 90.6mg n.s.s. 4/50
15 c54717 100.mg n.s.s. 0/50
a c54717 25.0mg n.s.s. 36/50
b c54717 67.8mg n.s.s. 23/50
c c54717 134.mg n.s.s. 13/50
16 c54717 17.3mg n.s.s. 38/50
a c54717 276.mg n.s.s. 1/50
17 c54717 59.7mg 934.mg 1/50
a c54717 58.6mg n.s.s. 0/50
b c54717 66.7mg n.s.s. 1/50
c c54717 17.3mg n.s.s. 38/50









































0/48 5.85mg 0/24 7.67mg 0/16 11.2mg 0/8
















































2-AMINO-3-METHYL-9H-PYRIDO- 12,3-b - INDOLE (NeA-aLpha-C) 68006-83-7
18 1616 23.7mg 67.3mg 0/40 104.mg 28/40
a 1616 23.7mg 67.3mg 0/40 104.mg 28/40
b 1616 53.9mg 210.mg 0/40 104.mg 15/40
c 1616 62.1mg 267.mg 0/40 104.mg 13/40
d 1616 299.mg n.s.s. 0/40 104.mg 1/40
e 1616 273.mg n.s.s. 2/40 104.mg 2/40
19 1616 9.38mg 26.7mg 0/40 96.0mg 35/40
a 1616 25.6mg 81.9mg 0/40 96.0mg 21/40
b 1616 46.6mg 214.mg 0/40 96.0mg 12/40
c 1616 59.7mg 372.mg 0/40 96.0mg 9/40
d 1616 132.mg n.s.s. 3/40 96.0mg 4/40
1616 192.mg n.s.s. 11/40 96.0mg 5/40
Griciute; iarc,813-822; 1980
Angsubhakorn; ij cn,28,621-626; 1981
Lij insky;fctx,22,715-720;1984












Spa Strain Site Xpo+Xpt TD50 2Taitpvt
Sex Route Hist Notes DR AuOp
2-ANINO-6-NETHYLDIPYRID011,2-a:31,2'-dIINIDAZOLE ..:.10 ...:.100... le.Ig... .10 ....100...I:.g ....10
20 N f cdt eat Liv mix 67w67 a + .5.08mg P<.0005+
a N f cdf eat bLv mix 67w67 a 10.9mg P<.0005+
b N f cdf eat bLv hms 67w67 a 13.8mg Pcz.0005
c N f cdf eat Liv hpc 67w67 a 18.5mg P<.0005
d N f cdt eat Liv hpa 67w67 a 44.1mg P<.0005
a N f cdf eat Lun ada 67w67 a 166.mg P<.02
f N f cdt eat Lun mix 67w67 a 308.mg P<.4
21 N m cdt eat bLv mix 57w57 a 5.77mg P<.0005+
a N m cdf eat bLv hms 57w57 a 7.81mg P<.0005
b N m cdt eat btv has 57w57 a 98.7mg P<.02
c N m cdt eat Liv hpa 57w57 a 98.7mg P<.02 +
d N amcdt eat Lun ada 57w57 a 1.00gm P<.9
a N amcdt eat Lun mix 57w57 a no dre Pa.1
22 R tft34 eat Liv mix 67w67 a 8.39mg P<.0005+
a R f t34 eat zym sqc 67w67 a 12.7mg P<.0005+
b R f t34 eat smi mix 67w67 a 26.1mg P<.0005+
c R f t34 eat cot mix 67w67 a 39.0mg P<.002 +
d R f t34 eat smi adc 67w67 a 56.1mg P<.005 +
a R f t34 eat cti tue 67w67 a 56.1mg Pcz.005 +
f R f t34 eat cot ada 67w67 a 71.0mg P<.02 +
g R tft34 eat smi mcc 67w67 a 71.0mg P<.02 +
h R f t34 eat cot adc 67w67 a 95.9mg P<.03 +
i R f t34 eat bra act 67w67 a 95.9mg P<z.03 +
R f t34 eat smi ada 67w67 a 146.mg P<.08 +
23 Re m34 eat Liv mix 67w67 a 3.25mg P<.0005+
a R m t34 eat smi mix 67w67 a 5.89mg P<.0005+
b R m t34 eat smi adc 67w67 a 6.71mg P<.0005+
c R amt34 eat cmi ada 67w67 a 8.21mg P<.0005+
d R m t34 eat cot mix 67w67 a 9.45mg P<.0005+
a R amt34 eat zym sqc 67w67 a 10.2mg P<.0005+
f R amt34 eat cot ada 67w67 a 15.4mg P<.0005+
g R m t34 eat cot adc 67w67 a 16.9mg P<.0005+
h R m t34 eat smi mcc 67w67 a 236.mg P<.3 +
2-ANIN0-3-METHYLIMIDAZOf4,5-fIQUINOLINE..:..1ug... .10 ...:.100..le:.Ig... .10 ....100... .Ig ...:.10
24 N f cdt eat Liv mix 96w96 a .+ .17.5mg P<.0005+
a N f cdt eat Liv hpc 96w96 a 24.1mg P<.0005
b N f cdt eat tor mix 96w96 a 62.4mg P<.0005+
c N f cdt eat Lun mix 96w96 a 67.9mg P<.03 +
25 N amcdt eat Lun mix 96w96 a .+ .22.4mg P<.0005+
a N m cdt eat tor mix 96w96 a 42.3mg P<.0005+
b N m cdt eat Liv mix 96w96 a 48.6mg P<.002 +
c N amcdt eat Lun adc 96w96 a 60.2mg P<.007
d N amcdt eat Liv hpc 96w96 a 91.6mg P<.002
a N amcdt eat tor sqc 96w96 a 153.mg P<.02
trans-5-AMINO-312-(5.NITRO.2-FURYL)VINYL-1,2,4-OXADIAZOLE....:.100..le:.Ig... -10 ....100...:.Ig ...:.10
26 N f cdl eat tor sqc 31w75 as .+ .105.mg P<.0005+
a N f cdl eat the Lye 31w75 as 262.mg P<.005 +
b N f cdl eat tor sqp 31w75 as 1.15gm P<.1 +
c N f cdl eat Lun ada 31w75 as 1.01gm P<.5
d N f cdl eat Liv hem 31w75 as no dre P-1.
a N f cdl eat ret mix 31w75 as no dre P-1. +
f N f cdl eat tba mix 31w75 as no dre P-1.
27 N amcdl eat the Lye 38w75 as .+ .121.mg P<.0005+
a N amcdl eat tor sqc 38w75 as 130.mg P<.0005+
b N m cdl eat tor sqp 38w75 as 514.mg P<.008 +
c N m cdl eat ret mix 38w75 as 492.mg P<.08 +
d N amcdl eat Liv hem 38w75 as no dre P-1.
a N a cdl eat tun ada 38w75 as no dre P-1.
N m cdl eat tba mix 38w75 as 29.2mg P<.0005
2-ANINO.9M-PYRID0(2,3-b)IND0LE bOOng..:. .lug... .10 ...:.100. le :.Ig... .10... ..100... .Ig ...:.10
28 N f cdt eat Liv mix 97w97 .+ .35.6mg P<.0005+
a N f cdt eat Liv hpc 97w97 44.7mg P<.0005
b N f cdt eat btv has 97w97 381.mg P<.004 +
c N f cdt eat Lun ada 97w97 795.mg P<.04
d N f cdt eat tun mix 97w97 1.15gm P<.4
29 N e cdt eat bLv mix 97w97 .+.82.6mg P<.0005+
a N m cdt eat bLv hes 97w97 103.mg P<.0005
b N amcdt eat Liv mix 97w97 122.mg P<.0005+
c N amcdt eat Liv hpc 97w97 225.mg P<.0005
d N m cdt eat Liv hpa 97w97 352.eg P<.004
a N m cdt eat Lun ada 97w97 no dre P-1.
f N amcdt eat Lun mix 97w97 no dre P-I.SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
2-AMINO-6-METHYLDIPYRIDOII,2-a:3',2'-dIIMIDAZOLE (GLu-P-1) 67730-11-4
20 1616 2.33mg 9.78mg 0/40 65.0mg 37/38
a 1616 6.63mg 18.9mg 0/40 65.0mg 31/38
b 1616 8.44mg 24.3mg 0/40 65.Omg 28/38
c 1616 11.1mg 33.6mg 0/40 65.0mg 24/38
d 1616 23.1mg 99.8mg 0/40 65.0mg 13/38
1616 57.4mg n.s.s. 0/40 65.0mg 4/38
f 1616 65.6mg n.s.s. 2/40 65.0mg 4/38
21 1616 3.31mg 10.4mg 0/39 60.0mg 30/34
a 1616 4.63mg 14.0mg 0/39 60.0mg 27/34
b 1616 34.1mg n.s.s. 0/39 60.0mg 4/34
c 1616 34.1mg n.s.s. 0/39 60.0mg 4/34
d 1616 50.9mg n.s.s. 3/39 60.0mg 3/34
1616 50.5mg n.s.s. 11/39 60.0mg 6/34
22 1619m 5.07mg 15.1mg 0/50 25.0mg 24/42
a 1619m 7.24mg 25.1mg 0/50 25.0mg 18/42
b 1619m 12.7mg 67.7mg 0/50 25.0mg 10/42
c 1619m 16.8mg 142.mg 0/50 25.0mg 7/42
d 1619m 21.3mg 463.mg 0/50 25.0mg 5/42
1619m 21.3mg 463.mg 0/50 25.0mg 5/42
f 1619m 24.5mg n.s.s. 0/50 25.0mg 4/42
9 1619m 24.5mg n.s.s. 0/50 25.Omg 4/42
h 1619m 29.0mg n.s.s. 0/50 25.0mg 3/42
i 1619m 29.0mg n.s.s. 0/50 25.0mg 3/42
j 1619m 35.8mg n.s.s. 0/50 25.0mg 2/42
23 1619m 1.99mg 5.58mg 2/50 20.0mg 35/42
a 1619m 3.61mg 10.4mg 0/50 20.0mg 26/42
b 1619m 4.06mg 12.1mg 0/50 20.0mg 24/42
c 1619m 4.84mg 15.4mg 0/50 20.0mg 21/42
d 1619m 5.45mg 18.3mg 0/50 20.0mg 19/42
* 1619m 5.80mg 20.1mg 0/50 20.0mg 18/42
f 1619m 8.06mg 34.7mg 0/50 20OOmg 13/42
9 1619m 8.68mg 39.6mg 0/50 20.0mg 12/42
h 1619m 38.4mg n.s.s. 0/50 20.0mg 1/42
2-AMINO-3-METHYLIMIDAZOI4,5-fIQUINOLINE (IQ) 76180-96-6
24 1617 10.2mg 33.6mg 3/38 39.0mg 27/36
a 1617 14.2mg 44.9mg 0/38 39.0mg 22/36
b 1617 31.2mg 154.mg 0/38 39.0mg 11/36
c 1617 27.9mg n.s.s. 7/38 39.0mg 15/36
25 1617 12.2mg 60.4mg 7/33 36.0mg 27/39
a 1617 22.6mg 109.mg 1/33 36.0mg 16/39
b 1617 24.0mg 241.mg 3/33 36.0mg 16/39
c 1617 27.9mg 811.mg 3/33 36.0mg 14/39
d 1617 41.4mg 347.mg 0/33 36.0mg 8/39
1617 58.1mg n.s.s. 0/33 36.0mg 5/39
trans-5-AMINO-312-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE (SQ 18506) 28754-68-9
26 1601 59.8mg 206.mg 0/50 134.mg 18/49
a 1601 115.mg 2.33gm 1/50 134.mg 9/49
b 1601 283.mg n.s.s. 0/50 134.mg 2/49
c 1601 188.mg n.s.s. 4/50 134.mg 6/49
d 1601 705.mg n.s.s. 3/50 134.mg 0/49
* 1601 234.mg n.s.s. 9/50 134.mg 7/49
f 1601 138.mg n.s.s. 32/50 134.mg 24/49
27 1601 69.5mg 240.mg 0/50 152.mg 18/50
a 1601 73.6mg 263.mg 0/50 152.mg 17/50
b 1601 195.mg 9.94gm 0/50 152.mg 5/50
c 1601 171.mg n.s.s. 2/50 152.mg 7/50
d 1601 586.mg n.s.s. 3/50 152.mg 1/50
1601 652.mg n.s.s. 6/50 152.mg 1/50
f 1601 16.6mg 59.4mg 18/50 152.mg 45/50
2-AMINO-9H-PYRIDO(2,3-b)INDOLE (A-aLpha-C) 26148-68-5
28 1616 21.8mg 60.7mg 0/40 104.mg 33/40
a 1616 27.6mg 77.0mg 0/40 104.mg 30/40
b 1616 155.mg 2.30gm 0/40 104.mg 6/40
c 1616 241.mg n.s.s. 0/40 104.mg 3/40
d 1616 234.mg n.s.s. 2/40 104.mg 4/40
29 1616 48.1mg 158.mg 0/40 96.0mg 20/40
a 1616 58.1mg 209.mg 0/40 96.0mg 17/40
b 1616 66.3mg 259.mg 0/40 96.0mg 15/40
c 1616 105.mg 657.mg 0/40 96.0mg 9/40
d 1616 143.mg 2.12gm 0/40 96.0mg 6/40
1616 288.mg n.s.s. 3/40 96.0mg 3/40









Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD5O 2TaiLpvL
DR AuOp
2-AMINODIPYRIDO[1,2-a:3',2'-dIIMIDAZOLE..:..ug.:10. :100. :. :10. :100.. : :10
30
M
f cdf eat liv mix 82w82 . . 12.0mg
a N f cdf eat liv hpc 82w82 20.0mg
b
M
cdf eat bLv mix 82w82 39.9mg
c
M cdf eat blv hms 82w82 43.0mg
d N cdf eat Liv hpa 82w82
N f cdf eat Lun ado 82w82 1.09gm
N cdf eat Lun mix 82w82 dre
31
M cdf eat bLv mix 84w84 . + . 23.9mg
a
M cdf eat blv hes 84w84 27.3mg
b
M cdf eat Liv mix 84w84 93.2mg
c N cdf eat Liv hpa 84w84 201.mg
d N cdf eat Liv hpc 84w84 255.mg
N cdf eat lun ade 84w84 483.mg
M cdf eat Lun mix 84w84
32 R f34 eat cLi tue 24m24 . + . 56.4mg
a R f34 eatsmi mix 24m24
b R f34 eat coL mix 24m24 81.1mg
c R
f f34 eat zymsqc 24m24 94.0mg
d R
f f34 eat coL ade 24m24 111.mg
R f34 eatsmi adc 24m24
R f34 eatsmi ade 24m24 171.mg
R
f f34 eat Liv mix 24.24 .mg
h R f34 eat col adc 24.24 351.mg
R f34 eatsmi mcc 24m24 711.mg
33 R f34 eatsmi mix 24m24 . + . 33.8mg
a R f34 eatsmi adc 24m24 45.1mg
b R f34 eatliv mix 24m24 52.1mg
c R f34 eat cot mix 24m24 88.9mg
d R f34 eatsmi ade 24m24 137.mg
R f34 eat coL ade 24m24 185.mg
f R f34 eat coL adc 24.24 185.mg
R
m f34 eatsmi mcc 24m24 281.mg
h R mf34 eat bra ast 24m24 281.mg



































3-ANJNOTRIAZOLE*** lOOng. .:.. lug... .10 .... 100. 1. :.mg... .10 ...:. 100...I:.g .... 10
34 H syg eat Lun tum 28m28 ae .> P-1.
a H syg eat Liv ben 28m28 ae P-1.
b H f syg eat tba mix 2M28 ae P-I.
c H f syg eat tba mat 28m28 ae 570.mg P<.6
35 H m syg eat Liv ben 31m32 ae .> P-I.
a H syg eat Lun tum 31.32 ae
b H syg eat tba mix 31m32 ae P-I.
c H syg eat tba maL 31m32 ae P-I.
36 N nur eat Liv tum 33m33 ae .> P-I.
N nur eat Lun tur 33m33 P-I.
b N nut eat tba maL 33m33 ae 6.92mg
N nut eat tba mix 33m33 ae P-I.
37 N nmr eat Liv mal 34m34 ae
.> 2.76gm
nmr eat Lun tur 34.34 ae P-I.
b
M
nmr eat tba maL 34.34 ae 347.mg
N nmr eat tba mix 34m34 ae P-I.
38 R f wis eat thy ben 38m38 ae 11.5mg
a R f wis eat thy maL 38m38 ae 17.7mg
b R f wis eat pit ben 38m38 ae 20.8mg P<.0005+
c R f wis eat Liv tur 38m38 ae P-I.
d R f wis eat tba mix 38.38 ae 7.55mg P<.00 R f wis eat tba maL 38.38 ae
39 R wis eat thy ben 38.38ae . + . 8.75mg
a R wim eat thy mat 38m38 ae 27.Omg
b R m vim eat Liv hpc 38m38 ae P-I.
c R vim eat tba mix 38m38 13.8mg
d R
w is eat tba maL 38.38 a. 135.mg
ANETHOLE lOOng .:ug.:10 :..100.. : 1. :10 : 100.1 :0 :10
40 f cdl eat Liv tur 50v78 v .>
P-I.
N f cdl eat tun ado 50v78 v P-I.
ARECOLINE CL
41 N f swi gavliv tur 25m25
a N f swci gav Lun tun 25m25
b f sw i gay tba tun 25m25
42 N f swi gay Lun adc 25.25 b
a N f swi gay Liv hem 25.25 b
b f sw i gay tba mix 25.25 b
1O0ng .:. .lug. :10. :100.: ..:10. :100..:.g :10
.> no dre PP-.
no dte P-I.
no dte P-I.
A 61.9mg P<.07 +
116.mg P<.06 +
33.6mg P<.008 +
246SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or PathoLogy
2-AMINODIPYRIDOII,2-a:3',2'-djIMIDAZOLE (Glu-P-2) 67730-10-3
30 1616 7.10mg 20.7mg 0/40 65.0mg 36/40
a 1616 12.3mg 34.4mg 0/40 65.0mg 30/40
b 1616 23.3mg 76.3mg 0/40 65.0mg 20/40
c 1616 24.8mg 83.5mg 0/40 65.0mg 19/40
d 1616 69.4mg 1.03gm 0/40 65.0mg 6/40
1616 178.mg n.s.s. 0/40 65.0mg 1/40
f 1616 224.mg n.s.s. 2/40 65.0mg 1/40
31 1616 14.6mg 41.9mg 0/40 60.0mg 27/40
a 1616 16.6mg 48.9mg 0/40 60.0mg 25/40
b 1616 45.3mg 248.mg 0/40 60.0mg 10/40
c 1616 76.2mg 3.49gm 0/40 60.0mg 5/40
d 1616 87.9mg n.s.s. 0/40 60.0mg 4/40
o 1616 92.2mg n.s.s. 3/40 60.0mg 5/40
f 1616 105.mg n.s.s. 11/40 60.0mg 8/40
32 1619 28.2mg 138.mg 0/50 25.0mg 11/42
a 1619 36.6mg 252.mg 0/50 25.0mg 8/42
b 1619 36.6mg 252.mg 0/50 25.0mg 8/42
c 1619 40.5mg 341.mg 0/50 25.0mg 7/42
d 1619 45.3mg 525.mg 0/50 25.0mg 6/42
e 1619 51.3mg 1.12gm 0/50 25.0mg 5/42
f 1619 59.1mg n.s.s. 0/50 25.0mg 4/42
9 1619 86.3mg n.s.s. 0/50 25.0mg 2/42
h 1619 86.3mg n.s.s. 0/50 25.0mg 2/42
i 1619 116.mg n.s.s. 0/50 25.0mg 1/42
33 1619 18.1mg 73.9mg 0/50 20.0mg 14/42
a 1619 22.6mg 111.mg 0/50 20.0mg 11/42
b 1619 24.0mg 290.mg 2/50 20.0mg 11/42
c 1619 36.2mg 420.mg 0/50 20.0mg 6/42
d 1619 47.3mg n.s.s. 0/50 20.0mg 4/42
e 1619 56.0mg n.s.s. 0/50 20.0mg 3/42
f 1619 56.0mg n.s.s. 0/50 20.0mg 3/42
9 1619 69.1mg n.s.s. 0/50 20.0mg 2/42
h 1619 69.1mg n.s.s. 0/50 20.0mg 2/42
i 1619 92.6mg n.s.s. 0/50 20.0mg 1/42
3-AMINOTRIAZOLE*** (amitrol) 61-82-5
34 1557o 2.00mg n.s.s.
a 15570 242.mg n.s.s.
b 1557o 59.5mg n.s.s.
c 15570 81.3mg n.s.s.
35 1557o 2.29mg n.s.a.
a 1557o 2.29mg n.s.s.
b 15570 85.6mg n.s.s.
c 1557o 160.mg n.s.s.
36 1557n 3.29mg n.s.s.
a 1557n 3.29mg n.s.s.
b 1557n 2.32mg n.s.s.
c 1557n 26.3mg n.s.s.
37 1557n 200.mg n.s.s.
a 1557n 3.20mg n.s.s.
b 1557n 41.1mg n.s.s.
c 1557n 43.7mg n.s.s.
38 1557m 7.53mg 19.8mg
a 1557m 11.4mg 30.1mg
b 1557m 11.3mg 61.3mg
c 1557m 1.71mg n.s.s.
d 1557m 3.11mg 626.mg
1557m 9.13mg 73.9mg
39 1557m 5.85mg 14.2mg
a 1557m 15.2mg 60.5m9
b 1557m 115.mg n.s.a.
c 1557m 6.31mg 441.mg


















































































1.05mg 0/76 10.5mg 0/76
1.05mg 0/76 10.5mg 0/76
1.05mg 12/76 10.5mg 11/76
1.05mg 3/76 10.5mg 3/76
.920mg 0/76 9.20mg 0/75
.920mg 0/76 9.20mg 0/75
.920mg 13/76 9.20mg 11/75
.920mg 5/76 9.20mg 2/75
1.30mg 0/74 13.0mg 0/74
1.30mg 0/74 13.0mg 0/74
1.30mg 46/74 (13.0mg 38/74)
1.30mg 59/74 13.0mg 55/74
1.20mg 1/73 12.0mg 1/72
1.20mg 0/73 12.0mg 0/72
1.20mg 26/73 12.0mg 32/72
1.20mg 47/73 12.0mg 46/72
.500mg 8/75 5.00mg 44/75
.500mg 4/75 5.00mg 28/75
.500mg 15/75 5.00mg 36/75
.500mg 0/75 5.00mg 0/75
.500mg 60/75 5.00mg 71/75
.500mg 29/75 5.00mg 45/75
.400mg 4/75 4.00mg 45/75
.400mg 3/75 4.00mg 18/75
.400mg 1/75 4.00mg 0/75
.400mg 44/75 4.00mg 53/75
.400mg 23/75 4.00mg 23/75
ANETHOLE (p-propenyLanisoLe) 104-46-1
40 1582 563.mg n.s.s. 0/30 162.mg 0/30
a 1582 563.mg n.s.s. 1/30 162.mg 0/30
ARECOLINE.HCl 61-94-9
41 1659m 114.mg n.s.s.
a 1659m 114.mg n.s.s.
b 1659m 114.mg n.s.s.
42 1659n 18.6mg n.s.s.
a 1659n 28.4mg n.s.s.
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43 N m swi gav liv hem 25m25
a N m swi gav sto sqc 25.25
b N m swi gav Lun adc 25.25
c N m swi gav tba mix 25m25 r
44 N m swi gav Liv hem 25m25 b
a N m swi gav Lun adc 25m25 b
















AROCLOR 1260*** lOOng.. :. .ug.:10. :100. m :g.:10. :100.:Ig .:10
45 R m wis eat Liv hpc 27.27 er . +. 5.39mg P<.0005+
L-ASCORBIC ACID
46 N f b6c eat TBA MXB 24m24
a N f b6c eat Liv MXB 24m24
b N f b6c eat Lun MXB 24m24
47 N m b6c eat TBA MXB 24.24
a N m b6c eat Liv MXB 24m24
b N m b6c eat Lun MXB 24m24
48 R f f34 eat TBA MXB 24m24
a R f f34 eat Liv MXB 24m24
49 R m f34 eat TBA MXB 24m24
a R m f34 eat Liv MXB 24.24











ASPIRIN*** lOOng. .. : 10 : 100.: g :10. :100.1:0 :10
50 R b alb gav for tum 78w78 r .> no dre P-1.
a R b alb gav stg tum 78w78 r no dre P-1.
AZASERINE*** lOOng..: ..ug.:10 :..100. 1. : 1. :10 : 100..1 :019 :10
51 R m wis ipj pan tum 24.24 r .> no dre P-1.
AZATHIOPRINE 1O0ng : lug. :10. :100. : :10 :100.:Ig. :10
52 R f f34 eat edu sqc 52w52 ekr .> 10.1mg P<.2
a R f f34 eat Liv tum 52w52 ekr no dre P-1.
AZOXYMETHANE
53 R m f34 wat liv mix
a R m f34 wat Liv hpc
b R m f34 wat kid mix
c R m f34 wat coL a/2
d R m f34 wat liv has
R m f34 wat liv nnd









54 N f b6c gav MXB MXB 24.24
a M f b6c gav MXB MXB 24.24
b N f b6c gav Liv hpa 24m24
c N f b6c gav liv MXA 24.24
d N f b6c gav ova mtb 24m24
M f b6c gav lun MXA 24.24
f N f b6c gav lun a/c 24.24
g M f b6c gav ova MXB 24.24
h M f b6c gav mgl MXA 24m24
i N f b6c gav ova MXA 24m24
j M f b6c gav ova gct 24.24
k M f b6c gav ova tua 24.24
L M f b6c gav mgL cas 24.24
m N f b6c gav hag can 24m24
n N f b6c gav MXA MXA 24.24
o N f b6c gav MXA MXA 24m24
p M f b6c gav hag MXA 24.24
q M f b6c gav Lun a/a 24.24
r M f b6c gav MXA MXA 24.24
s M f b6c gav ova lut 24.24
t N f b6c gav zym sqc 24.24
u N f b6c gav ova pcy 24.24
v N f b6c gav TBA MXB 24m24
w N f b6c gav Liv MXB 24m24
x M f b6c gav Lun MXB 24m24
55 M m b6c gav MXB MXB 24m24
a M m b6c gav pre MXA 24.24
b M m b6c gav pro sqc 24m24
O0ng.. : ..lug. :10. :100.:1g. :10. :100.:Ig :10








..ug.:10. :100.:1.. :10. :100.. :. :10










157.mg * P<.002 c
+historical * P<.006 a
382.mg * P<.005 c
509.mg * P<.006
79.1mg * P<.04
94.2mg * P<.07 c
128.mg * P<.02
169.mg * P<.02 c
173.mg * P<.02
+historicaL * P<.05 a
421.mg * P<.02 c
















P-I.SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RofNum LoConf UpConf CntrL lDose lInc 2Dos. 2Inc
43 1659. 30.6mg 524.mg
a 1659. 59.4mg n.s.s.
b 1659. 55.5mg n.s.s.
c 1659. 17.8mg 143.mg
44 1659n 34.5mg n.s.s.
a 1659n 40.6mg n.s.s.

















AROCLOR 1260*** (PCB, clophon A 60) 11096-82-5
45 1605 3.90mg 7.75mg 1/131 4.00mg 61/129 Schaeffer;txap,75,278-288; 1984
L-ASCORBIC ACID (vitamin C) 50-81-7
46 c54808 8.40gm n.s.s. 30/50 3.19gm
a c54808 30.69m n.s.s. 3/50 3.199m
b c54808 24.1gm n.s.s. 1/50 3.199m
47 c54808 11.9gm n.s.s. 29/50 2.94gm
a c54808 16.4gm n.s.s. 16/50 2.94gm
b c54808 16.5gm n.s.s. 5/50 2.94gm
48 c54808 1.86gm n.s.s. 41/50 1.23gm
a c54808 28.7gm n.s.s. 2/50 1.23gm
49 c54808 2.05gm n.s.s. 37/50 981.mg


















50 1571 125.mg n.s.s.
a 1571 125.mg n.s.s.
Tsung-Hsien; jnci ,70,1067-1069;1983 0/23 26.9mg 0/40
0/23 26.9mg 0/40
AZASERINE*** 115-02-6
51 1746 .736mg n.s.s.
AZATHIOPRINE 446-86-6
52 1695 3.04mg n.s.s.
a 1695 9.66mg n.s.s.
AZOXYMETHANE 25843-45-2
53 1641 14.6ug 73.4ug
a 1641 33.1ug .168mg
b 1641 .192mg .957mg
c 1641 .263mg 1.73mg
d 1641 .354mg n.s.s.
1641 .465mg n.s.s.
f 1641 n.s.s. n.s.s.
0/9 .714mg 0/5 McGuinness;sjge, 18,189-192;1983































54 c55276 14.9mg 50.7mg
a c55276 15.3mg 54.6mg
b c55276 15.9mg 880.mg
c c55276 26.3mg 2.27gm
d c55276 34.6mg 156.mg
c55276 44.0mg 354.mg
f c55276 63.4mg 390.mg
g c55276 63.8mg 374.mg
h c55276 73.1mg 294.mg
i c55276 74.0mg 571.mg
j c55276 77.1mg 793.mg
k c55276 120.mg 3.25gm
I c55276 143.mg 3.12gm
m c55276 174.mg 5.94gm
















o c55276 37.2mg n.s.s. 15/50
p c55276 57.4mg n.s.s.
q c55276 72.8mg n.s.s.
r c55276 77.4mg n.s.s.
s c55276 106.mg n.s.s.
t c55276 146.mg n.s.s.
u c55276 174.mg n.s.s.
v c55276 16.1mg 158.mg
w c55276 26.3mg 2.27gm
x c55276 44.0mg 354.mg
55 c55276 10.1mg 26.0mg
a c55276 15.1mg 32.6mg


































































41/50 70.7mg 42/50 Lun:a/a,a/c; mgt:can,cas,sqc;
mul:mlh,mLm,mlp,mlu,mno; ova:gct,Lut,mtb,pcy,tua; spl:mlm. T
40/50 70.7mg 41/50 Lun:a/a,a/c; mgL:can,cas,sqc;
muL:mlh,mLm,mLp,mLu,mno; ova:gct,mtb; spl:mLm,mlu,mno; ute:mLh. C
5/50 70.7mg 4/50) S
13/50 (70.7mg 7/50) Liv:hpa,hpc. S
12/50 (70.7mg 7/50)
10/50 70.7mg 13/50 Lun:a/a,a/c.
6/50 70.7mg 6/50
7/50 70.7mg 5/50 ova:Lut,pcy,tua. A
5/50 70.7mg 10/50 mgl:can,sqc.




0/50 70.7mg 4/50 S
26/50 70.7mg 22/50 muL:lkn,mLh,mlm,mLp,mlu,mno,uLe; spl:mlm,mLu,mno;
ute:mlh. S
24/50 70.7mg 20/50 mul:mLh,mLm,mLp,mLu,mno; spL:mlm,mlu,mno;
ute:mth.










5/50 35.4mg 19/50 71.4mg
3/50 35.4mg 18/50 71.4mg
9/50







42/50 hag:adn; Lun:a/a,a/c; mul:mLh,mtm,mlp,mlu,mno;




Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
c N m b6c gav hag MXA 24.24
d N m b6c gav hag adn 24.24
a N m b6c gav Lun MXA 24m24
f M m b6c gav MXA MXA 24.24
g N m b6c gav MXA MXA 24.24
h N m b6c gav zym sqc 24.24
i Mm b6c gav Lun a/c 24.24
j M m b6c gav Lun a/a 24.24
k N m b6c gav adr phe 24.24
l M m b6c gav ski MXA 24.24
* M m b6c gav MXA MXA 24.24
n M m b6c gav MXA MXA 24.24
o M m b6c gav cst sqp 24.24
p M m b6c gav TBA MXB 24.24
q M m b6c gav Liv MXB 24.24
r N m b6c gav Lun MXB 24.24
56 R f f34 gav NXB MXB 24.24
a R f f34 gav zym MXA 24,24
b R f f34 gav zym can 24m24
c R f f34 gav MXA NXA 24m24
d R f f34 gav ut. esp 24m24
a R f f34 gav MXA MXA 24,24
f R f f34 gav MXA MXA 24,24
g R f f34 gav ton MXA 24m24
h R f f34 gav ton sqc 24m24
i R f f34 gav pat MXA 24m24
j R f f34 gav MXA MXA 24m24
k R f f34 gav TBA MXB 24m24
l R f f34 gav Liv MXB 24m24

























186.mg * P<.01 c
290.mg * P<.002 c
295.mg * P<.003 c
368.mg * P<.003 c





a R m f34 gav MXA MXA 24m24
b R m f34 gav MXA MXA 24m24
c R m f34 gav zym MXA 24m24
d R m f34 gav zym can 24.24
e R m f34 gav ski MXA 24.24
f R m f34 gav ski MXA 24m24
g R m f34 gav Lpp MXA 24m24
h R m f34 gav pal MXA 24m24
i R m f34 gav pal sqp 24m24
j R m f34 gav ski sqc 24m24
k R m f34 gav lpp sqp 24m24
L R m f34 gav MXA MXA 24m24
m R m f34 gav ski sqp 24m24
n R m f34 gav ton MXA 24m24
o R m f34 gav ton sqc 24m24
p R m f34 gav Lpp sqc 24m24
q R m f34 gav TBA MXB 24m24











284.mg * P<.002 c
295.mg * P<.0005c
427.mg * P<.003 c
382.mg * P<.02 c
430.mg * P<.02 c
1.15gm * P<.02 c
68. 1mg * P<.006
1.91gm * P<.7
BENZIDINE.2HCL*** lOOng ..:. lug.:10. :100. m :g.:10. :100.:Ig. :10
58 N f cbn wat Liv hpc 33m33 e .+. 18.9mg * P<.0005+
a N f cbn wat hag ade 33,33 e
b N f cbn wat ute agm 33.33 a
59 M m cbn wat Liv hpc 33.33 e
a N m cbn wat hag ade 33,33 e
60 N f cff wat liv hpc 33m33 e
a N f cfdf wat hag ado 33,33 a
b N f cff wat ute agm 33.33 e
61 N m cff wat liv hpc 33m33 e
a N m cff wat hag ado 33,33 e
BENZO(a)PYRENE***
62 N f c5v gav lun ben 52w92
a N f c5v gav liv tum 52w92
b N f c5v gav tba mix 52w92
41.1mg Z P<.0005e
402.mg * P<.005 +
60.5mg * P<.0005+
208.mg * P<.02 +
10.9mg * P<.0005+
51.7mg Z P<.0005+
335.mg * P<.006 +
31.2mg * P<.0005+
129.mg * P<.0005+
bO0ng. . .. :1ug. 10. :100. 1m : g.:10. :100.:Ig. :10
*> 12.1ug P<.2 -
no dre P-I.
2.68ug P<.2 -SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or PathoLogy
c c55276 24.5mg 79.0mg
d c55276 25.7mg 73.Omg
c55276 24.1mg 121.mg
f c55276 28.4mg 141.mg
g c55276 28.8mg 141.mg
h c55276 33.8mg 101.mg
i c55276 31.8mg 214.mg
j c55276 48.7mg 900.mg
k c55276 47.9mg 14.1gm
l c55276 94.4mg 1.96gm
m c55276 98.0mg 2.24gm
n c55276 66.5mg n.s.s.
o c55276 80.3mg n.s.s.
p c55276 10.4mg 38.6mg
q c55276 35.1mg n.s.s.
r c55276 24.1mg 121.mg
56 c55276 37.2mg 96.2mg
a c55276 60.8mg 179.mg
b c55276 66.3mg 207.mg
c c55276 65.7mg 333.mg
d c55276 73.3mg 4.18gm
c55276 90.9mg 13.1gm
f c55276 141.mg 1.14gm
g c55276 143.mg 1.56gm
h c55276 166.mg 1.76gm
i c55276 118.mg n.s.s.
j c55276 157.mg n.s.s.
k c55276 23.3mg 567.mg
l c55276 238.mg n.s.s.
57 c55276 35.9mg 83.8mg
a c55276 59.4mg 174.mg
b c55276 84.2mg 334.mg
c c55276 92.8mg 363.mg
d c55276 98.3mg 401.mg
c55276 102.mg 544.mg
f c55276 105.mg 656.mg
g c55276 120.mg 519.mg
h c55276 135.mg 635.mg
i c55276 138.mg 668.mg
j c55276 143.mg 859.mg
k c55276 145.mg 986.mg
l c55276 156.mg 977.mg
* c55276 192.mg 2.56gm
n c55276 173.mg n.s.s.
o c55276 206.mg n.s.s.
p c55276 349.mg n.s.s.
q c55276 33.7mg 799.mg



































































































































5/50 35.4mg 6/50 70.7mg
5/50 35.4mg 5/50 70.7mg
5/50 35.4mg 12/50 70.7mg
7/50 35.4mg 7/50 70.7mg
4/50 35.4mg 8/50 70.7mg
1/50 35.4mg 4/50 70.7mg
1/50 35.4mg 5/50 70.7mg
0/50 35.4mg 4/50 70.7mg
4/50 35.4mg 5/50 70.7mg
2/50 35.4mg 3/50 70.7mg
39/50 35.4mg 41/50 70.7mg
3/50 35.4mg 1/50 70.7mg













































































cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp;
zym:can. C
zym:adn,can. S
cst:sqp; Lpp:sqp; pal:sqc,sqp; ton:sqc,sqp.
S



















58 1563n 15.2mg 25.0mg 1
a 1563n 25.9mg 104.mg
b 1563n 201.mg 3.98gm
59 1563n 43.3mg 97.6mg 1
a 1563n 99.0mg n.s.s. 1
60 1563m 9.29mg 13.0mg
a 1563m 33.3mg 130.mg
b 1563m 163.mg 4.82gm
61 1563m 24.9mg 41.2mg 1
a 1563m 73.0mg 462.mg
10/125 4.00mg 54/119 6.00mg
24.0mg 56/72
6/121 4.00mg 28/117 6.00mg
24.0mg 8/68)
3/124 4.00mg 1/114 6.00mg
24.0mg 5/71
17/123 5.00mg 20/118 6.67mg
26.7mg 32/71
10/122 5.00mg 19/113 6.67mg
26.7mg 13/66
3/124 4.00mg 51/120 6.00mg
24.0mg 64/72
5/123 4.00mg 21/118 6.00mg
24.0mg 8/71)
4/122 4.00mg 5/117 6.00mg
24.0mg 10/71
14/125 5.00mg 24/119 6.67mg
26.7mg 49/71
6/124 5.00mg 21/117 6.67mg
26.7mg 17/68
43/95 8.00mg 31/71 12.0mg 37/72 16.0mg 51/69
Littlefield; jtxe,12,671-685;1983/1984/NaLson pers.comm.
16/94 8.00mg 17/71 (12.0mg 10/70 16.0mg 9/67
3/94 8.00mg 2/71 12.0mg 5/70 16.0mg 7/68
20/95 10.0mg 23/72 13.3mg 24/71 20.0mg 37/71
17/92 10.0mg 13/72 13.3mg 13/68 20.0mg 16/69
52/95 8.00mg 45/72 12.0mg 55/71 16.0mg 60/69
22/95 8.00mg 20/70 12.0mg 11/68 (16.0mg 12/68
5/95 8.00mg 5/68 12.0mg 4/72 16.0mg 5/71
30/96 10.0mg 23/71 13.3mg 35/71 20.0mg 51/71
19/93 10.0mg 18/70 13.3mg 16/70 20.0mg 13/67
BENZO(a)PYRENE*** 50-32-8
62 1636 2.97ug n.s.s. 0/11 3.23ug 2/15
a 1636 7.8lug n.s.s. 0/11 3.23ug 0/15




Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
63 M m c5v gav Lun ben 52w92
a M m c5v gav liv mal 52w92
b M . c5v gav liv ben 52w92
c M m c5v gav tba mix 52w92
C.I. DISPERSE BLUE 1
64 N f b6c eat Liv hpa 24,25
a N f b6c eat TBA MXB 24m25
b M f b6c eat liv MXB 24.25
c M f b6c eat lun MXB 24m25
65 N m b6c eat Lun a/a 24.24
a N m b6c eat liv MXA 24.24
b N m b6c eat TBA MXB 24.24
c M m b6c eat Liv MXB 24.24
d M m b6c eat lun MXB 24.24
66 R f f34 eat ubL MXB 24.24
a R f f34 eat ubL MXA 24.24
b R f f34 eat ubL MXA 24,24
c R f f34 eat ubL Lei 24m24
d R f f34 eat ubl tcc 24.24
e R f f34 eat ubl tpp 24.24
f R f f34 eat ubl MXA 24.24
9 R f f34 eat ubl sqp 24m24
h R f f34 eat ubL Ley 24.24
i R f f34 eat ubL sqc 24m24
j R f f34 eat pni isc 24m24
k R f f34 eat MXA MXA 24.24
l R f f34 eat TBA MXB 24.24
m R f f34 eat Liv MXB 24.24
67 R m f34 eat ubl MXB 24.24
a R m f34 eat ubL MXA 24m24
b R m f34 eat ubL Lei 24m24
c R m f34 eat ubL MXA 24m24
d R m f34 eat ubL tpp 24m24
e R m f34 eat pni MXA 24.24
f R m f34 eat ubL tcc 24m24
9 R m f34 eat ubL MXA 24.24
h R m f34 eat ubL sqp 24m24
i R m f34 eat sub srn 24.24
j R m f34 eat tes ict 24m24
k R m f34 eat thy MXA 24.24
l R m f34 eat thy cca 24.24
m R m f134 eat pni isa 24.24
n R m f34 eat TBA MXB 24.24
o R m f34 eat Liv MXB 24,24
HC BLUE NO. 1
68 M f b6c eat Liv MXA 24.24
a M f b6c eat liv hpc 24.24
b N f b6c eat liv hpa 24.24
c M f b6c eat TBA MXB 24.24
d M f b6c eat liv MXB 24.24
a M f b6c eat Lun MXB 24m24
69 M m b6c eat Liv MXA 24.24
a M m b6c eat liv hpa 24.24
b M m b6c eat MXB MXB 24.24
c M m b6c eat Liv hpc 24.24
d N m b6c eat thy fca 24m24
a M m b6c eat TBA MXB 24m24
f M m b6c eat Liv MXB 24.24
9 N m b6c eat Lun MXB 24.24
70 R f f34 eat ute esp 24,24
a R f f34 eat Lun MXA 24.24
b R f f34 eat Lun a/c 24.24
c R f f34 eat TBA MXB 24.24
d R f f34 eat liv MXB 24.24
71 R m f34 eat Liv MXA 24.24
a R m f34 eat liv nnd 24m24
b R m f34 eat TBA MXB 24m24
c R m f34 eat liv MXB 24m24
HC BLUE NO. 2
72 M f b6c eat TBA MXB 24m24 s
a M f b6c eat Liv MXB 24.24 s
b M f b6c eat Lun MXB 24.24 s
73 M m b6c eat MXA MXA 24m24





no dre P-1. -
no dre P-1. -
no dre P-1. -
lOOng .:. .lug.. : 10. :100.. :.1mg.. : 10. :100.. : Ig. :10

















1.54gm * P<.004 c












803.mg * P<.002 c


















389.mg * P<.002 c





702.mg * P<.03 a
1.19gm * P<.02 a
no dre P-1.
3.31gm * P<.3




bO0ng .. : lug.. : 10. :100.. :1.mg.. : 10. :100.. :I1g. :10
:> 42.0gm * P<.9 -
19.0gm / P<.4
no dre P-1.
A * #970.mg \ P<..02 -
4.04gm * P<.05SUPPLEMENT TO THE CARCINOGENIC POTENCYDATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
63 1636 2.66ug n.s.s. 1/20
a 1636 6.5lug n.s.s. 2/20
b 1636 6.5lug n.s.s. 2/20
c 1636 3.15ug n.s.s. 11/20
C.I. DISPERSE BLUE 1 2475-45-8
64 c54900 67.2mg 19.8g. 2/50
a c54900 275.mg n.s.s. 29/50
b c54900 904.mg n.s.s. 3/50
c c54900 791.mg n.s.s. 1/50
65 c54900 386.mg n.s.s. 1/50
a c54900 187.mg n.s.s. 9/50
b c54900 164.mg n.s.s. 35/50
c c54900 187.mg n.s.s. 9/50
d c54900 275..g n.s.s. 4/50
66 c54900 92.4mg 192.mg 0/50
a c54900 131.mg 318.mg 0/50
b c54900 158.mg 424..g 0/50
c c54900 181.mg 520.mg 0/50
d c54900 186.mg 559.mg 0/50
c54900 192.mg 571.mg 0/50
f c54900 338.mg 1.55gm 0/50
g c54900 454.mg 3.15g. 0/50
h c54900 579..g 10.3gm 0/50
i c54900 599.mg 10.9gm 0/50
j c54900 135.mg n.s.s. 10/50
k c54900 139.mg n.s.s. 12/50
l c54900 65.7mg 1.28gm 44/50
m c54900 1.04gm n.s.s. 1/50
67 c54900 63.0mg 130.mg 0/50
a c54900 86.9mg 196.mg 0/50
b c54900 88.0mg 200..g 0/50
c c54900 141.mg 463.mg 0/50
d c54900 183.mg 910.mg 0/50
e c54900 178.mg 4.62gm 1/50
f c54900 249.mg 1.18gm 0/50
g c54900 311.mg 3.41gm 0/50
h c54900 401.mg 15.0gm 0/50
i c54900 548.mg 99.7gm 0/50
j c54900 41.2mg n.s.s. 44/50
k c54900 187.mg n.s.s. 2/50
l c54900 213.mg n.s.s. 1/50
c54900 278.mg n.s.s. 1/50
n c54900 24.9mg 79.8mg 49/50
o c54900 540.mg n.s.s. 4/50
HC BLUE NO. 1 2784-94-3
68 c04159 129.mg 274.mg
a c04159 150.mg 304.mg
b c04159 314.mg 4.97gm
c c04159 199.mg 1.72gm
d c04159 129.mg 274.mg
a c04159 2.59gm n.s.s.
69 c04159 142.mg 1.13gm
a c04159 133.mg 6.59gm
b c04159 202.mg 1.61gm
c c04159 210.mg 1.95gm
d c04159 846.mg 39.1gm
c04159 165.mg n.s.s.
f c04159 142.mg 1.13gm
g c04159 1.129m n.s.s.
70 c04159 185.mg n.s.s.
a c04159 299.mg n.s.s.
b c04159 453.mg n.s.s.
c c04159 108.mg n.s.s.
d c04159 809.mg n.s.s.
71 c04159 334.mg n.s.s.
a c04159 499.mg n.s.s.
b c04159 117.mg n.s.s.




















































































































































































































































































































HC BLUE NO. 2 33229-34-4
72 c54897 2.249m n.s.s.
a c54897 4.32gm n.s.s.
b c54897 8.92gm n.s.s.
73 c54897 416.mg n.s.s.





















Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
b N m b6c eat --- mLp 24.24
c M m b6c eat TBA NXB 24.24
d M m b6c eat Liv NXB 24m24
e M a b6c eat Lun NXB 24.24
74 R f f34 eat liv MXA 24.24
a R f f34 eat TBA MXB 24.24
b R f f34 eat Liv MXB 24,24
75 R m f34 eat thy ccr 24m24
a R m f34 eat TBA MXB 24.24
b R m f34 eat Liv NXB 24.24
BROMATE, POTASSIUM***
76 R f f34 wat kid mix 26.26 o
a R f f34 wat kid adc 26.26 e
b R f f34 wat kid ado 26m26 e
c R f f34 wat thy mix 26m26 e
d R f f34 wat liv mix 26m26 o
e R f f34 wat tba mix 26m26 a
77 R m f34 wat kid mix 26m26 ev
a R m f34 wat kid adc 26m26 ev
b R m f34 wat per mso 26m26 ev
c R m f34 wat kid ade 26m26 ev
d R m f34 wat liv mix 26m26 ev
e R m f34 wat tba mix 26.26 ev
1 ,3-BUTADIENE
78 N f b6c inh MXB MXB 61w61
a N f b6c inh MXA NXA 61w61
b N f b6c inh lun MXA 61w61
c N f b6c inh lun a/c 61w61
d N f b6c inh lun a/a 61w61
e N f b6c inh --- mno 61w6l
f N f b6c inh hea hes 61w61
g N f b6c inh ova MXA 61w61
h N f b6c inh for MXA 61w61
i N f b6c inh for sqp 61w61
j M f b6c inh for MXA 61w61
k N f b6c inh for MXA 61w61
l N f b6c inh mgl acc 61w61
m N f b6c inh liv MXA 61w61
n N f b6c inh liv hpa 61w61
o N f b6c inh ova gcc 61w61
p N f b6c inh TBA MXB 61w61
q N f b6c inh liv MXB 61w61
r N f b6c inh lun MXB 61w61
79 M m b6c inh MXB MXB 60w60
a M * b6c inh Lun MXA 60w60
b N * b6c inh MXA MXA 60w60
c M m b6c inh hea hes 60w60
d M m b6c inh lun a/a 60w60
e NM b6c inh ... mno 6Ow6O
f M m b6c inh for MXA 60w60
g M m b6c inh for MXA 60w60
h M m b6c inh lun a/c 60w60
i M m b6c inh pro MXA 60w60
j M m b6c inh pre sqc 60w60
k M m b6c inh for NXA 60w60
l N m b6c inh TBA MXB 60w60
* N m b6c inh liv NXB 60w60
n M m b6c inh lun MXB 60w60
N-BUTYL CHLORIDE
80 N f b6c gav lun a/c 24m24
a M f b6c gav TBA NXB 24m24
b N f b6c gav liv NXB 24.24
c M f b6c gav lun NXB 24.24
81 M f b6c gav TBA MXB 24m24
a N f b6c gav liv MXB 24.24
b M f b6c gav lun MXB 24m24
82 N m b6c gav liv MXA 24.24
a M m b6c gav MXA MXA 24m24
b M m b6c gav TBA MXB 24m24
c M m b6c gav Liv NXB 24.24
d N m b6c gav lun NXB 24.24
83 M m b6c gav TBA NXB 24,24







#8.15gm * P<.04 -
3130.gm P<I.
8.15gm * P<.04
: A ##1.99gm * P<.02 -
no dre P-1.
20.3gm * P<.7













lOOng . . .:ug.:10. :100. g :. 1g :10. :100..:g. :10









461.mg \ P<.005 c
462.mg * P<.0005
483.mg * P<.0005
1.03gm * P<.002 c
1.17gm * P<.004 c
1.59gm * P<.009 c



















lOOng..: ..ug.:10. :100. 1g : . . :10. :100.. : . :10




:> no dre P-I.
no dre P-1.
13.1gm P<1.





:> no dre P-I.
623.mg P<.3SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrt lDose lInc 2Dose 2Inc
b c54897 2.359m n.s.s.
c c54897 777.mg n.s.s.
d c54897 1.189m n.s.s.
c54897 2.449m n.s.s.
74 c54897 3.08gm n.s.s.
a c54897 800.mg n.s.s.
b c54897 3.089m n.s.s.
75 c54897 902.mg n.s.s.
a c54897 302.mg n.s.s.












76 1550 9.90mg 19.5mg 0/47
a 1550 11.7mg 23.7mg 0/47
b 1550 49.6mg 234.mg 0/47
c 1550 48.2mg 7.87gm 3/52
d 1550 220.mg n.s.s. 2/52
1550 3.96mg 62.6mg 44/52
77 1550 6.93mg 13.9mg 3/53
a 1550 9.00mg 18.6mg 3/53
b 1550 16.1mg 49.8mg 6/53
c 1550 22.5mg 124.mg 0/53
d 1550 62.8mg n.s.s. 2/53













































































78 c50602 30.6mg 106.mg
a c50602 73.4mg 333.mg
b c50602 126.mg 411.mg
c c50602 91.8mg 825.mg
d c50602 153.mg 585.mg
o c50602 114.mg 1.03gm
f c50602 179.mg 483.mg
g c50602 214.mg 728.mg
h c50602 133.mg 2.44gm
i c50602 140.mg 5.15gm
j c50602 252.mg 1.03gm
k c50602 259.mg 1.10gm
l c50602 462.mg 4.19gm
m c50602 496.mg 6.82gm
n c50602 596.mg 36.9gm
o c50602 1.23gm n.a.s.
p c50602 25.1mg 75.8mg
q c50602 496.mg 6.82gm
r c50602 126.mg 411.mg
79 c50602 17.5mg 50.0mg
a c50602 38.7mg 128.mg
b c50602 51.1mg 198.mg
c c50602 51.1mg 198.mg
d c50602 54.4mg 203.mg
a c50602 70.1mg 158.mg
f c50602 49.6mg 391.mg
g c50602 53.3mg 600.mg
h c50602 126.mg 1.08gm
i c50602 150.mg 1.92gm
j c50602 181.mg 4.83gm
k c50602 197.mg 4.31gm
l c50602 17.3mg 52.5mg
m c50602 149.mg n.s.s.
n c50602 38.7mg 128.mg





































































































































---:mno; for:sqp; hea:hes; liv:hpa,hpc; lun:a/a,a/c; mgl:acc;
ova:gcc,gct. C




















80 c06155 592.mg n.s.s. 0/50
a c06155 295.mg n.s.s. 31/50
b c06155 442.mg n.s.s. 3/50
c c06155 411.mg n.s.s. 3/50
81 c06156 198.mg n.s.s. 35/50
a c06156 521.mg n.s.s. 9/50
b c06156 366.mg n.s.s. 6/50
82 c06155 359.mg n.s.s. 12/50
a c06155 1.039m n.s.s. 1/50
b c06155 199.mg 49.9gm 32/50
c c06155 359.mg n.s.s. 12/50
d c06155 742.mg n.s.s. 6/50
83 c06156 135.mg n.s.s. 41/50






















13/50 707.mg 15/50 Liv:hpa,hpc. S
3/50 707.mg 4/50 bom:hes; k/p:hes; Liv:hes; mul:hes; omt:hes; spl:hes; thx:hes. S
38/50 707.mg 29/50
13/50 707.mg 15/50 l iv:hpa,hpc,nnd.




Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
b M m b6c gav lun NXB 24.24
84 R f f34 gav TBA MXB 24.24
a R f f34 gav Liv MXB 24m24
85 R m f34 gav tes ict 24.24
a R m f34 gav TBA MXB 24.24





100.mg * P<.3 -
1.51gm * P<.8
#45.1mg * P<.02 -
40.5mg * P<.009
no dre P-1.
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** .: .. lug.: 10. :100. g : . . :10. :100..:19 :10
86 R m f34 wat ubL mix 25m26 ae . + . .432mg * P<.0005+
a R m f34 wat ubl pam 25.26 ae .447mg * P<.0005
87 R m sda gav ubL mix 39w74 .+ . 1.17mg P<.0005+
a R m sda gav lun car 39w74 166.mg P<.3
b R m sda gav liv tur 39w74 no dre P-1.
N-N-BUTYL-N-NITROSOUREA
88 R f f3d wat dgt mix 5Ow5O ev
a R f f3d wat for mix 50w50 ev
b R f f3d wat eso mix 50w50 ev
c R f f3d wat for pam 5Ow5O ev
d R f f3d wat vag mix 5Ow5O ev
e R f f3d wat vag pam 50w50 ev
f R f f3d wat eso pam 5Ow5O ev
g R f f3d wat eso sqc 50w50 ev
h R f f3d wat phr mix 5Ow5O ev
i R f f3d wat for sqc 5Ow5O ev
j R f f3d wat phr sqc 5Ow5O ev
k R f f3d wat ton mix 50w50 ev
l R f f3d wat edu mix 50w50 ev
m R f f3d wat ton pam 50w50 ev
n R f f3d wat edu ssc 50w50 ev
o R ff3d wat --- mix 5Ow5S ev
p R f f3d wat tba mix 5Ow5O ev
89 R m f3d wat dgt mix 50w50 ev
a R m f3d wat for mix 5Ow5O ev
b R m f3d wat eso mix 5Ow5O ev
c R m f3d wat for pam 50w50 ev
d R m f3d wat eso pam 5Ow5O ev
e R mf3d wat --- mix 5Ow5S ev
f R m f3d wat duo mix 50w50 ev
g R m f3d wat edu mix 50w50 ev
h R m f3d wat pLs mix 50w50 ev
i R m f3d wat eso sqc 50w50 ev
j R m f3d wat pLs sqc 5Ow5O ev
k R m f3d wat tba mix 5Ow5O ev
BUTYLATED HYDROXYANISOLE***
90 R f f34 eat for pam 24m26 a
a R f f34 eat for sqc 24m26 a
b R f f34 eat Liv hnd 24m26 a
91 R m f34 eat for pam 24m26 a
a R m f34 eat for sqc 24m26 a
b R m f34 eat Liv hnd 24m26 o
92 R m f34 eat liv tum 60w60 or
CAFFEINE***
93 R f sda wat Liv cad 24m24 e
a R f sda wat Liv cLc 24.24 o
b R f sda wat Liv hpa 24m24 a
c R f sda wat tba mix 24m24 o
94 R m sda wat Liv cLc 24m24 e
a R m sda wat Liv hpa 24m24 a
b R masda wat tba mix 24m24 a
CAPTAFOL
95 N f b6c eat Liv mix 22m24 ae
a M f b6c eat smi mix 22m24 ae
b N f b6c eat Liv hpc 22m24 ae
c N f b6c eat smi adc 22m24 ae
d M f b6c eat hea hae 22m24 ae
e M f b6c eat spL hem 22m24 ae
f M f b6c eat for mix 22m24 ae
g M f b6c eat for sqc 22m24 ae
h N f b6c eat Lun adc 22m24 ae
i N f b6c eat Lun mix 22m24 ae
96 N m b6c eat smi mix 22m24 o
a M m b6c eat Liv hpc 22m24 a
b M m b6c eat smi adc 22m24 e
c N m b6c eat hea hae 22m24 o


















































































lOOng .. : lug.:10. :100.:1mg.:10. :100 :1.Ig. :10
+ . 89.4mg Z P<.0005+
359.mg Z P<.0005+
398.mg Z P<.003 +
512.mg Z P<.0005+
1.40gm * P<.0005+
1.47gm Z P<.02 +
2.19gm * P<.03 +




138.mg Z P<.003 +
151.mg Z P<.0005+
647.mg Z P<.0005+SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
b c06156 354.mg n.s.s. 14/50
84 c06155 28.6mg n.s.s. 47/50
a c06155 187.mg n.s.s. 1/50
85 c06155 21.3mg n.s.s. 46/50
a c06155 19.8mg 1.01gm 48/50
b c06155 265.mg n.s.s. 3/50
Citation or Pathology
177.mg 11/50
42.0mg 46/50 84.1mg 25/50
42.0mg 4/50 84.1mg 0/50
42.0mg 45/50 84.5mg 39/50
42.Omg 48/50 84.5mg 42/50




86 1606 .281mg .680mg 0/50 50.Oug 0/29 .250mg 6/30 .500mg 23/30 2.50mg 30/30
a 1606 .298mg .691mg 0/50 50.Oug 2/29 .250mg 7/30 .500mg 23/30 2.50mg 29/30
87 1637 .641mg 2.03mg 0/40 10.5mg 44/46
a 1637 27.1mg n.s.s. 0/40 10.5mg 1/46
b 1637 50.6mg n.s.s. 0/40 10.5mg 0/46
N-N-BUTYL-N-NITROSOUREA 869-01-2
88 1620m .779mg 2.24mg
a 1620m 1.48mg 4.31mg
b 1620m 1.91mg 5.96mg
c 1620m 2.30mg 7.77mg
d 1620m 2.80mg 10.5mg
e 1620m 3.21mg 13.1mg
f 1620m 3.45mg 14.9mg
9 1620m 4.03mg 19.9mg
h 1620m 4.03mg 19.9mg
i 1620m 4.78mg 29.5mg
j 1620m 4.78mg 29.5mg
k 1620m 4.78mg 29.5mg
l 1620m 5.25mg 38.3mg
m 1620m 5.82mg 54.3mg
n 1620m 7.38mg 282.mg
o 1620m 8.51mg n.s.s.
p 1620m n.s.s. 1.08mg
89 1620n .519mg 1.60mg
a 1620n 1.57mg 4.80mg
b 1620n 1.77mg 5.68mg
c 1620n 1.89mg 6.21mg
d 1620n 2.29mg 8.25mg
e 1620n 4.60mg 34.5mg
f 1620n 5.09mg 49.9mg
9 1620n 5.09mg 49.9mg
h 1620n 5.09mg 49.9mg
i 1620n 6.45mg 362.mg
j 1620n 6.45mg 362.mg



























































































90 1568 334.mg 744.mg
a 1568 1.51gm 5.82gm
b 1568 8.36gm n.s.s.
91 1568 238.mg 528.mg
a 1568 1.04gm 3.56gm
b 1568 4.38gm n.s.s.

































93 1615 849.mg n.s.s.
a 1615 1.32gm n.s.s.
b 1615 1.21gm n.s.s.
c 1615 281.mg n.s.s.
94 1615 1.18gm n.s.s.
a 1615 1.65gm n.s.s.
b 1615 366.mg n.s.s.
CAPTAFOL 2425-06-1
95 1625 52.7mg 188.mg
a 1625 216.mg 666.mg
b 1625 216.mg 2.43gm
c 1625 286.mg 1.09gm
d 1625 770.mg 3.35gm
e 1625 599.mg n.s.s.
f 1625 1.07gm n.s.s.
9 1625 3.68gm n.s.s.
h 1625 n.s.s. n.s.s.
i 1625 2.61gm n.s.s.
96 1625 93.5mg 212.mg
a 1625 68.5mg 901.mg
b 1625 101.mg 237.mg







































































































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
d N m b6c eat spl hea 22.24 e
e N * b6c eat Liv six 22.24 e
f e o b6c eat for six 22.24 e
g N m b6c eat for sqc 22.24 a
h N m b6c eat spL mix 22.24 e
m m b6c eat spt hae 22.24 e
* m b6c eat Lun adc 22.24 e
k N * b6c eat Lun mix 22.24 a
CARBON TETRACHLORIDE***
97 N f b6c gav liv hpc 78w90 ej
a N f b6c gav adr mix 78w90 ej
b N f b6c gav tba mix 78w90 ej
98 N m b6c gav Liv hpc 78w90 ej
a N m b6c gav adr mix 78w90 ej
b N m b6c gav tba mix 78w90 ej
99 R f osm gav liv nnd 18.26 ej
a R f osm gav liv hpc 18.26 ej
b R f osm gav tba mix 18.26 ej
100 R m osm gav liv nnd 18.26 ej
a R m osm gav liv hpc 18.26 ej
b R m osm gav tba mix 18.26 ej
CARBOXYNETHYLNITROSOUREA***
101 R f don wat mgL mix 68w68 e
a R f don wat ugl fba 68w68 o
b R f don wat itn mix 68w68 o
c R f don wat smi ade 68w68 a
d R f don wat smi adc 68w68 a




1.57g. Z P<.008 +
166.mg Z P<.03
1.81gm * P<.02 +
6.19g. * P<.06 +
2.56g. Z P<.3
79.1g. * P<.9 +
no dre P-1.
no dre P-1.




+ . 127.mg * P<.0005+
683.mg * P<.0005+
130.mg * P<.0005
390.sg * P<.3 +
no dre P-a.
no dre P-1.
529.mg * P<.2 +
666.mg * P<.4
166.mg * P<.4
lOOng.. : .ug.:10. :100.:1mg.:10. :100.:Ig. :10






CHLORINATED PARAFFINS (C23, 43% CHLORINE) . .lug. :10. :100. g : . 1g :10. :100.:Ig. :10
102 N f b6c gav liv NXA 24.24 s : 10.5gm * P<.1 a
a N f b6c gav Liv hpc 24,24 s 14.09m * P<.05 o
b N f b6c gav Liv hpa 24m24 s 16.29m * P<.2 e
c N f b6c gav TBAMXB 24.24 s 5.839g * P<.5
d N f b6c gav Liv NXB 24.24 s 10.5g. * P<.1
a N f b6c gav lun NXB 24m24 s 1220.gm P<1.
103 N m b6c gav NXA NXA 24.24 : * 6.54g. * P<.03 c
a N * b6c gav MXA NXA 24.24 22.9g. * P<.04 c
b N m b6c gav mul uth 24.24 43.29m * P<.05 c
c N m b6c gav thy fcc 24m24 44.0gm * P<.05
d N m b6c gav NXAMXA 24m24 12.1gm * P<.2 c
N m b6c gav TBA NXB 24.24 36.4gm * P<.9
f N m b6c gav liv NXB 24.24 12.3gm * P<.4
g N m b6c gav lun NXB 24.24 31.1 g * P<.7
104 R f f34 gav amd NXA 24m24 : 2.35gm * P<.06 a
a R f 134 gav TBAMXB 24m24 no dre P-I.
b R ff34 gav Liv NXB 24.24 24.8gm * P<.7
105 R mf34 gav liv nnd 24.24 #14.5gm * P<.04 -
a R m f34 gav pni isa 24.24 17.6gm * P<.02
b R mf34 gav TBAMXB 24.24 no dre P-1.
c R m f34 gav Liv NXB 24m24 14.5g. * P<.04
CHLORINATED PARAFFINS (C12, 60% CHLORINE) .. ug. :10. :100.. g : .9 :10. :100.. g . 10
106 N f b6c gav MXB NXB 24m24 + 86.8mg * P<.0005
a N f b6c gav liv MXA 24.24 93.8mg * P<.0005c
b Nf b6c gav liv hpa 24m24 105.mg * P<.0005c
c Nf b6c gav mul mlp 24.24 599.mg * P<.002
d Nf b6c gav thy NXA 24.24 307.mg * P<.03 c e Nf b6c gav hagadn 24m24 347.mg\ P<.04
f Nf b6c gav thy fca 24.24 372.mg* P<.06 c
g Nf b6c gav Liv hpc 24.24 596..g* P<.03
h N f b6c gav TBA NXB 24m24 170.mg* P<.2
I f b6c gav liv NXB 24m24 93.8mg* P<.0005
N
M
f b6c gav Lun NXB 24.24 no dre P-1.
107 M o b6c gav Liv MXA 24.24 + 143.mg * P<.006 c
a N m b6c gav Liv hpa 24.24 157.mg * P<.002 c
b N m b6c gav Lun a/c 24.24 606.mg * P<.004
c N . b6c gav TBAMXB 24.24 211.mg * P<.2
d N m b6c gav Liv MXB 24.24 143.mg * P<.006 e Nmb6c gav lun NXB 24.24 851.mg* P<.3
108 Rf f34 gav mul onL 24.24 s : + 345.mg\ P<.009
a Rf f34 gav MXB NXB 24.24s 583..g* P<.0005
b Rf f34 gav thyfca 24m24 s 736.mg\ P<.003
c R ff34 gav LivMXA 24m24s 1.14gm* P<.002 c
d Rf f34 gav thyMXA 24.24s 1.16gm* P<.003 cSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
d 1625 596.mg 30.9gm
1625 75.7mg n.sa.s.
f 1625 882.mg n.s.s.
9 1625 1.87g. n.s.s.
h 1625 674.mg n.s.s.
i 1625 3.37gm n.s.s.
j 1625 1.68g. n.s.s.











83.1mg 0/51 166.mg 5/46 (332.mg 0/47)
83.1mg 41/51 166.mg 31/46 (332.mg 8/47)
83.1mg 2/51 166.mg 4/46 332.mg 4/47
83.1mg 0/51 166.mg 1/46 332.mg 2/47
83.1mg 0/51 166.mg 5/46 (332.mg 1/47)
83.1mg 0/51 166.mg 0/46 332.mg 1/47
83.1mg 2/51 166.mg 3/46 332.mg 1/47
83.1mg 5/51 166.mg 4/46 332.mg 1/47
CARBON TETRACHLORIDE*** 56-23-5
97 1469m 119.mg 287.mg 1/18 774.mg 40/42 1.559m 43/45 Weisburge
a 1469. 490.mg 2.35gm 0/18 774.mg 15/42 (1.559m 10/45)
b 1469m 123.mg 324.mg 3/18 774.mg 40/42 1.55gm 43/45
98 1469m 70.1mg 220.mg 3/18 774.mg 49/49 1.55gm 47/48
a 1469m 487.mg 1.219m 0/18 774.mg 28/49 1.559m 28/48
b 1469m 70.9mg 230.mg 4/18 774.mg 49/49 1.55gm 47/48
99 1469n 140.mg n.s.s. 1/20 40.5mg 11/50 81.0mg 9/49
a 1469n 415.mg n.s.s. 1/20 40.5mg 4/50 81.0mg 2/49
b 1469n 144.mg n.s.s. 10/20 40.5mg 34/50 81.0mg 20/49
100 1469n 201.mg n.s.s. 0/20 23.8mg 2/49 47.6mg 3/50
a 1469n 230.mg n.s.s. 0/20 23.8mg 2/49 47.6mg 2/50
b 1469n 48.7mg n.s.s. 7/20 23.8mg 21/49 47.6mg 24/50
CARBOXYNETHYLNITROSOUREA*** (CMNU) 60391-92-6
101 1547 1.44mg 4.77mg 9/36 5.71mg 28/40 11.4mg 30/38 (22.9mg 11/34)
a 1547 1.75mg 7.34mg 9/36 5.71mg 27/40 11.4mg 27/38 (22.9mg 10/34)
b 1547 3.75mg 7.98mg 0/36 5.71mg 5/40 11.4mg 19/38 22.9mg 27/34
c 1547 5.45mg 12.7mg 0/36 5.71mg 4/40 11.4mg 15/38 22.9mg 20/34
d 1547 7.38mg 19.5mg 0/36 5.71mg 1/40 11.4mg 9/38 22.9mg 19/34
e 1547 .854mg 2.48mg 14/36 5.71mg 34/40 11.4mg 35/38 22.9mg 34/34
CHLORINATED PARAFFINS (C23, 43% CHLORINE) (ChLorowax 40, Avg. NoL. Wt. . 560) 63449-39-8
102 c53543 3.849m n.s.s. 4/50 1.759m 3/50 3.549m 10/50
a c53543 5.22gm n.s.s. 1/50 1.759m 1/50 3.54gm 6/50
b c53543 4.969m n.s.s. 3/50 1.75gm 2/50 3.54gm 7/50
c c53543 1.349m n.s.s. 32/50 1.75gm 29/50 3.54gm 38/50
d c53543 3.849m n.s.s. 4/50 1.75gm 3/50 3.54gm 10/50
c53543 8.559m n.s.s. 3/50 1.75gm 3/50 3.54gm 3/50
103 c53543 2.96gm n.s.s. 6/50 1.77gm 12/50 3.54gm 16/50 Liv:mno; mln:mLm
a c53543 8.63gm n.s.s. 0/50 1.77gm 2/50 3.54gm 3/50
b c53543 13.0gm n.s.s. 0/50 1.77gm 0/50 3.54gm 3/50
c c53543 13.2gm n.s.s. 0/50 1.77gm 0/50 3.54gm 3/50
d c53543 4.09gm n.s.s. 5/50 1.77gm 10/50 3.54gm 10/50
c53543 2.12gm n.s.s. 43/50 1.77gm 41/50 3.54gm 43/50
f c53543 3.069m n.s.s. 18/50 1.77gm 21/50 3.54gm 23/50
g c53543 4.75gm n.s.s. 11/50 1.77gm 10/50 3.54gm 13/50
104 c53543 868.mg n.s.s. 1/50 70.1mg 4/50 210.mg 6/50 631.mg 7/50
a c53543 511.mg n.s.s. 46/50 70.1mg 45/50 210.mg 40/50 631.mg 41/50
b c53543 2.49gm n.s.s. 1/50 70.1mg 2/50 210.mg 1/50 631.mg 2/50
105 c53543 5.89gm n.s.s. 0/50 1.319m 3/50 2.63gm 3/50
a c53543 6.56gm n.s.s. 0/50 1.31gm 1/50 2.63gm 4/50
b c53543 1.78gm n.s.s. 46/50 1.31gm 42/50 2.63gm 41/50
c c53543 5.89gm n.s.s. 0/50 1.31gm 3/50 2.63gm 3/50





o,mlp; mul:mlh,mlm,mLp; smi:mLm; spL:mLm.
mLn:mLp; mul:mLp.








CHLORINATED PARAFFINS (C12, 60% CHLORINE) (ChLorowax 500c, Avg. NoL. Wt. . 411) 63449-39-8
106 c53587 53.3mg 200.mg 11/50 87.6mg 29/50 176.mg 34/50
a c53587 62.2mg 169.mg 3/50 87.6mg 22/50 176.mg 28/50
b c53587 70.9mg 164.mg 0/50 87.6mg 18/50 176.mg 22/50
c c53587 278.mg 2.56gm 0/50 87.6mg 3/50 176.mg 6/50
d c53587 136.mg n.s.s. 8/50 87.6mg 12/50 176.mg 15/50
e c53587 126.mg n.s.s. 1/50 87.6mg 6/50 (176.mg 2/50)
f c53587 150.mg n.s.s. 8/50 87.6mg 12/50 176.mg 13/50
g c53587 247.mg n.s.s. 3/50 87.6mg 4/50 176.mg 9/50
h c53587 64.1mg n.s.s. 40/50 87.6mg 42/50 176.mg 42/50
i c53587 62.2mg 169.mg 3/50 87.6mg 22/50 176.mg 28/50
j c53587 581.mg n.s.s. 3/50 87.6mg 4/50 176.mg 1/50
107 c53587 71.9mg 1.83gm 20/50 87.6mg 34/50 177.mg 38/50
a c53587 83.9mg 811.mg 11/50 87.6mg 20/50 177.mg 29/50
b c53587 284.ng 1.65gm 0/50 87.6mg 3/50 177.mg 6/50
c c53587 74.9mg n.s.s. 37/50 87.6mg 44/50 177.mg 46/50
d c53587 71.9mg 1.83gm 20/50 87.6mg 34/50 177.mg 38/50
e c53587 263.mg n.s.s. 5/50 87.6mg 6/50 177.mg 9/50
108 c53587 158.mg 11.0gm 11/50 221.mg 22/50 (442.mg 16/50)
a c53587 351.mg 1.17gm 0/50 221.mg 11/50 442.mg 12/50
b c53587 290.mg 3.62gm 0/50 221.mg 6/50 (442.mg 3/50)
c c53587 577.mg 4.00gm 0/50 221.mg 5/50 442.mg 7/50


















259260 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
e R f f34 gav liv nnd 24m24 s
f R f f34 gav ute MXA 24.24 s
g R f f34 gav pan ana 24.24 s
h R f f34 gav thy fcc 24m24 s
i R f f34 gav TBA MXB 24.24 s
j R f f34 gav Liv MXB 24m24 s
109 R m f34 gav tes ict 24.24 s
a R m f34 gav MXB MXB 24m24 s
b R m f34 gav Liv MXA 24.24 s
c R m f34 gav pan MXA 24.24 s
d R m f34 gav pan ana 24m24 s
e R m f34 gav Liv nnd 24.24 s
f R m f34 gav adr MXA 24e24 s
g R m f34 gav kid MXA 24.24 s
h R m f34 gav MXA MXA 24.24 s
i R m f34 gav kid tLa 24m24 s
j R m f34 gav Liv hpc 24m24 s
k R m f34 gav MXA MXA 24m24 s
t R 1 f34 gav pre MXA 24.24 s
m R m f34 gav mgL fba 24m24 s
n R m f34 gav pre adn 24.24 s
o R m f34 gav TBA MXB 24.24 s
p R m f34 gav Liv MXB 24m24 s
TD50 2Tailpvl
DR AuOp























14-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIOIACETIC ACID***..:..100.:1.mg. : 10. :100.. : 1 : 10
110 N m csb eat liv hpc 53w63 erv <+ noTD50 P<.0005+
111 R m f34 eat liv thc 69w69 ar <+ noTD50 P<.0005+
CHLOROBENZENE
112 M f b6c gav TBA MXB 24.24
a M f b6c gav Liv MXB 24.24
b M f b6c gav Lun MXB 24m24
113 M m b6c gav TBA MXB 24m24
a M m b6c gav Liv MXB 24m24
b M m b6c gav lun MXB 24m24
114 R f f34 gav MXA MXA 24,24
a R f f34 gav TBA MXB 24m24
b R f f34 gav Liv MXB 24.24
115 R m f34 gav Liv nnd 24.24
a R m f34 gav TBA MXB 24.24
b R m f34 gav Liv MXB 24,24
CHLORODIBROMOMETHANE*
116 M f b6c gav Liv MXA 24m25
a M f b6c gav Liv hpa 24m25
b M f b6c gav TBA MXB 24m25
c M f b6c gav Liv MXB 24m25
d M f b6c gav Lun MXB 24.25
117 M m b6c gav Liv MXA 24.25 s
a M m b6c gav Liv hpc 24m25 s
b M m b6c gav TBA MXB 24m25 s
c M m b6c gav Liv MXB 24m25 s
d M m b6c gav Lun MXB 24.25 s
118 R f f34 gav TBA MXB 24.24
a R f f34 gav Liv MXB 24m24
119 R m f134 gav TBA MXB 24m24
a R m f34 gav Liv MXB 24.24
lOOng .:. .lug.. : 10. :100.. : 1ug. : 10. :100.. : Ig. :10
:> 373.mg * P<.5
235.mg \ P<.09
623.mg * P<.08
:> 60.1mg * P<.2 -
382.mg * P<.7
190.mg * P<.2
A + #520.mg * P<.05 -
no dre P-1.
867.mg * P<.2
A + 247.mg * P<.02 a
190.mg * P<.4
328.mg * P<.08
1O0ng..:. .ug.. : 10. :100.. :.1mg.:10. :100.. : g. : 10
A + 139.mg * P<.03 a




:+ : #20.7mg \ P<.006




:> no dre P-I1.
591.mg * P<.1
:> no dre P-I.
150.mg \ P<.2
CHLORPHENIRAMINE MALEATE lOOng ..:.lug. 1 : 10 :..100.:1.mg. 1 : 10 :..100..:10 : 10
120 R f f34 eat liv nnd 25.30 ev .> no dre P-1.
121 R m f34 eat Liv nnd 25m30 ev .> no dre P-1.
CIPROFIBRATE
122 R m f34 eat liv hpc 60w60 er
a R m f34 eat Liv mix 60w60 er
b R m f34 eat Liv nnd 60w60 er




CITRININ 100ng ..:.:lug. : 10 : 100 1 . : mg. : 100.. : 1g. :10
123 R m f34 eat kid cLa 60w60 kr <+ noTD50 P<.0005+
124 R m f34 eat kid cLa 80w80 r <+ noTD50 P<.0005+
CLOPHEN A 30 bO0ng..:. .:ug.:10. :100. 1m : 1g .:10:.. 100.. : 1g. :10
125 R m wis eat Liv hpc 27m27 e .> 157.mg P<.2 +SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
c53587 597.mg 2.94gm
f c53587 167.mg n.s.s.
g c53587 286.mg n.s.s.
h c53587 1.23gm n.s.s.
i c53587 205.mg n.s.s.
j c53587 577.mg 4.00gm
109 c53587 41.7mg 187.mg
a c53587 61.4mg 202.mg
b c53587 65.6mg 240.mg
c c53587 76.1mg 369.mg
d c53587 77.5mg 409.mg
c53587 88.6mg 335.mg
f c53587 88.0mg 864.mg
g c53587 75.8mg 591.mg
h c53587 169.mg 2.48gm
i c53587 164.mg 1.43gm
j c53587 184.mg 3.24gm
k c53587 90.5mg n.s.s.
l c53587 173.mg n.s.s.
c53587 172.mg n.s.s.
n c53587 183.mg n.s.s.
o c53587 41.8mg 193.mg


























































































110 1656 n.s.s. 10.8mg 0/10 76.3mg 18/18
111 1656 n.s.s. 7.47mg 0/10 40.0mg 15/15
CHLOROBENZENE (monochlorobenzene) 108-90-7
112 c54886 82.2mg n.s.s. 25/50 42.0mg 26/50 84.1mg 29/50
a c54886 79.9mg n.s.s. 2/50 42.0mg 7/50 (84.1mg 2/50)
b c54886 223.mg n.s.s. 1/50 42.0mg 2/50 84.1mg 5/50
113 c54886 22.3mg n.s.s. 30/50 21.0mg 31/50 42.0mg 35/50
a c54886 48.4mg n.s.s. 16/50 21.0mg 15/50 42.0mg 14/50
b c54886 62.2mg n.s.s. 6/50 21.0mg 4/50 42.0mg 10/50
114 c54886 198.mg n.s.s. 0/50 42.4mg 2/50 84.9mg 3/50
a c54886 64.1mg n.s.s. 36/50 42.4mg 30/50 84.9mg 36/50
b c54886 263.mg n.s.s. 0/50 42.4mg 1/50 84.9mg 2/50
115 c54886 109.mg n.s.s. 2/50 42.4mg 4/50 84.9mg 8/50
a c54886 48.4mg n.s.s. 33/50 42.4mg 36/50 84.9mg 28/50
b c54886 119.mg n.s.s. 4/50 42.4mg 4/50 84.9mg 8/50
CHLORODIBROMONETHANE* (dibromochloromethane) 124-48-1
116 c55254 64.4mg n.s.s. 6/50 35.0mg 10/50 70.4mg 19/50
a c55254 96.2mg n.s.s. 2/50 35.0mg 4/50 70.4mg 11/50
b c55254 61.6mg n.s.s. 33/50 35.0mg 32/50 70.4mg 37/50
c c55254 64.4mg n.s.s. 6/50 35.0mg 10/50 70.4mg 19/50
d c55254 276.mg n.s.s. 5/50 35.0mg 0/50 70.4mg 5/50
117 c55254 8.25mg 294.mg 23/50 35.0mg 14/50 (70.8mg 27/50)
a c55254 12.5mg 491.mg 10/50 35.0mg 9/50 (70.8mg 19/50)
b c55254 5.19mg 58.7mg 41/50 35.0mg 23/50 (70.8mg 31/50)
c c55254 8.25mg 294.mg 23/50 35.0mg 14/50 (70.8mg 27/50)
d c55254 22.3mg n.s.s. 11/50 35.0mg 5/50 (70.8mg 4/50)
118 c55254 23.7mg n.s.s. 43/50 28.3mg 38/50 (56.6mg 32/50)
a c55254 204.mg n.s.s. 0/50 28.3mg 2/50 56.6mg 2/50
119 c55254 31.5mg n.s.s. 43/50 28.3mg 37/50 (56.6mg 29/50)
a c55254 46.3mg n.s.s. 3/50 28.3mg 8/50 (56.6mg 3/50)
CHLORPHENIRANINE NALEATE 113-92-8
120 1654 141.mg n.s.s. 4/24 42.0mg 3/24
121 1654 122.mg n.s.s. 5/24 33.6mg 3/24
CIPROFIBRATE 52214-84-3
122 1640 n.s.s. 1.09mg 0/25 10.0mg 25/25
a 1640 n.s.s. 1.09mg 0/25 10.0mg 25/25
b 1640 n.s.s. 1.09mg 0/25 10.0mg 25/25
CITRININ (antimycin) 518-75-2
123 1533m n.s.s. 5.28mg 0/5 40.0mg 17/17
124 1533n n.s.s. 12.8mg 0/10 40.0mg 10/10
CLOPHEN A 30 55600-34-5






















Brkly Code262 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist 1ol
COMPOUND 50-892
126 N f cdl eat lun a/c 86w86
a M f cd1 eat Lun a/a 86w86
b M f cdl eat Liv hes 86w86
c M f cdl eat Lun rhb 86w86
127 M e cdl eat Lun a/c 86w86
a M m cdl eat Lun a/a 86w86
b M m cdl eat Liv hes 86w86
128 R f sdz eat Liv nnd 24.24
a R f sdz eat Liv hpc 24.24
b R f sdz eat ear fba 24.24
129 R r sdz eat adr maL 24.24
a R m sdz eat liv tur 24.24
CYCLOPHOSPHAMIDE***
130 R b sda wat ubL tcc 32m36 ae
a R b sda wat --- mix 32.36 as
b R b sda wat vse hus 32.36 ae
c R b sda wat Liv tur 32r36 ae
d R b sda wat ner ngs 32r36 ae
a R b sda wat tba .aL 32r36 ae
131 R m sda ivj mix hae 12r24 a
a R m sda ivj tba ral 12.24 a
p,p' *DDE***
132 H f syg eat Liv nnd 28n28 a
a H f syg eat adr mnix 28r28 a
b H f syg eat Lun tur 28r28 a
c H f syg eat tba mnix 28r28 a
133 H r syg eat Liv nnd 28.28 a
a H r syg eat Lun tur 28r28 a
b H r syg eat tba mix 28r28 a
DDT***
134 H f syg eat adr ada 28.28 a
a H f syg eat liv hem 28r28 a
b H f syg eat lun tur 28r28 a
c H f syg eat tba mnix 28r28 a
135 H m syg eat liv tur 28r28 e
a H r syg eat lun tur 28r28 a
b H r syg eat tba mix 2828
DECABROMODIPHENYL OXIDE
136 M f b6c eat TBA MXB 24r24
a M f b6c eat Liv MXB 24.24
b M f b6c eat Lun MXB 24.24
137 M r b6c eat thy MXA 24r24
a M m b6c eat liv MXA 24r24
b M r b6c eat TBA MXB 24r24
c M r b6c eat Liv MXB 24.24
d M r b6c eat Lun MXB 24r24
138 R f f34 eat liv MXA 24r24
a R f f34 eat Liv nnd 24r24
b R f f34 eat TBA MXB 24r24
c R f f34 eat Liv MXB 24r24
139 R m f34 eat Liv nnd 24n24
a R r f34 eat Liv MXA 24.24
b R m f34 eat pan ana 24r24
c R r f34 eat TBA MXB 24r24
d R r f34 eat liv MXB 24r24
DEXTRAN
140 R f aci eat ubL tur 68w68
141 R r aci eat ubL tur 68w68
TD50 2TaiLpvl
DR AuOp teas
lOOng .:.lug.:10. :100.:1g..:10. :100.. : . :10




8.40g. * P<.8 -
no dre P-1. -
no Ore P-1.
2.22gr * P<.7 -
no dre P-1.
no dre P-1.
+ 113.mg Z P<.003 -
no dre P-1.
lOOng .. :. .ug.:10. :100. r : ng.:10. :100.. : g :10
+ 21.4rg * P<.0005+
34.9rg * P<.2 +
65.6rg * P<.3
189.mg * P<.3
no dre P-1. +
12.8rg * P<.05 +
+ . 3.38rg P<.007
1.41mg P<.002 +
lOOng.. :. .lug.:10. :100.:lg..:10. :100..:19 :10




141.rg * P<.04 +
no dre P-1.
1.30g * P<.8















O0ng..:. .lug.:10. :100. g :. 1g :10. :100.. : :.10
:> no dre P-1.
33.4gr * P<.5
no dre P-1.
:20.5g * P<.09 a




+ 6.58gr * P<.004
7.74gr * P<.005 a
4.38gr * P<.5
6.58gm * P<.004





lOOng.. : ..ug.:10. :100. g :. 1g :10. :100.. : g. :10
A 1.64gm P<.02 -
3.19gm P<.4 -
DEXTRAN SULFATE SODIUM (DS-M-1)*** .. : ..lug.:10. :100. . : g..:10. :100.:Ig. :10
142 R f aci eat cLr par 68w68 . + . 219.mg
a R f aci eat cLr adc 68w68 373.mg
b R f aci eat clr ade 68w68 977.mg
c R f aci eat cec ada 68w68 1.27g.
d R f aci eat cLr sqc 68w68 1.769r
143 R m aci eat cLr adc 68w68 . + . 182.mg
a R m aci eat clr pa. 68w68 466.mg
b R r aci eat cLr sqc 68w68 2.O05gm










t,SUPPLEMENT TO THE CARCINOGENIC POTENCYDATABASE
RofNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
COMPOUND 50-892 (1-isopropyt-4-(m-methoxyphenyt)-7-methyl-2(IH)-quinazolinone) 65765-07-3
126 1667 455.mg n.s.s. 1/50 25.0mg 2/50 150.mg 2/50
a 1667 96.6mg n.s.s. 10/50 25.0mg 4/50 (150.mg 3/50)
b 1667 1.089m n.s.s. 2/50 25.0mg 1/50 150.mg 0/50
c 1667 802.mg n.s.s. 0/50 25.0mg 1/50 150.mg 0/50
127 1667 463.mg n.s.s. 0/50 25.0mg 2/50 150.mg 1/50
a 1667 261.mg n.s.s. 13/50 25.0mg 8/50 150.mg 11/50
b 1667 1.08gm n.s.s. 2/50 25.0mg 1/50 150.mg 0/50
128 1667 286.mg n.s.s. 7/50 4.30mg 4/50 20.0mg 6/50 102.mg 7/50
a 1667 35.2mg n.s.s. 1/50 4.30mg 0/50 20.0mg 0/50 102.mg 0/50
b 1667 156.mg n.s.s. 22/50 4.30mg 32/50 20.0mg 27/50 102.mg 25/50
129 1667 48.7mg 566.mg 0/50 4.30mg 1/50 20.0mg 6/50 (102.mg 1/50)
a 1667 35.2mg n.s.s. 0/50 4.30mg b/50 20.0mg 0/50 102.mg 0/50
Brkly Code
CYCLOPHOSPHAMIDE*** (Endoxan) 50-18-0
130 1705 12.1mg 70.4mg 0/74 .221mg
a 1705 12.1mg n.s.s. 0/74 .221mg
b 1705 17.1mg n.s.s. 1/74 .221mg
c 1705 46.4mg n.s.s. 0/74 .221mg
d 1705 29.6mg n.s.s. 1/74 .221mg
1705 5.20mg n.s.s. 9/74 .221mg
131 1703 1.29mg 65.1mg 1/52 .929mg
a 1703 .656mg 6.75mg 6/52 .929mg
p,p'-DDE*** 72-55-9
132 1556 166.mg 1.76gm
a 1556 205.mg n.s.s.
b 1556 1.139m n.s.s.
c 1556 163.mg n.s.s.
133 1556 77.0mg n.s.s.
a 1556 273.mg n.s.s.









134 1556 152.mg 3.14gm 2/42
a 1556 551.mg n.s.s. 0/42
b 1556 1.03gm n.s.s. 2/42
c 1556 158.mg n.s.s. 13/42
135 1556 883.mg n.s.s. 0/31
a 1556 883.mg n.s.s. 1/31
b 1556 167.mg n.s.s. 15/31
DECABROMODIPHENYL OXIDE 1163-19-5
136 c55287 5.88gm n.s.s. 35/50
a c55287 6.93gm n.s.s. 8/50
b c55287 22.49m n.s.s. 6/50
137 c55287 8.82gm n.s.s. 0/50
a c55287 3.50gm n.s.s. 8/50
b c55287 2.36gm n.s.s. 21/50
c c55287 3.50gm n.s.s. 8/50
d c55287 12.7gm n.s.s. 5/50
138 c55287 3.25gm 48.39m 1/50
a c55287 3.68gm 61.99m 1/50
b c55287 1.06gm n.s.s. 49/50
c c55287 3.25gm 48.3gm 1/50
139 c55287 1.22gm 5.14gm 1/50
a c55287 1.23gm 6.55gm 2/50
b c55287 4.77gm n.s.s. 0/50
c c55287 681.mg n.s.s. 49/50
































































































SchmahL; i cn,23,706-712; 1979















140 1540 494.mg n.s.s. 0/20 1.259m 3/15
141 1540 540.mg n.s.s. 1/20 1.00gm 2/15
Hirono;cLet, 18,29-34; 1983
DEXTRAN SULFATE SODIUM (DS-M-1)***
142 1540 103.mg 525.mg 0/20
a 1540 174.mg 982.mg 0/20
b 1540 368.mg 5.89gm 0/20
c 1540 437.mg 31.1gm 0/20
d 1540 532.mg n.s.s. 0/20
143 1540 84.0mg 452.mg 0/20
a 1540 197.mg 1.53gm 0/20
b 1540 502.mg n.s.s. 0/20
c 1540 419.mg n.s.s. 1/20












Van Ryzin;dact,3,361-379;1980GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2TaiLpvL
DR AuOp
DEXTRAN SULFATE SODIUM (DST-H) lOOng.. :. :10. :100.. : g :10. :100. :Ig :10
144 R f aci eat ubl tur 68w68 . A 2.56gm P<.06 -
145 R m aci eat cec ada 68w68 .> 4.25gm P<.2
DEXTRAN SULFATE SODIUM (KMDS-H) lOOng. .. :1ug 10. :100. u: 1g :10. :100. :Ig :10
146 R f aci eat ubL tur 68w68 . * 1.64gm P<.02 -







swi gav lun mix 95w95 rs
swi gav Lun mix 34w95 rs
swi gav lun mix 95w95 rs
swi gav Lun mix 34w95 rs
DIALLYL PHTHALATE
152 N f b6c gav for ppn 24m25
a M f b6c gav TBA MXB 24m25
b N f b6c gav Liv MXB 24m25
c M f b6c gav Lun MXB 24m25
153 M b6c gav --- mno 24m25
a N m b6c gav liv hpa 24m25
b M m b6c gav for ppn 24.25
c M m b6c gav TBA MXB 24m25
d M m b6c gav Liv MXB 24m25
M m b6c gav lun MXB 24m25
154 R f f34 gav - -- mnl 24m24
a R f f34 gav TBA MXB 24m24
b R f f34 gav Liv MXB 24m24
155 R m f34 gav TBA MXB 24m24
a R m f34 gav Liv MXB 24m24
1,1 -DIALLYLHYDRAZINE
156 M f swa wat Lun mix 23m23 es
a M f swa wat Lun ada 23m23 as
b M f swa wat Lun adc 23m23 es
c N f swa wat for sqp 23m23 es
d f swa wat Liv ang 23m23 es
N f swa wat Liv agm 23.23 as
157 N m swa wat Lun mix 93w93 es
a N m swa wat Lun ada 93w93 as
b N m swa wat Lun adc 93w93 es
c M m swa wat for sqp 93w93 es
d M m swa wat Liv ang 93w93 as
N m swa wat Liv agm 93w93 as
DIBROMONEOPENTYL GLYCOL
158 R f sss eat Liv hph 24.24
a R f sss eat liv hpc 24m24
b R f sss eat tba mix 24.24
159 R m sss eat Liv hph 24.24
a R m sss eat Liv hpc 24m24 e
b R m sss eat tba mix 24.24
DICHLOROACETYLENE
160 N f nmr inh hag cye 18m28 es
a M f nmr inh kid cye 18.28 es
b M f nmr inh Lun ada 18.28 es
c M f nmr inh Lun car 18.28 es
d N f nmr inh Lun mix 18m28 es
161 M f nmr inh kid cye 52w98 es
a M f nmr inh hag cye 52w98 es
b M f nmr inh Lun ado 52w98 es
c M f nmr inh Lun car 52w98 es
162 M f n,r inh hag cye 18m30 es
a M f n,r inh kid cye 18.30 es
b M f n,r inh Lun ada 18.30 es
c M f nmr inh Lun car 18.30 as
163 M m nmr inh kid cyo 18m29 es
a M m nmr inh kid cyc 18m29 as
b N m nmr inh hag cyo 18.29 es
c M m nmr inh Lun ada 18m29 es
d M m nur inh Lun car 18m29 es
164 N m nmr inh kid cye 52w92 es
a M m n,r inh kid cyc 52w92 as
b M m nmr inh hag cye 52w92 es
c M m nmr inh Lun ado 52w92 es
lOOng .. :. .lug :.10. :100 : 1g : 10. :100 ..
.> no dre P-1.
.> no dre P-1.
.> 411.mg * P<.7
.> 144.mg P<.8














:> 2.99gm * P<1l. -
no dre P-1.













































































264SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc Citation or Pathology
DEXTRAN SULFATE SODIUM (DST-H) (MoL. Wt. 9500) 9011-18-1
144 1540 628.mg n.s.s. 0/20 1.25gm 2/15
145 1540 691.mg n.s.s. 0/20 1.00gm 1/15
DEXTRAN SULFATE SODIUM (KMDS-H) (MoL. Wt. - 520,000) 9011-18-1
146 1540 494.mg n.s.s. 0/20 1.25gm 3/15





148 1661. 59.0mg n.s.s. 3/20
149 1661n 29.5mg n.s.s. 3/20
150 1661. 43.8mg n.s.s. 2/20
151 1661n 10.9mg n.s.s. 2/20
DIALLYL PHTHALATE 131-17-9
152 c50657 n.s.s. n.s.s. 0/50
a c50657 215.mg n.s.s. 31/50
b c50657 736.mg n.s.s. 1/50
c c50657 911.mg n.s.s. 1/50
153 c50657 304.mg n.s.s. 6/50
a c50657 740.mg n.s.s. 0/50
b c50657 n.s.s. n.s.s. 0/50
c c50657 180.mg n.s.s. 23/50
d c50657 517.mg n.s.s. 7/50
e c50657 587.mg n.s.s. 5/50
154 c50657 58.3mg n.s.s. 15/50
a c50657 37.9mg n.s.s. 41/50
b c50657 371.mg n.s.s. 5/50
155 c50657 61.9mg n.s.s. 36/50































































156 1676 20.6mg 70.2mg 25/99
a 1676 22.6mg 74.3mg 20/99
b 1676 58.3mg 312.mg 6/99
c 1676 105.mg n.s.s. 4/61
d 1676 336.mg n.s.s. 3/61
e 1676 421.mg n.s.s. 5/67
157 1676 15.0mg 53.2mg 26/96
a 1676 17.9mg 58.3mg 16/96
b 1676 22.8mg 80.1mg 12/96
c 1676 27.0mg 97.4mg 0/63
d 1676 120.mg n.s.s. 4/68














158 1642 409.mg n.s.s. 3/48 5.00mg
a 1642 49.1mg n.s.s. 1/48 5.00mg
b 1642 23.6mg n.s.s. 47/50 5.00mg
159 1642 49.1mg n.s.s. 1/50 5.00mg
a 1642 1.01gm n.s.s. 1/50 5.00mg
b 1642 74.9mg n.s.s. 39/50 5.00mg
DICHLOROACETYLENE 7572-29-4
160 1651m .264mg 2.65mg 3/30
a 1651m .467mg 4.34mg 0/30
b 1651m .827mg n.s.s. 0/30
c 1651m 2.60mg n.s.s. 4/30
d 1651m 1.18mg n.s.s. 4/30
161 1651n .554mg 2.19mg 0/30
a 1651n 1.10mg n.s.s. 2/24
b 1651n 4.98mg n.s.s. 5/30
c 1651n 6.42mg n.s.s. 1/30
162 16510 .280mg 1.01mg 1/28
a 16510 1.44mg n.s.s. 4/30
b 16510 3.40mg n.s.s. 1/30
c 1651o 3.40mg n.s.s. 1/30
163 1651m .221mg 2.66mg 4/30
a 1651m .256mg 1.18mg 0/30
b 1651m .332mg n.s.s. 6/30
c 1651m .842mg n.s.s. 4/30
d 1651m 1.79mg n.s.s. 5/30
164 1651n .248mg 1.50mg 8/30
a 1651n 1.34mg n.s.s. 0/30
b 1651n 1.18mg n.s.s. 6/26
c 1651n 3.08mg n.s.s. 5/30










































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
165 N m nmr inh hag cym 18m27 as
a N m nmr inh kid cye 18.27 es
b N m nmr inh kid cyc 18.27 es
c N m nmr inh Lun ade 18.27 es
d N m nmr inh Lun car 18m27 as
166 R f wis inh sLy 18m35 es
a R f wis inh Liv cho 18m35 es
b R f wis inh kid cym 18.35 es
c R f wis inh Liv hpa 18.35 es
167 R m wis inh kid cy. 18.36 es
a R m wis inh Liv cho 18.36 es
b R m wis inh Liv hpa 18m36 as
c R m wis inh kid cyc 18m36 es
d R a wis inh Liv cvh 18.36 as
a R a wis inh Liv hpc 18.36 es
1 ,2-DICHLOROBENZENE
168 N f b6c gav --- mLh 24m24
a f b6c gav TBA MXB 24m24
b N f b6c gav Liv MXB 24.24
c
M f b6c gav Lun MXB 24m24
169 N m b6c gav --- mLh 24m24
a N m b6c gav TBA MXB 24m24
b N m b6c gav Liv MXB 24m24
c
M m b6c gav Lun NXB 24m24
170 R f f34 gav TBA MXB 24m24
a R
f f34 gav Liv MXB 24m24
171 R m f34 gav tes ict 24m24
a R m f34 gav TBA MXB 24.24


































lOOng .. :. .lug. : 10. : 100. : g :. 100.... : Ig. : 10








:> 11.16gm * P<-9 -
1.13gm * P<.4
A+ #48.5mg * P<.03 -
81.4mg * P<.05
696.mg * P<.09
DIFTALONE lOOng . . .:ug.:10. :100. g :. 1g :10. :100.:Ig. :10
172 N f bld eat Liv ang 19m28 a . + . 852.mg * P<.002 +
a N f bLd eat Liv hpa 19m28 a 1.15gm * P<.009 +
b N f bLd eat lun mix 19m28 a 269.mg * P<.04 -
c M f bLdeat Liv hpc 19m28 a 3.54gm * P<.08 +
d N f bLd eat Liv agm 19m28 a 7.139m * P<.3
173 N m bLd eat Liv ang 19.28 o . + . 879.mg Z P<.0005+
a N m bLd eat Liv agm 19m28 a 1.37gm Z P<.03 +
b N m bLd eat Lun mix 19m28 a 412.mg a P<.3
c N m bLd eat Liv hpc 19m28 a no dre P-1.
d N m bLd eat liv hpa 19m28 a no dre P-1.
DINETHYL HYDROGEN PHOSPHITE 1 OOng. ... lug. 1 :10 :..100. . :. .1.: 10 . 100.1:0 1 :10
174 Nfb6c gav Liv hpa 24m24 : + #286.mg \ P<.005 -
a Nf b6c gav TBAMXB 24m24 no dre P-1.
b N f b6c gav LivMXB 24m24 1.71gm* P<.6
c Nf b6c gav lunMXB 24m24 no dre P-1.
175 M m b6c gav TBAMXB 24m24 :> 864.mg* P<.7
a N m b6c gav LivMXB 24m24 no dre P-1.
b N m b6c gav Lun NXB 24m24 2.43gm* P<.8
176 Rf f34 gav Lun a/c 24m24 A 600.mg a P<.04 a
a Rf f34 gav forMXA 24m24 +historicaL * P<.09 a
b R f f34 gav TBAMXB 24.24 183.mg a P<.5
c R f f34 gav Liv NXB 24m24 2.46gm P<. 3
177 R mf34 gav MXBMXB 24m24s + 105.mg/ P<.0005
a R mf34 gav LunMXA 24.24s 139..g/ P<.0005c
b R mf34 gav Lun a/c 24m24s 167.mg/ P<.0005c
c R m f34 gav forMXA 24m24s 577.mg * P<.002 c
d R m f34 gav Lun a/a 24m24 a 903.mg* P<.006 c
a R m f34 gav Lun sqc 24m24s 951.mg * P<.006 c
f R sf34 gav for sqp 24m24s 990.mg * P<.03 c
g R m f34 gav forsqc 24m24s 1.42gm* P<.03 c
h R m f34 gav TBAMXB 24.24s 119.mg * P<.04
R f34 gav LivMXB 24m24s no dre P.1.
DIMETHYL MORPHOLINOPHOSPHORAMIDATE ..:..lug. 1 :10 : . 100. 1g : . 1. :10 :..100.1:0 1 :10
178 N f b6c gav TBAMXB 24m24s :> no dre P-1. -
a M f b6c gav LivMXB 24m24s no dre P-1.
b N f b6c gav LunMXB 24m24s 17.6gm * P<.9
179 N m b6c gav TBAMXB 24.24 :> no dre P-1. -
a N m b6c gav LivMXB 24.24 1.27gm * P<.4
b N m b6c gav Lun NXB 24.24 3.90gm * P<.8
180 R f f34 gav -- nL 24.24s a 788.mg* P<.02 a
a R f f34 gav TBAMXB 24m24s 774.mg * P<.3
b R f f34 gav LivMXB 24.24 a 8.24g * P<.2
* +SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
165 16510 .345mg 2.45mg
a 1651o .376mg 3.31mg
b 1651o 1.37mg n.s.s.
c 16510 2.49mg n.s.s.
d 16510 4.30mg n.s.s.
166 1651n 1.52mg n.s.s.
a 1651n 1.52mg n.s.s.
b 1651n 3.47mg n.s.s.
c 1651n 4.31mg n.s.a.
167 1651n 1.44mg 13.4mg
a 1651n 1.62mg 22.8mg
b 1651n 3.16mg n.s.s.
c 1651n 4.26mg n.s.s.
d 1651n 8.00mg n.s.s.

















































168 c54944 335.mg n.s.s. 0/50 42.0mg 0/50 84.1mg
a c54944 120.mg n.s.s. 32/50 42.0mg 28/50 84.1mg
b c54944 319.mg n.s.a. 4/50 42.0mg 5/50 84.1mg
c c54944 306.mg n.s.s. 3/50 42.0mg 4/50 84.1mg
169 c54944 245.mg n.s.s. 0/50 42.0mg 1/50 84.1mg
a c54944 109.mg n.s.s. 38/50 42.0mg 32/50 84.1mg
b c54944 93.2mg n.s.s. 19/50 42.0mg 14/50 (84.1mg
c c54944 130.mg n.s.s. 8/50 42.0mg 8/50 84.1mg
170 c54944 57.8mg n.s.s. 39/50 42.0mg 40/50 84.9mg
a c54944 269.mg n.s.s. 1/50 42.0mg 1/50 84.9mg
171 c54944 22.1mg n.s.s. 47/50 42.2mg 49/50 84.9mg
a c54944 34.0mg n.s.s. 33/50 42.2mg 38/50 84.9mg















172 1638 386.mg 2.959m
a 1638 471.mg 39.9gm
b 1638 118.mg n.s.s.
c 1638 871.mg n.s.s.
d 1638 1.169m n.s.s.
173 1638 398.mg 2.78gm
a 1638 507.mg n.s.s.
b 1638 122.mg n.s.s.
c 1638 847.mg n.s.s.





















DIMETHYL HYDROGEN PHOSPHITE (DMHP) 868-85-9
174 c54773 117.mg 2.00gm
a c54773 145.mg n.s.s.
b c54773 331.mg n.s.s.
c c54773 839.mg n.s.s.
175 c54773 124.mg n.s.s.
a c54773 277.mg n.s.s.
b c54773 251.mg n.s.s.
176 c54773 207.mg n.s.s.
a c54773 312.mg n.s.s.
b c54773 42.8mg n.s.s.
c c54773 401.mg n.s.s.
177 c54773 68.4mg 172.mg
a c54773 85.7mg 246.mg
b c54773 98.8mg 311.mg
c c54773 248.mg 2.58gm
d c54773 339.mg 8.99gm
c54773 358.mg 3.71gm
f c54773 342.mg n.s.s.
g c54773 426.mg n.s.s.
h c54773 52.0mg n.s.s.




















































































































178 c54740 493.mg n.s.s. 31/50
a c54740 2.18gm n.s.s. 7/50
b c54740 1.34gm n.s.s. 4/50
179 c54740 247.mg n.s.s. 26/50
a c54740 310.mg n.s.s. 11/50
b c54740 458.mg n.s.s. 6/50
180 c54740 362.mg n.s.s. 9/50
a c54740 229.mg n.s.s. 35/50
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181 R m f34 gay --- mnL 24.24
a R m f34 gay tes ict 24.24
b R m f34 gay TBA MXB 24.24
c R m f34 gay Liv MXB 24.24




N,N-DIMETHYLDODECYLANINE-N-OXIDE lOOng..:. .lug.....10 ...:.100... lu.g...:.10 ....100...:.Ig ...:.10
182 R f f34 wet Liv nnd 22.30 e .> no dre
183 R m f34 wet Liv mix 22.30 e .> 231.mig
a R m f34 wet Liv nnd 22.30 e 496.mug





2,4-DINITROPHENOL, SODIUM bOOng. .: ..lug...:.10 ...:.100...:.lug.....10 ...:.100...I:g....-10
184 M f dbx eat ugi car 90w90 er .> no dre P-1.
1,4.DINITROSO-2,6-DIMETHYLPIPERAZINE . .:..lug...:.10 ...:.100...:.lug.....10 ...:.100...: g ...:.10
185 H m syg gay for pa. 35w76 A 3.10mg
a H m syg gay Lun ade 35w76 6.04mg
b H m syg gay Liv ang 35w76 8.30mg





DIPHENHYDRAMINE.HCL lOOng.. :. .lug...:.10 ...:.100... l.g...:.10 ...:.100...I:g ...:.10
186 R f f34 eat Liv nnd 25m30 a .> no dre P-I. -
187 R m f34 eat Liv nnd 25m30 e .> no dre P-I. -
DIPYRONE
188 N f b6c wet
a f b6c wat
189 M m b6c wet
ENFLURANE
190 N f sic inh
a M f sic inh
191 M f sic inh
a M f sic inh
192 N m sic inh
a N m sic inh
193 N m sic inh
a N m sic inh
lOOng. .: ..lug...:.10 ...:. 100. 1. : mg.....10 ...:. 100...: g ...:. 10
Liv mix 75w86 aee + .742.mg IP<.0005+
Liv hpc 75w86 as 7.12gm *P<.02
Liv mix 77w86 ase + 547.mg *P<.0005+
lOOng..:. .lug...:.10 ...:.100. 1.:mg.....10 ...:.100...:.Ig ...:.10
Lun ads 52w52 ek .> 8.93gm P<.4 -
Liv tum 52w52 ek no dre P-I. -
Lun ads 78w82 s .>18.9gm P<.2 -
Liv mix 78w82 a no dre P-I. -
Liv mix 52w52 ek *8.12gm P<.1 -
Lun ads 52w52 ek no dre P-I. -
Liv mix 78w82 ae 11.7gm P<.1 -
Lun ads 78w82 e 60.9gm P<.8 -
EPHEDRINE SULPHATE
194 M f b6c seat TBA NXB 24m24
a M f b6c eat Liv MXB 24m24
b M f b6c eat Lun MXB 24m24
195 M m b6c eat MXA MXA 24m24
a N m b6c eat TBA MXB 24m24
b M m b6c sat Liv MXB 24m24
c N m b6c sat Lun MXB 24m24
196 R f f34 sat TBA MXB 24m24
a R f f34 eat Liv MXB 24m24
197 R m f34 eat TBA MXB 24m24
a R m f34 eat Liv MXB 24m24
ERYTHORBATE, SODIUM
198 R f f3d wet Liv hpa 24m26 a
a R f f3d wet tba mix 24m26 a
199 R m f3d wet Liv hpa 24m26 a
a R m f3d wet tba mix 24m26 e
lOOng.. :. .lug... .10 ....100...1:.mg... .10 ...:.100...I:.g ....10
:> ~~~~~259.mg * P<.9
no dre P-I.
789.mg * P<.6




:> ~~~~~no dre P-1. -
no dre P-I.
:> ~~~~~no dre P-I. -
166.mg * P<.7
lOOng.. :. .lug... .10 ...:.100...1:.mg... .10 ...:.100...I:.g ....10
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
ESTRAGOLE bOOng. .: . .ug...:.10 ....100. 1. : mg.....10 ...:.100...:.Ig ...:.10
200 N f cdl sat Liv hpt 51w86 v . +. 51.8mg * P<.0005+
a M f cdl eat Lun ads 51w86 v no dre P-I.
ETHOXYQUIN lOOng. .:. .lug...:.10 ...:.100...1:mg...:.10... .100....Ig ...:.10
201 R m f34 eat Liv tum 60w60 or .> no dre P-I.
ETHYL ALCOHOL*** lOOng. .: ..lug...:.10 ...:.100. 1mg . 10 . :.100...:. lg ...:.10
202 M f c3s wet main adc 86w86 r no dre P-I.
1-ETHYL-I1-NITROSOUREA
203 R f f3d wet - -- mnL
a R f f3d wet ut easp
b R f f3d wet bra mix
c R f f3d wet mgL adc
d R f f3d wet utm sar
a R f f3d wet dgt mix
f R f f3d wet duo mix
g R f f3d wet ute ads
lOOng..:. .lug...:.10 ....100. 1. :mg... 10. 100...:.o...:.Ig.10.:.l
24m26 ae .+ ..151mg Z
24m26 as .883mg *
24m26 as .904mg *
24m26 as 2.54mg *
24m26 as 2.56mg *
24m26 as 2.56mg *
24m26 as 7.68mg *








P<.1ISUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
181 c54740 247.mg 6.519m 14/50 105.mg 21/50 210.mg 19/50 420.mg 25/50
a c54740 124.mg n.s.s. 45/50 105.mg 45/50 210.mg 44/50 420.mg 46/50
b c54740 122.mg n.s.s. 49/50 105.mg 47/50 210.mg 48/50 420.mg 49/50
c c54740 880.mg n.s.s. 1/50 105.mg 3/50 210.mg 3/50 420.mg 3/50
N,N-DIMETHYLDODECYLAMINE-N-OXIDE
182 1654 107..g n.s.s. 4/24
183 1654 45.1mg n.s.s. 3/24
a 1654 61.5mg n.s.s. 2/24















185 1570 1.17mg n.s.s. 3/20 3.68mg 9/20
a 1570 2.08mg n.s.s. 0/20 3.68mg 4/20
b 1570 2.50mg n.s.s. 0/20 3.68mg 3/20
c 1570 .448mg 2.63mg 3/20 3.68mg 16/20
DIPHENHYDRAMINE.HCL 147-24-0
186 1654 277.mg n.s.s. 4/24
187 1654 193.mg n.s.s. 5/24
DIPYRONE (suLpyrin) 68-89-3
188 1545 484.mg 1.22gm 3/51
a 1545 2.77gm n.s.s. 1/51
189 1545 300.mg 1.79gm 8/44
ENFLURANE 13838-16-9
190 1677m 1.84gm n.s.s.
a 1677m 6.11gm n.s.s.
191 1677n 6.69gm n.s.s.
a 1677n 56.1gm n.s.s.
192 1677m 2.009m n.s.s.
a 1677m 3.10gm n.s.s.
193 1677n 4.41gm n.s.s.









Lij insky;fctx,22,715-720; 1984 82.5mg 3/24
66.0mg 4/24
Kumagai;jnci ,71,1295-1297;1983 448.mg 3/47 1.71gm 36/44
448.mg 1/47 1.71gm 6/44
189.mg 16/46 746.mg 27/48









194 c55652 19.8mg n.s.s. 43/50
a c55652 67.6mg n.s.s. 9/50
b c55652 132.mg n.s.s. 1/50
195 c55652 79.1mg n.s.s. 0/50
a c55652 27.8mg n.s.s. 38/50
b c55652 37.9mg n.s.s. 19/50
c c55652 98.7mg n.s.s. 9/50
196 c55652 13.6mg n.s.s. 45/50
a c55652 98.6mg n.s.s. 2/50
197 c55652 8.33mg n.s.s. 43/50
a c55652 21.5mg n.s.s. 3/50
16.1mg 45/50 32.2mg 41/50
16.1mg 3/50 (32.2mg 3/50)
16.1mg 1/50 32.2mg 2/50
14.9mg 2/50 29.7mg 4/50
14.9mg 31/50 29.7mg 36/50
14.9mg 18/50 29.7mg 21/50
14.9mg 11/50 29.7mg 4/50
6.19mg 43/50 12.4mg 45/50
6.19mg 2/50 12.4mg 0/50
4.95mg 47/50 9.90mg 45/50
4.95mg 5/50 9.90mg 5/50
L iv:hpa,hpc,nnd.
Lun:a/a,a/c.





ERYTHORBATE, SODIUM (isoascorbate) 6381-77-7
198 1736 15.5gm n.s.s. 1/48 663.mg 1/49 1.33gm 0/45
a 1736 1.69gm n.s.s. 45/48 663.mg 43/49 1.33gm 35/45
199 1736 12.5gm n.s.s. 1/49 580.mg 0/48 1.16gm 1/50
a 1736 n.s.s. n.s.s. 49/49 580.mg 48/48 1.16gm 50/50
ESTRAGOLE 140-67-0
200 1582 37.3mg 74.3mg 0/50 74.2mg 27/50 148.mg 35/50
a 1582 666.mg n.s.s. 2/50 74.2mg 1/50 148.mg 2/50
ETHOXYQUIN 91-53-2
201 1640 343.mg n.s.s. 0/25 200.mg 0/25
ETHYL ALCOHOL*** 64-17-5
202 1632 15.3gm n.s.s. 23/30 24.0gm 8/15
1-ETHYL-1-NITROSOUREA (ENU, N-ethyl-N-nitrosourea) 759-73-9
203 1614 90.2ug .351mg 5/52 12.Oug 8/51 40.2ug 18/52
a 1614 .419mg 6.46mg 9/52 12.Oug 10/51 40.2ug 16/52
b 1614 .544mg 1.66mg 0/52 12.Oug 0/51 40.2ug 0/52
c 1614 1.12mg 12.3mg 1/52 12.Oug 1/51 40.2ug 1/52
d 1614 1.10mg 18.2mg 2/52 12.Oug 1/51 40.2ug 1/52
1614 1.10mg 18.2mg 2/52 12.Oug 1/51 40.2ug 1/52
f 1614 2.32mg 106.mg 0/52 12.Oug 0/51 40.2ug 0/52





























Maekawa;gann,75, 117- 125; 1984
269270 GOLD ETAL.
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
h R f f3d wat tyf ppa 24.26 ae
i R f f3d wat Liv nnd 24.26 ae
j R f f3d wat tba mix 24.26 ae
204 R m f3d wat per mso 23.26 ae
a R m f3d wat Lun ade 23.26 ae
b R m f3d wat mgl fib 23.26 ae
c R m f3d wat bra mix 23.26 ae
d R m f3d wat dgt six 23.26 ae
e R m f3d wat Lun adc 23.26 ae
f R m f3d wat sub fib 23.26 ae
9 R m f3d wat tyf ppa 23.26 ae
h R a f3d wat tyf pac 23.26 ae
i R m f3d wat pns mix 23.26 ae
; R o f3d wat Liv nnd 23.26 ae
k R m f3d wat duo mix 23.26 ae











3.90mg * P<.05 +
8.53mg * P<.09 +
10.2mg * P<.4 +
16.4mg * P<.7
31.2mg * P<.5 +
25.Oug * P<.3
ETHYLENE OXIDE*** 100ng..:. .1ug. 1 :10 :..100 :.1mg.:10. 1 :100.. : . :10
205 R m f3h inh per mso 23,24 eis pool .(+) . 30.8mg * P<.0005+
a R m f3h inh bra gLi 23m24 eis 121.mg * P<.01 +
b R m f3h inh spL mnL 23m24 eis 47.3mg * P<.3 +
c R m f3h inh Liv nnd 23.24 eis no dre P-1.
206 R f fmf inh pit mde 76w78 ikr pooL . (W) 29.8mg P<.08 -
a R f fmf inh bra mix 76w78 ikr 237.mg * P<.6 +
207 R f fmf inh bra mix 23m24 ir pooL . (*) 143.mg * P<.02 +
208 R m fmf inh adr phe 76w78 ikr pooL . (*) 26.1mg P<.08 -
a R m fmf inh bra ast 76w78 ikr 102.mg * P<.7 +
b R m fmf inh pit ade 76w78 ikr no dre P-1. -
c R m fmf inh tes ict 76w78 ikr no dre P-1. -
209 R m fmf inh bra mix 24m25 ir pool . (+) . 70.7mg * P<.002 +
EUGENOL
210 N f b6c eat liv MXA 24m24
a N f b6c eat TBA MXB 24m24
b N f b6c eat liv MXB 24m24
c N f b6c eat lun MXB 24m24
211 N m b6c eat liv MXA 24m24
a N m b6c eat liv hpc 24m24
b N m b6c eat liv hpa 24m24
c N m b6c eat thy fca 24m24
d M m b6c eat TBA NXB 24m24
a M m b6c eat Liv NXB 24m24
f M m b6c eat Lun MXB 24m24
212 M f cdl eat Lun ada 50w78 v
a M f cdl eat Liv tum 50w78 v
213 R f f34 eat TBA MXB 24m24
a R f f34 eat Liv MXB 24m24
214 R m f34 eat Lun MXA 24m24
a R m f34 eat TBA NXB 24m24
b R m f34 eat liv MXB 24m24
FENVALERATE
215 R f sda eat mgL fib 24m24 e
a R f sda eat mai ben 24m24 o
b R f sda eat mgL fba 24m24 o
c R f sda eat mai maL 24m24 e
216 R f sda eat mas ben 24m24 e
a R f sda eat Liv rcs 24m24 e
b R f sda eat mai maL 24m24 e
217 R i sda eat sub fbs 24m24 o
218 R ada eat sub scs 24.24 e
FLECAINIDE ACETATE
219 N f cdl eat Lun ado 78w78 e
a N f cdl eat Liv ado 78w78 o
220 N cdl eat Lun ade 78w78 e
a N cdl eat Liv ada 78w78 e
b N cdl eat Liv hpc 78w78 e
221 R f crw eat Liv ade 24m24 e
222 R i crw eat tes ica 24m24 e
a R i crw eat Liv ado 24a24 e
lOOng..:. .ug.:10. :100. g :. 1g :10. :100.:Ig. :10




451.mg \ P<.02 a
710.mg \ P<.03 e






no dre P-1. -
no dre P-I.
no dre P-1.
A #424.mg \ P<.02 -
293.mg \ P<.5
no dre Pa1.
lOOng .. : ..ug.:10. :100. g :.g :10..:100.. g . 10
A 2.55mg Z P<.02 -
43.7mg * P<.2 -
58.0mg * P<.3 _
150.mg * P<.5 -
247.mg P<.4 -
no dre PI. -
no dre P-I.
+ . 5.04mg Z P<.003 -
+ . 266.mg P<.009 -
bO0ng.. : .ug.:10. :100. g :.lg :10. :100.. : g. :10
938.mg * P<.7 -
no dre P-I.
no dre PI. 1
no dre Pl. 1
no dre P-1.
no dre P-I.
79.1mg * P<.004 -
3.58gm * P<.2 -
FLUORIDE, SODIUM*** 1 OOng..:. . lug. 1 : 10 :..100. 1mg : .. : 10 :..100..:. 1 : 10
223 N f dbx eat mgt car 90w90 or .> no dre P-I.SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
h 1614 2.35mg n.s.s.
i 1614 4.88mg n.s.s.
j 1614 32.6ug .202mg
204 1614 71.Oug .200mg
a 1614 .326mg .976mg
b 1614 .460mg 3.25mg
c 1614 .588mg 1.90mg
d 1614 .629mg 2.84mg
e 1614 .942mg 7.80mg
f 1614 .961mg n.s.s.
9 1614 1.29mg n.s.s.
h 1614 2.27mg n.s.s.
i 1614 2.34mg n.s.s.
j 1614 1.73mg n.s.s.
k 1614 3.55mg n.s.s.



















































































































205 1624 18.3mg 77.8mg 3/78p 5.42mg
a 1624 52.3mg 4.81gm 0/76p 5.42mg
b 1624 14.3mg n.s.s. 24/77p 5.42mg
c 1624 88.2mg n.s.s. 2/78p 5.42mg
206 1666m 8.48mg n.s.s. 2/40p 13.3mg
a 1666m 24.7mg n.s.s. 1/40p 1.31mg
207 16660 61.7mg n.s.s. 0/154p 1.31mg
208 1666m 6.94mg n.s.s. 1/40p 9.29mg
a 1666m 16.5mg n.s.s. 0/40p .920mg
b 1666m 9.53mg n.s.s. 7/40p 9.29mg
c 1666m 2.56mg n.s.s. 35/40p 9.29mg














210 c50453 1.299m n.s.s. 2/50 383.mg 7/50 773.mg
a c50453 1.12gm n.s.s. 27/50 383.mg 22/50 773.mg
b c50453 1.29gm n.s.s. 2/50 383.mg 7/50 773.mg
c c50453 2.22gm n.s.s. 4/50 383.mg 6/50 773.mg
211 c50453 208.mg 124.gm 14/50 353.mg 28/50 (713.mg
a c50453 298.mg n.s.s. 10/50 353.mg 20/50 (713.mg
b c50453 336.mg n.s.s. 4/50 353.mg 13/50 (713.mg
c c50453 2.58gm n.s.s. 0/50 353.mg 0/50 713.mg
d c50453 464.mg n.s.s. 27/50 353.mg 36/50 713.mg
c50453 208.mg 124.gm 14/50 353.mg 28/50 (713.mg
f c50453 1.77gm n.s.s. 13/50 353.mg 8/50 713.mg
212 1582 370.mg n.s.s. 1/30 176.mg 1/30
a 1582 612.mg n.s.s. 0/30 176.mg 0/30
213 c50453 723.mg n.s.s. 33/40 294.mg 41/50 619.mg
a c50453 n.s.s. n.s.s. 0/40 294.mg 0/50 619.mg
214 c50453 158.mg n.s.s. 0/40 118.mg 5/50 (238.mg
a c50453 62.8mg n.s.s. 30/40 118.mg 40/50 (238.mg


































FENVALERATE (cyano-(3-phenoxyphenyt)methyl-4-chtoro-alpha-(1-mothylethyL)benzene acetate) 51630-58-1
215 1650m .882mg n.s.s. 0/102 50.Oug 1/51 .250mg 3/51 (1.25mg 1/51 12.5mg 0/48)
a 1650m 14.0mg n.s.s. 25/102 50.Oug 16/51 .250mg 18/51 1.25mg 21/51 12.5mg 20/48
b 1650m 15.8mg n.s.s. 25/102 50.Oug 18/51 .250mg 18/51 1.25mg 19/51 12.5mg 19/48
c 1650m 26.2mg n.s.s. 18/102 50.Oug 9/51 .250mg 11/51 1.25mg 9/51 12.5mg 11/48
216 1650n 60.6mg n.s.s. 16/50 50.0mg 20/49
a 1650n 505.mg n.s.s. 1/50 50.0mg 0/49
b 1650n 179.mg n.s.s. 10/50 50.0mg 7/49
217 1650m 2.18mg 38.3mg 0/103 40.Oug 1/51 .200mg 3/51 1.00mg 5/51 (10.0mg 0/51)
218 1650n 101.mg 6.25gm 0/50 40.0mg 5/51
FLECAINIDE ACETATE (2,5-bis(2,2,2-triftuorethoxyL)-N-(2-piperidyLmmthyL)benzamide acetate) 54143-56-5
219 1649n 136.mg n.s.s. 5/69 15.0mg 5/69 30.0mg 7/68 60.0mg 6/67
a 1649n 68.0mg n.s.s. 1/69 15.0mg 0/69 30.0mg 0/68 60.0mg 0/67
220 1649n 165.mg n.s.s. 10/67 15.0mg 7/69 30.0mg 7/69 60.0mg 7/60
a 1649n 269.mg n.s.s. 10/67 15.0mg 4/69 30.0mg 5/69 60.0mg 4/60
b 1649n 584.mg n.s.s. 2/67 15.0mg 0/69 30.0mg 1/69 60.0mg 0/60
221 1649m 820.mg n.s.s. 2/49 15.0mg 0/50 30.0mg 1/50 60.0mg 0/50
222 1649m 40.8mg 561.mg 19/50 15.0mg 16/50 30.0mg 23/50 60.0mg 32/50
a 1649m 583.mg n.s.s. 0/50 15.0mg 0/50 30.0mg 0/50 60.0mg 1/50
FLUORIDE, SODIUM*** 7681-49-4








Brkly Code272 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
FLUOROCARBON 31
224 R f aap gav sto mix
a R f aap gav sto sqc
b R f aap gav sto fbs
c R f aap gav sto car
d R f aap gav sto sar
225 R m aap gav sto mix
a R m aap gav sto sqc
b R m aap gav sto fbs
TD50 2TaiLpvl
DR AuOp
lOOng..: ..ug.:10. :100..:lg.:10. :100..:g. :10





12m23 a pooL . + . 28.5mg
12.23 a 46.9mg
12.23 a 88.1mg
FLUOROCARBON 133a lOOng ... .lug.:10. :100. 1m : g.:10. : 100.. : g. :10
226 R f aap gav ute adc 12m29 a pool . + . 160.mg












228 M f b6c
a M f b6c
b M f b6c
229 N f b6c
a M f b6c
b M f b6c
230 M f b6c
a M f b6c
b M f b6c
231 M f b6c
a M f b6c
b M f b6c
232 M m b6c
a M m b6c
b M m b6c
233 N m b6c
a N m b6c
b M m b6c
234 R f f34
a R f f34
235 R f f34
a R f f34
b R f f34
236 R f f34
a R f f34
b R f f34
237 R m f34
a R m f34
238 R m f34
a R m f34
b R m f34
239 R m f34
a R m f34
b R m f34
FUSARENON-X
240 R m don
a R m don
241 R m don
a R m don
inh nas tum 52w52 ek
inh lun tum 52w52 ek
inh liv tum 52w52 ek
inh nas tum 78w78 ek
inh Liv mix 78w78 ek
inh Lun tum 78w78 ek
inh Lun mix 24.24 ok
inh Liv mix 24m24 ek
inh nas tum 24m24 ek
inh nas tum 24m27 a
inh Lun mix 24m27 a
inh Liv tum 24m27 a
inh Liv hpc 52w52 ek
inh Lun tur 52w52 ek
inh nas tum 52w52 ek
inh ntu sqc 24m24 es
inh Liv mix 24m24 es
inh Lun mix 24m24 es
inh nas tum 52w52 ek
inh Liv tur 52w52 ek
inh ntu sqc 78w78 ek
inh Liv nnd 78w78 ek
inh ntu pLa 78w78 ek
inh ntu sqc 25m25 s
inh ntu pLa 25m25 s
inh Liv nnd 25m25 es
inh nas tur 52w52 ek
inh Liv tur 52w52 ek
inh ntu sqc 78w78 ek
inh ntu pLa 78w78 ek
inh Liv tur 78w78 ek
inh ntu sqc 24.24 s
inh ntu pla 24.24 s






242 M m cbL eat Liv tur
a N m cbL eat Lun tur
b M m cbL eat tba tur





















+ . 3.67mg * P<.005 +
192.mg P<1.
no dre P-1.





+ . 2.57mg * P<.005 +
5.39mg * P<.2
no dre P-1.
:+: .798mg Z P<.0005+
3.01mg * P<.03
no dre P-1.
lOOng.. : ..lug.:10. :100..: mg.:10. :100.:Ig. :10
24.24 * .> no dre
24m24 e no dre
18m24 ae .> no dre
18m24 ae no dre
lOOng .. : ..Iug.:10. :100.:g.:10. :100.:g..:10
24.24 e .> no dre
24.24 e no dre








NEXACHLOROCYCLOHEXANE lOOng .:..Iug.:10. :100. 1m :g.:10. :100.:Ig. :10
243 N m swi eat Liv hpc 52w52 kr . 25.3mg P<.05 +
HYDRAZINE SULFATE*** 0 OOng. ... : 1ug .1.0.: 100. g :.. :10. 1 :100.. : . :10
244 M b swi gav lun adc 95w95 r .+ . 9.81mg P<.0005+
N-HYDROXY-2-ACETYLANINOFLUORENE*** .. : .ug..:.1 : 00 :.1mg. : 10. :100.1:0 1 :10
245 M f ddd eat for mix 30w76 a . + . 6.23mg
a M f ddd eat ubl mix 30w76 a 7.32mg
b N f ddd eat liv hpt 30w76 e 16.0mg
c N f ddd eat ubL epc 30w76 e 16.0mg
d M f ddd eat eso ept 30w76 e 28.8mg
a N f ddd eat k/p apt 30w76 e 164.mg







P-1. -SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrt IDose lInc 2Dose 2Inc
FLUOROCARBON 31 (chtorofLuoromethane) 593-70-4
224 1623 14.0mg 48.8mg 1/104p 103.mg 34/36
a 1623 41.4mg 126.mg 0/104p 103.mg 24/36
b 1623 66.8mg 242.mg 0/104p 103.mg 17/36
c 1623 441.mg n.s.s. 0/104p 103.mg 1/36
d 1623 441.mg n.s.s. 0/104p 103.mg 1/36
225 1623 16.0mg 51.3mg 1/104p 111.mg 33/36
a 1623 28.2mg 82.9mg 0/104p 111.mg 28/36
b 1623 50.8mg 171.mg 1/104p 111.mg 20/36
FLUOROCARBON 133a (2-chloro-1,1,1-trifLuoroethane) 75-88-7
226 1623 86.4mg 351.mg 1/104p 89.1mg 15/35






228 1566a .271mg n.s.s.
a 1566a 2.98mg n.s.s.
b 1566a 2.98mg n.s.s.
229 1566b 1.21mg n.s.s.
a 1566b 8.42mg n.s.s.
b 1566b 12.8mg n.s.s.
230 1566c 10.9mg n.s.s.
a 1566c 14.4mg n.s.s.
b 1566c 3.10mg n.s.s.
231 1566m 6.06mg n.s.s.
a 1566m 44.5mg n.s.s.
b 1566m 72.5mg n.s.s.
232 1566a 1.28mg n.s.s.
a 1566a 2.49mg n.s.s.
b 1566a .226mg n.s.s.
233 1566c 10.8mg n.s.s.
a 1566c 9.67mg n.s.s.
b 1566c 6.53mg n.s.s.
234 1566n 64.6ug n.s.s.
a 1566n .710mg n.s.s.
235 15660 1.27mg 33.9mg
a 1566o 1.81mg n.s.s.
b 15660 3.23mg n.s.s.
236 1566r .952mg 2.06mg
a 1566r 1.25mg n.s.s.
b 1566r 4.13mg n.s.s.
237 1566n 45.2ug n.s.s.
a 1566n .497mg n.s.s.
238 15660 .886mg 23.8mg
a 15660 1.32mg n.s.s.
b 15660 2.24mg n.s.s.
239 1566r .510mg 1.23mg
a 1566r 1.10mg n.s.s.
b 1566r 2.85mg n.s.s.
FUSARENON-X 23255-69-8
240 1748m .319mg n.s.s.
a 1748m .684mg n.s.s.
241 1748n .218mg n.s.s.
a 1748n .464mg n.s.s.
L-GLUTAMIC ACID 56-86-0
242 1631 4.06gm n.s.s.
a 1631 4.06gm n.s.s.










































.772mg 0/10 2.32mg 0/10 5.79mg 0/10
5.79mg 0/10
5.79mg 0/10





.772mg 0/26 2.32mg 0/41 5.79mg 0/28





.644mg 0/10 1.93mg 0/10 4.83mg 0/10
.644mg 0/22 1.93mg 0/19 4.83mg 2/17
4.83mg 6/40
4.83mg 4/18
.184mg 0/10 .552mg 0/10 1.38mg 0/10
1.38mg 0/10
.184mg 0/20 .552mg 0/20 1.38mg 4/19
1.38mg 1/19
.184mg 1/20 .552mg 0/20 1.38mg 0/19
.184mg 0/79 .552mg 1/76 1.38mg 48/73
.184mg 3/79 .552mg 0/76 1.38mg 1/73
1.38mg 0/14
.129mg 0/10 .386mg 0/10 .965mg 0/10
.965mg 0/10
.129mg 0/20 .386mg 0/20 .965mg 4/19
.129mg 0/20 .386mg 1/20 .965mg 1/19
.965mg 0/20
.129mg 0/80 .386mg 1/79 .965mg 47/73
.129mg 4/80 .386mg 5/79 .965mg 3/73
.965mg 1/22
100.ug 0/22 .210mg 0/25
100.ug 3/22 .210mg 2/25
100.ug 0/24 .105mg 0/18
100.ug 2/24 .105mg 1/18
Pavkov;cii t; 1981/Kerns 1983
Saito;jjem,50,293-302;1980/Ohtsubo pers.comm.
1.209m 0/20 4.80gm 0/29
1.20gm 0/20 4.809m 0/29
1.20gm 0/20 4.80gm 0/29
HEXACHLOROCYCLOHEXANE 608-73-1
243 1744 10.9mg n.s.s. 0/6
HYDRAZINE SULFATE*** 10034-93-2
244 1552 6.55mg 15.7mg 1/20
60.0mg 7/21 Kandarkar; i jor,78, 155-161; 1983
27.6mg 51/63 Menon;zkko, 105,258-261; 1983
N-HYDROXY-2-ACETYLANINOFLUORENE*** (hydroxy-N-2-ftuorenyLacetamide) 53-95-2
245 1628 3.08mg 14.3mg 0/16 25.6mg 14/18
a 1628 3.62mg 17.1mg 0/16 25.6mg 13/18
b 1628 7.10mg 52.5mg 0/16 25.6mg 8/18
c 1628 7.10mg 52.5mg 0/16 25.6mg 8/18
d 1628 10.9mg 632.mg 0/16 25.6mg 5/18
a 1628 26.7mg n.s.s. 0/16 25.6mg 1/18
f 1628 34.0mg n.s.s. 2/16 25.6mg 1/18
273
Ebert;txtt,3,65-70;1979
Enomoto; j jem,44,37-54; 1974GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
1'-HYDROXYESTRAGOLE 1 OOng..:..iug. :10. :100.:g :10. :100.. :. :10
246 N f cdl eat Liv hpt 51w86 v . + . 57.8mg P<.0005+
a N f cdl eat Lun ade 51w86 v no dre P-1.
8 HYDROXYQUINOLINE***
247 M f b6c eat --- MXA
a N f b6c eat TBA MXB
b N f b6c eat liv MXB
c N f b6c eat lun MXB
248 N b6c eat TBA MXB
a N b6c eat liv MXB
b N b6c eat lun MXB
249 R f f34 eat TBA MXB
a R f f34 eat liv MXB
250 R m f34 eat lun MXA
a R f34 eat thy ccr
b R m f34 eat TBA MXB















251 f b6b eat liv hpt 52w69 ev
252 N f b6n eat liv hpt 52w69 ev
253 N f cdl eat Liv hpt 52w69 mv
a N f cdl eat Lun ada 52w69 ov
lOOng .:ug. :10. :100.:1g. :10. :100. :Ig :10




:> no dre P-1.
17.7gm P<l.
2.77gm P<.6
:> 434.mg 9 P<.6 -
no dre P-1.




1O0ng..: ..ug. :.10. :100.:lg. :10. :100. :Ig :10
1.53gm * P<.3
+ . 53.3mg * P<.0005+
49.1mg * P<.0005+
3.67gm * P<.9
ISONIAZID*** 1O0ng..:. lug.:10 : 100. 1. : 1. :10 :.100.1 :0 :10
254 N b swi gav Lun adc 95w95 r . + . 28.8mg P<.0005+
ISONICOTINAMIDE
255 N f swa wat liv hpt 28e28
a N f swa wat Lun mix 28m28 a
256 N swa wat lun mix 27m27 a
a N m swa wat liv mix 27m27
ISOPHORONE
257 N f b6c gav TBA NXB 24m24
a N f b6c gav Liv MXB 24m24
b N f b6c gav lun MXB 24m24
258 N m b6c gav --- mLh 24m24 s
a N m b6c gav ... MXA 24m24 s
b N m b6c gav -- MXA 24m24 s
c N m b6c gav sub MXA 24m24 s
d N b6c gav sub MXA 24m24
N m b6c gav sub fbs 24m24 s
f M m b6c gav sub fib 24m24 s
g M m b6c gav Liv MXA 24m24 s
h N m b6c gav MXA MXA 24m24 s
i N m b6c gav NXA NXA 24m24 s
j N m b6c gav NXA NXA 24m24
k M m b6c gav sub MXA 24m24 s
L N m b6c gav TBA NXB 24m24 s
M m b6c gav Liv MXB 24m24 s
n N m b6c gav Lun MXB 24m24 s
259 R f f34 gav TBA MXB 24m24 s
a R f f34 gav liv NXB 24m24 s
260 R f34 gav NXB NXB 24m24
a R m f34 gav kid MXA 24m24
b R m f34 gav pro can 24m24
c R m f34 gav TBA MXB 24m24
d R m f34 gav Liv MXB 24m24
lOOng. : ..ug. :10. :100. :. .. :10. :100.. : :10
.> 21.3gm P<.2 -
no dre P-1.
.> no dre P-1.
no dre P-1.
lOOng.. : ..ug. :10. :100.. : mg. :10. :100.. : g :10
:> no dre P-1.
2.749m * P<.5
no dre P-1.















:> 16.6gm * P<I. -
no dre P-1.
+ 774.mg * P<.0005
1.219m * P<.008 a
2.25gm * P<.005 a
237.mg * P<.05
9.08gm * P<.9
KAEMPFEROL 1OOng.. : ..ug. :10. :100. : :10 : 100..:.19 :10
261 R f aci eat tba aix 77w77 .> 55.3mg P<.4
262 R m aci eat adr coa 77w77 . 17.9mg P<. 1
LOFEXIDINE.HCl lO0ng..:. .ug. :10. :100. : g :10. :100.. :g :10
263 R f lyv eat tba tum 52w52 o . 2.30mg \ P<.09 -
264 R lav eat tba tum 52w52 . 2.30mg \ P<.09 -
NELANINE
265 N f b6c mat
a N f b6c eat
b MNf b6c eat
266 N m b6c eat
a N m b6c eat







1O0ng. .ug :10. :100. :1mg.:10. :100.. :. :10
:> no dre P-1.
no dre P-1.
no dre P-1.
:> 3.209m * P<.7
4.379m * P<.6
no dre P-1.
274SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
1' -HYDROXYESTRAGOLE 51410-44-7
246 1582 35.2mg 104.mg 0/50 80.7mg 24/50
a 1582 383.mg n.s.s. 2/50 80.7mg 1/50
8-HYDROXYQUINOLINE*** (8-quinoLinoL) 148-24-3
247 c55298 305.mg n.s.s. 0/50
a c55298 172.mg n.s.s. 33/50
b c55298 1.36gm n.s.s. 5/50
c c55298 713.mg n.s.s. 2/50
248 c55298 373.mg n.s.s. 35/50
a c55298 478.mg n.s.s. 14/50
b c55298 550.mg n.s.s. 6/50
249 c55298 84.9mg n.s.s. 40/50
a c55298 552.mg n.s.s. 4/50
250 c55298 277.mg n.s.s. 0/50
a c55298 362.mg n.s.s. 0/50
b c55298 141.mg n.s.s. 43/50
c c55298 693.mg n.s.s. 7/50
1' t-HYDROXYSAFROLE*** 5208-87-7
251 1581n 404.mg n.s.s. 1/44
252 1581n 36.6mg 81.6mg 1/49
253 1581m 32.7mg 77.2mg 0/32
a 1581m 597.mg n.s.s. 0/32
ISONIAZID*** (INH) 54-85-3
254 1552 17.2mg 80.7mg 1/20
ISONICOTINAMIDE 1453-82-3
255 1732 3.47gm n.s.s. 0/28
a 1732 6.83gm n.s.s. 15/91
256 1732 5.77gm n.s.s. 22/88
a 1732 13.9gm n.s.s. 2/62
ISOPHORONE 78-59-1
257 c55618 136.mg n.s.s.
a c55618 604.mg n.s.s.
b c55618 1.88gm n.s.s.
258 c55618 109.mg 928.mg
a c55618 80.2mg n.s.s.
b c55618 85.7mg n.s.s.
c c55618 293.mg n.s.s.
d c55618 301.mg n.s.s.
e c55618 444.mg n.s.s.
f c55618 460.mg n.s.s.
g c55618 162.mg n.s.s.
h c55618 308.mg n.s.s.
i c55618 309.mg n.s.s.
j c55618 434.mg n.s.s.
k c55618 451.mg n.s.s.
l c55618 174.mg n.s.s.
c55618 162.mg n.s.s.
n c55618 1.39gm n.s.s.
259 c55618 192.mg n.s.s.
a c55618 1.45gm n.s.s.
260 c55618 378.mg 2.07gm
a c55618 492.mg 21.4gm
b c55618 818.mg 19.3gm
c c55618 99.5mg n.s.s.



























261 1662 6.92mg n.s.s. 1/22
262 1662 3.71mg n.s.s. 2/30
BrkLy Code
Mi ltler;canr,43, 1124-1134;1983
193.mg 5/50 (386.mg 1/50)
193.mg 30/50 (386.mg 25/50)
193.mg 2/50 386.mg 4/50
193.mg 5/50 386.mg 5/50
178.mg 35/50 357.mg 35/50
178.mg 15/50 357.mg 17/50
178.mg 10/50 357.mg 10/50
74.3mg 44/50 149.mg 45/50
74.3mg 2/50 149.mg 4/50
59.4mg 3/50 119.mg 4/50
59.4mg 0/50 119.mg 4/50
59.4mg 42/50 119.mg 36/50










135.mg 2/41 260.mg 3/42
135.mg 24/38 260.mg 27/38
135.mg 17/29 260.mg 25/32






















































































- - - :mLh,mLm,mtp.


















263 1668 .563mg n.s.s. 0/10 3.00mg 2/10 (8.00mg 0/20)
264 1668 .563mg n.s.s. 0/10 3.00mg 2/10 (8.00mg 0/20)
Tsai ;arzn,31,955-962; 1982
MELAMINE 108-78-1
265 c50715 804.mg n.s.s. 28/50
a c50715 2.61gm n.s.s. 4/50
b c50715 3.53gm n.s.s. 5/50
266 c50715 525.mg n.s.s. 23/50
a c50715 820.mg n.s.s. 12/50
b c50715 2.379m n.s.s. 5/50
287.mg 33/50 574.mg 26/50
287.mg 6/50 574.mg 2/50
287.mg 1/50 574.mg 3/50
265.mg 22/50 530.mg 20/50
265.mg 8/50 530.mg 12/50






Spa Strain Site Xpo+Xpt
Sex Route Hist Notes
267 R f f34 eat thy MXA 24m24
a R f f34 eat thy ccr 24.24
b
R f f34 eat TBA MXB 24.24
c
R f f34 eat liv MXB 24m24
268 R m f34 eat ubl MXA 24.24
a R m f34 eat ubl tcc 24.24
b R m f34 eat TBA MXB 24,24
c R m f34 eat liv MXB 24.24
TD50 2TaiLpvl
DR AuOp




+ 679.mg / P<.0005
735.mg / P<.002 c
149.mg * P<.04
no dre P-1.
2-MERCAPTOETHANESULFONATE, SODIUM lOOng..:. .lug. 1 : 10 :..100... g : .. : 10 :..100.. : 1g :..10
269 R m sda wat liv tur 9.24 .> no dre
a R m sda wat Lun tur 9.24 no dre




METHAPYRILENE.HCL lOOng.. u. : lug 10 . .. : 100.. g : . 1. :10 :..100..1:0 . :10
270 H m syg gav Liv nnd 58w61 .> 150.mg P<.4
a H m syg gav tba tum 58w61 no dre P-1.
271 R f f34 eat Liv mix 26.31 . + . 7.65mg * P<.0005+
a R f f34 eat Liv nnd 26m31 11.8mg * P<.0005
b R f f34 eat Liv hpc 26.31 61.6mg / P<.004 +
272 R m f34 eat Liv bsa 73w73 ekr <+ noTD50 P<.009 +
a R m f34 eat Liv esa 73w73 ekr noTD50 P<.009 +
b R m f34 eat Liv hpc 73w73 ekr 14.7mg P<.02 +
c R m f34 eat Liv hps 73w73 ekr 26.4mg P<.08 +
d R m f34 eat Liv thc 73w73 ekr 26.4mg P<.08 +
273 R m f34 eat Liv mix 26.31 . + . 7.70mg * P<.0005+
a R m f34 eat Liv nnd 26.31 11.1mg * P<.003
b R m f34 eat Liv hpc 26.31 77.0mg * P<.04 +
c R m f34 eat Liv cLc 26m31 400.mg * P<.3
N-METHYL-NI-NITRO-N-NITROSOGUANIDINE***..:..lug.:10. :100.. : mg.:10. :100.. : . :10
274 R b aLb wat for pam 78w78 r . 22.9mg P<.02
a R b aLb wat stg adc 78w78 r 22.9mg P<.02
275 R m f34 wat stg mix 12.29 . + . 1.42mg P<.0005+
a R m f34 wat stgade 12.29 2.38mg P<.003 +
b R m f34 watstg adc 12.29 5.22mg P<.04 +
c R m f34 watstgsar 12.29 16.5mg P<.3 +
d R m f34 wat Liv nnd 12.29 no dre P-1.
276 R m f34 watstg mix 12m24 . + . .592mg P<.0005+
a R m f34 watstgade 12.24 1.65mg P<.002 +
b R m f34 watstgsar 12m24 2.48mg P<.007 +
c R m f34 wat stg adc 12m24 3.19mg P<.02 +
d R m f34 wat Liv nnd12m24 no dre P-1.
277 R m wis wat git adc 28w58 r . + . .810mg P<.0005+
a R m wis watsmi adc 28w58 r 1.21mg P<.003
b R m wis watstg adc 28w58 r 4.31mg P<.1
278 R m wis wat duo tur 30w54er . 3.44mg P<.1 +
279 R m wis wat git mix 26w52 er . 1.60mg P<.04 +
a R m wis wat duo tum 26w52 er 2.21mg P<.07
b R m wis watstg a/2 26w52 er 7.06mg P<.3 +
280 R m wis wat git mix 26w52 er . 1.92mg P<.04 +
a R m wis wat stg a/2 26w52 er 2.28mg P<.06 +
b R m wis wat duo tum 26w52 er 7.28mg P<.3
METHYL 12-OXO-trans-10-OCTADECENOATE ..:..lug : :10: 100. g : . :10. :100..:. :10
281 M bstm eat
--- mLy 42w84 e .> 2.94gm P<.7 -
METHYLENE CHLORIDE
282 M f b6c inh MXB MXB 24m24
a M f b6c inhlun MXA 24m24
b M f b6c inhlun a/a 24m24
c M f b6c inhliv MXA 24m24
d M f b6c inh Lun a/c 24m24
e M f b6c inh Liv hpc 24m24
f M f b6c inh Liv hpa 24m24
9 M f b6c inh thy fca 24.24
h M f b6c inh TBA MXB 24m24
i M f b6c inhliv MXB 24m24
Mf b6c inhlun MXB 24m24
283 M m b6c inhlun MXA 24m24
a
M m b6c inh MXB MXB 24m24
b M m b6c inh Lun a/a 24m24
c M m b6c inh Lun a/c 24m24
d M m b6c inh Liv MXA 24m24
e M m b6c inhliv hpc 24m24
f M m b6c inhliv hpa 24m24
g Mmb6c inh--- hes 24m24
lOOng .:. .:ug.:10. :100. g :. 1g :10. :100..:g. :10


















12.9gm* P<.02SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrt IDose lInc 2Dose 21nc
267 c50715 937.mg n.s.s. 0/50
a c50715 1.26gm n.s.s. 0/50
b c50715 273.mg n.s.s. 42/50
c c50715 1.339m n.s.s. 0/50
268 c50715 308.mg 2.04gm 0/50
a c50715 322.mg 2.51g. 0/50
b c50715 65.3mg n.s.s. 30/50
c c50715 n.s.s. n.s.s. 0/50
221.mg 2/50 441.mg 3/50
221.mg 0/50 441.mg 3/50
221.mg 43/50 441.mg 37/50
221.mg 2/50 441.mg 1/50
88.3mg 0/50 177.mg 9/50
88.3mg 0/50 177.mg 8/50
88.3mg 36/50 177.mg 38/50









269 1637 717.mg n.s.s. 0/40
a 1637 717.mg n.s.s. 0/40
b 1637 717.mg n.s.s. 0/40
METHAPYRILENE.HCL 135-23-9
270 1572 24.4mg n.s.s. 0/12
a 1572 23.8mg n.s.s. 2/12
271 1644 4.54mg 15.6mg 3/20
a 1644 6.62mg 35.1mg 3/20
b 1644 25.1mg 363.mg 0/20
272 1618 n.s.s. 18.7mg 0/5
a 1618 n.s.s. 18.7mg 0/5
b 1618 4.11mg n.s.s. 0/5
c 1618 6.29mg n.s.s. 0/5
d 1618 6.29mg n.s.s. 0/5
273 1644 4.27mg 22.2mg 5/20
a 1644 5.69mg 68.0mg 5/20
b 1644 26.6mg n.s.s. 0/20


































274 1571 7.87mg n.s.s.
a 1571 7.87mg n.s.s.
275 1611m .658mg 4.00mg
a 1611m .963mg 12.4mg
b 1611m 1.58mg n.s.s.
c 1611m 2.69mg n.s.s.
d 1611m 3.94mg n.s.s.
276 1611n .302mg 1.33mg
a 1611n .708mg 6.27mg
b 1611n .936mg 28.6mg
c 1611n 1.10mg n.s.s.
d 1611n 3.31mg n.s.s.
277 1678 .444mg 1.92mg
a 1678 .617mg 4.60mg
b 1678 1.49mg n.s.s.
278 1724m .839mg n.s.s.
279 1724n .549mg n.sa.s.
a 1724n .665mg n.s.s.
b 1724n 1.15mg n.s.s.
280 1724o .827mg n.s.s.
a 17240 .927mg n.s.s.










































































DomeL Lof ;ajsu, 142,551-554;1981
Morishita;clet, 17,347-352;1983/pers.comm.
METHYL 12-OXO-trans-10-OCTADECENOATE 21308-79-2
281 1627 361.mg n.s.s. 2/30 239.mg 3/30
METHYLENE CHLORIDE (dichloromethane, Freon 30) 75-09-2
282 c50102 568.mg 1.28gm 5/50 2.14gm 36/50 4.28gm 46/50
a c50102 635.mg 1.43gm 3/50 2.14gm 30/50 4.28gm 41/50
b c50102 938.mg 2.39gm 2/50 2.14gm 23/50 4.28gm 28/50
c c50102 956.mg 2.31gm 3/50 2.14gm 16/50 4.28gm 40/50
d c50102 1.10gm 2.81gm 1/50 2.14gm 13/50 4.28gm 29/50
c50102 1.20gm 3.04gm 1/50 2.14gm 11/50 4.28gm 32/50
f c50102 1.85gm 6.50gm 2/50 2.14gm 6/50 4.28gm 22/50
g c50102 5.11gm n.s.s. 1/50 2.14gm 1/50 4.28gm 4/50
h c50102 652.mg 1.93gm 18/50 2.14gm 41/50 4.28gm 47/50
i c50102 956.mg 2.31gm 3/50 2.14gm 16/50 4.28gm 40/50
j c50102 635.mg 1.43gm 3/50 2.14gm 30/50 4.28gm 41/50
283 c50102 630.mg 1.46gm 5/50 1.79gm 27/50 3.57gm 40/50
a c50102 672.mg 2.27gm 27/50 1.79gm 35/50 3.57gm 45/50
b c50102 1.08gm 2.98gm 3/50 1.79gm 19/50 3.57gm 24/50
c c50102 1.09gm 2.95gm 2/50 1.79gm 10/50 3.57gm 28/50
d c50102 1.01gm 4.99gm 22/50 1.79gm 24/50 3.57gm 33/50
c50102 1.49gm 7.709m 13/50 1.79gm 15/50 3.57gm 26/50
f c50102 1.68gm 23.5gm 10/50 1.79gm 14/50 3.57gm 14/50











277278 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
h N m b6c inh --- MXA 24.24
i Mm b6c inh TBA MXB 24.24
j Mm b6c inh liv MXB 24.24
k M m b6c inh lun MXB 24m24
284 R f f34 inh mgl MXA 24m24
a R f f34 inh mgL MXA 24m24
b R f f34 inh mgl fba 24m24
c R f f34 inh mgL MXA 24.24
d R f f34 inh --- mnL 24.24
e R f f34 inh Liv MXA 24.24
f R f f34 inh TBA MXB 24.24
g R f f34 inh Liv MXB 24.24
285 R m f34 inh MXA NXA 24.24
a R m f34 inh MXA MXA 24m24
b R m f34 inh mgt NXA 24.24
c R m f34 inh tnv MXA 24.24
d R m f34 inh mg lfba 24.24
e R m f34 inh sub MXA 24m24
f R m f34 inh sub fib 24,24
g R m f34 inh tnv mai 24.24
h R m f34 inh TBA MXB 24m24
i R m f134 inh Liv MXB 24.24
286 R f ass inh mgL ben 24,24 e
a R f sss inh pit ad. 24m24 e
287 R m sss inh sLg mix 24.24 a

















1.64gm * P<.002 a
1.64g. * P<.005











288 M f b6c wat MXB MXB 24.24
a M f b6c wat liv MXA 24.24
b M f b6c wat --- MXA 24m24
c M f b6c wat thy MXA 24.24
d M f b6c wat Liv hpc 24m24
e M f b6c wat thy fca 24.24
f N f b6c wat Liv hpa 24.24
9 M f b6c wat Lun MXA 24m24
h M f b6c wat Lun a/a 24.24
i M f b6c wat TBA MXB 24m24
j M f b6c wat liv MXB 24.24
k M f b6c wat Lun MXB 24m24
289 N m b6c wat Liv MXA 24.24
a M m b6c wat Liv hpc 24.24
b N m b6c wat MXB MXB 24m24
c M m b6c wat adr phe 24,24
d M m b6c wat thy fca 24s24
e M m b6c wat TBA MXB 24m24
f N m b6c wat Liv MXB 24.24
g M m b6c wat lun MXB 24.24
290 R f f34 wat thy MXB 24,24
a R f f34 wat thy MXA 24.24
b R f f34 wat thy fca 24.24
c R f f34 wat thy cca 24,24
d R f f34 wat thy MXA 24m24
e R f f34 wat TBA MXB 24,24
f R f f34 wat Liv MXB 24m24
291 R m f34 wat MXB MXB 24m24
a R m f34 wat Liv nnd 24,24
b R m f34 wat thy MXA 24m24
c R m f34 wat thy fcc 24.24
d R m f34 wat TBA MXB 24,24
a R m f34 wat liv MXB 24.24
METHYLNITROSOCYANAMIDE
292 R f sda wat for .ix 60w95 er
a R f sda wat for car 60w95 er
METHYLTHIOURACIL***
293 M b cfi eat Liv hpt 51w78 er
a M b cfi eat thy tum 51w78 enr
MONOACETYL HYDRAZINE
294 M f swi gav lun mix 95w95 rs
295 M f swi gav Lun mix 34w95 rs
296 1M m swi gav Lun mix 95w95 rs
297 M m swi gav Lun mix 34w95 rs









lOng. .:. :.1ug . :10 . :100 . :1mg . :10 . :100 .:Ig . :10
4.
1.
lOOng..: ..lug...:.10 ...:.100...1.g...:.10 ...:.100...I:g ...:.10
2.6g * P<.0005
9.3mg * P<.0005c
4.7mg * P<.007 c
28.mg / P<.0005

































lOOng .. :. .ug.:10. :100. 1m : g.:10. :100..:g. :10
.> 53.8mg P<.3 +
A 18.8mg P<.1 +
A 35.6mg * P<.02 +
+ . 4.48mg P<.0005+
vSUPPLEMENT TO THE CARCINOGENIC POTENCYDATABASE
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
h c50102 4.829m n.s.s.
i c50102 688.mg 2.76gm
j c50102 1.01gm 4.99g.
k c50102 630.mg 1.46gm
284 c50102 361.mg 1.36gm
a c50102 371.mg 1.57gm
b c50102 378.mg 1.49gm
c c50102 385.mg 1.809m
d c50102 578.mg n.s.s.
e c50102 1.56g. n.s.s.
f c50102 244.mg 8.34gm
g c50102 1.56gm n.s.s.
285 c50102 477.mg 2.17gm
a c50102 686.mg 16.1gm
b c50102 693.mg 7.00ga
c c50102 739.mg 12.2ga
d c50102 716.mg 11.2gm
c50102 853.mg 11.1gm
f c50102 892.mg 28.3gm
g c50102 1.34gm n.s.s.
h c50102 186.mg n.s.s.
i c50102 1.43gm n.s.s.
286 1600 627.mg n.s.s.
a 1600 1.25gm n.s.s.
287 1600 2.28gm 12.1gm


























































































































288 c54604 19.1mg 95.5mg
a c54604 35.2mg 162.mg
b c54604 32.7mg 1.16gm
c c54604 71.6mg 265.mg
d c54604 72.0mg 611.mg
c54604 80.7mg 338.mg
f c54604 65.1mg n.s.s.
g c54604 109.mg n.s.s.
h c54604 129.mg n.s.s.
i c54604 22.1mg n.s.s.
j c54604 35.2mg 162.mg
k c54604 109.mg n.s.s.
289 c54604 9.07mg 65.8mg
a c54604 12.1mg 75.5mg
b c54604 17.1mg 78.7mg
c c54604 39.7mg 231.mg
d c54604 51.4mg 172.mg
e c54604 19.1mg n.s.s.
f c54604 9.07mg 65.8mg
g c54604 168.mg n.s.s.
290 c54604 13.9mg 38.4mg
a c54604 16.6mg 50.3mg
b c54604 19.5mg 66. 1ag
c c54604 34.7mg 873.mg
d c54604 30.6mg n.s.s.
e c54604 10.6mg n.s.s.
f c54604 31.5mg n.s.s.
291 c54604 8.33mg 22.0mg
a c54604 9.35mg 27.1mg
b c54604 24.4mg 535.mg
c c54604 36.9mg 422.mg
d c54604 15.3mg n.s.s.




































































292 1733 .283mg .828mg 0/9 .573mg






















































































2/12 1.08mg 12/15 2.23mg 15/15 4.39mg 14/14 Endo;pjpa,50,497-502;1974/pers.comm.
0/12 1.08mg 5/15 2.23mg 12/15 4.39mg 13/14
METHYLTHIOURACIL*** 56-04*2
293 1630 337.mg n.s.s. 0/9 375.mg 2/20
a 1630 869.mg n.s.s. 0/9 375.mg 0/20
Jemec;canc,40,2188-2202;1977
MONOACETYL HYDRAZINE 1068-57-1
294 1661m 13.9mg n.s.s. 3/20 22.9mg
295 1661n 5.77mg n.s.s. 3/20 11.4mg
296 1661m 15.2mg n.s.s. 2/20 19.0mg
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MONOCROTALINE lOOng..: ..lug. 1 : 10 :.100. : lmg :..10 :.100.. : . : 10
298 R a cdr gav Liv hpc 42w71 erv . A 1.16mg
299 R m cdr gav liv hpc 42w71 cerv . + . .790mg
DL-MONOSODIUM GLUTAMATE
300 M a cbl eat liv tum 24m24 a
a M m cbl eat lun ada 24.24 a
b M m cbl eat tba mix 24.24 e
L-MONOSODIUM GLUTAMATE
301 M m cbl eat liv tue 24.24 a
a M m cbL eat lun tue 24.24 a
b M m cbl eat tba tue 24.24 a
NICOTINAMIDE
302 M f swa wat Lun mix 26.26 e
a M f swa wat Liv tum 26m26 e
303 M e swa wat Lun mix 25.25 e
a M m swa wat Liv mix 25.25 e
NITRITE, SODIUM***
304 R f f34 eat Liv mix 24.30 e
a R f f34 eat liv nnd 24.30 e
b R f f34 eat Liv car 24.30 e
305 R f f34 eat Liv mix 24m30 e
a R f f34 eat liv nnd 24.30 e
b R f f34 eat Liv hpc 24.30 e
306 R f f34 wat adr edt 24.30 e
a R f f34 wat thy car 24.30 e
b R f f34 wat mai tum 24.30 a
c R f f34 wat Liv mix 24m30 a
d R f f34 wat Liv nnd 24.30 e
e R f f34 wat ute poL 24.30 a
f R f f34 wat Liv hpc 24.30 e
307 R m f34 eat Liv mix 24.30 e
a R m f34 eat Liv nnd 24.30 e
b R m f34 eat liv car 24.30 a
308 R m f34 eat Liv nnd 24.30 e
309 R m f34 wat Liv mix 24.30 a
a R m f34 wat liv hpc 24m30 e
b R m f34 wat liv nnd 24.30 e


































N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE*** ......10. :100.:1.. :10. :100.. : :10
310 M f cdl eat ubL tcc 36w68 e . + . 33.3mg P<.0005+
a M f cdl eat ubL spt 36w68 e 128.mg P<.002 +
b M f cdl eat ubL sqc 36w68 128.mg P<.002 +
c M f cdl eat Lun ade 36w68 e 1.12gm P<.6
d M f cdl eat Liv tue 36w68 e no dre P-1.
e M f cdl eat tba mix 36w68 a 18.7mg P<.0005
311 M m cdl eat ubL tcc 40w7? e . + . 30.5mg P<.0005+
a M m cdl eat ubL spt 40w77 97.1mg P<.0005+
b M m cdl eat ubL sqc 40w77 e 250.mg P<.009 +
c M m cdl eat Lun ade 40w77 e no dre P-1.
d M m cdl eat liv hpc 40w?7 e no dre P-1.
M m cdl eat tba mix 40w77 e 21.5mg P<.0005
312 R m f34 eat ubl car 7m24 . +. 3.18mg Z P<.0005+
313 R m fis eat liv tum 24.24
a R m fis eat ubl tue 24.24
314 R m f is eat ubl car 36w74
a R m fis eat ubL ivc 36w74
b R m fis eat ubL nvc 36w74
c R m fis eat Liv hnd 36w74
315 R m fis eat ubL car 77w77
a R m fis eat ubL ivc 77w77
b R m fis eat ubL nvc 77w77












...... ............. .......g... :1:100
316 M f bdl eat Lun adc 24.24 .> no dre
a M f bdl eat Liv hem 24.24 no dre
b M f bdl eat tba six 24m24 no dre
317 M m bd1 eat Lun ade 24m24 .> 53.9gm
a M m bdl eat Liv hem 24.24 no dre
b M e bdl eat Liv ade 24.24 no dre
c M m bd1 eat Liv mix 24.24 no dre
d M m bdl eat tba mix 24e24 no dre
318 R f sda eat mgL fba 24.24 . + . 54.3mg



















































P-I.SUPPLEMENT TO THE CARCINOGENIC POTENCYDATABASE
RefNum LoConf UpConf Cntrt lDose lInc 2Dose 2Inc
MONOCROTALINE 315-22-0
298 1719. .566mg n.s.s. 0/15 .813mg 10/50
299 1719n .424mg 4.36mg 0/15 .813mg 14/50
DL-MONOSODIUM GLUTAMATE 32221-81-1
300 1631 4.51gm n.s.s. 0/55 1.20g. 0/23 4.80gm
a 1631 17.69m n.s.s. 0/55 1.20gm 1/23 4.80gm
b 1631 17.6gm n.s.s. 0/55 1.20gm 1/23 4.80gm
L-MONOSODIUM GLUTAMATE 142-47-2
301 1631 4.689m n.s.s. 0/55 1.20g. 0/25 4.80gm
a 1631 4.68gm n.s.s. 0/55 1.20gm 0/25 4.80gm
b 1631 4.68gm n.s.s. 0/55 1.209m 0/25 4.80gm
NICOTINAMIDE 98-92-0
302 1732 7.039m n.s.s. 15/89
a 1732 23.89m n.s.s. 0/98
303 1732 9.349m n.s.s. 21/87
a 1732 15.8gm n.s.s. 2/61
NITRITE, SODIUM*** 7632-00-0
304 1645m 56.7mg 817.mg 4/24
a 1645m 78.9mg n.s.s. 4/24
b 1645m 162.mg n.s.s. 0/24
305 1654m 62.0mg 2.04gm 4/24
a 1654m 69.2mg n.s.s. 4/24
b 1654m 190.mg n.s.s. 0/24
306 1654n 73.1mg 523.mg 0/24
a 1654n 73.1mg 523.mg 0/24
b 1654n 44.1mg n.s.s. 8/24
c 1654n 60.7mg n.s.s. 4/24
d 1654n 68.2mg n.s.s. 4/24
e 1654n 85.8mg n.s.s. 1/24
f 1654n 252.mg n.s.s. 0/24
307 1645. 114.mg n.s.s. 3/24
a 1645m 125.mg n.s.s. 2/24
b 1645. 297.mg n.s.s. 1/24
308 1654. 235.mg n.s.s. 5/24
309 1654n 109.mg n.s.s. 3/24
a 1654n 143.mg n.s.s. 1/24
b 1654n 160.mg n.s.s. 2/24
N- 14-(5-NITRO-2-FURYL)-2-THIAZOLYL
310 1601 20.5mg 58.9mg 0/53
a 1601 58.0mg 449.mg 0/53
b 1601 58.0mg 449.mg 0/53
c 1601 148.mg n.s.s. 1/53
d 1601 333.mg n.s.s. 0/53
e 1601 10.6mg 45.9mg 19/53
311 1601 19.5mg 51.4mg 0/55
a 1601 49.9mg 230.mg 0/55
b 1601 95.0mg 6.08gm 0/55
c 1601 298.mg n.s.s. 4/55
d 1601 298.mg n.s.s. 4/55
e 1601 12.6mg 47.6mg 17/55
312 1575 2.25mg 4.56mg 0/40
(23.1
313 1574 8.24mg n.s.s. 0/30
a 1574 8.24mg n.s.s. 0/30
314 1657m 1.85mg 10.3mg 0/42
a 1657m 4.99mg 21.5mg 0/42
b 1657m 20.8mg 378.mg 0/42
c 1657m 42.8mg n.s.s. 0/42
315 1657n 5.36mg 17.5mg 0/42
a 1657n 11.3mg 30.5mg 0/42
b 1657n 79.4mg 1.19gm 0/42


































































































0/40 .577mg 0/40 1.15mg 0/40 5.77mg 34/40 11.5mg 39/40











1-1 (5-NITROFURFURYLIDENE)AMINO]HYDANTOIN*** (macrodantin, nitrofurantoin) 67-20-9
316 1747 3.26gm n.s.s. 0/54 97.5mg 1/54 390.mg 0/54
a 1747 3.65gm n.s.s. 1/54 97.5mg 2/54 390.mg 0/54
b 1747 956.mg n.s.s. 16/54 97.5mg 9/54 390.mg 14/54
317 1747 2.85gm n.s.s. 1/53 90.0mg 0/52 360.mg 1/52
a 1747 2.45gm n.s.s. 3/53 90.0mg 0/52 360.mg 2/52
b 1747 771.mg n.s.s. 6/53 90.0mg 1/52 (360.mg 0/52)
c 1747 3.179m n.s.s. 9/53 90.0mg 1/52 360.mg 2/52
d 1747 2.54gm n.s.s. 12/53 90.0mg 1/52 360.mg 4/52
318 1622 21.1mg 675.mg 2/11 94.0mg 9/12
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1-NITROPROPANE 1OOng..: .1ug.:10. 1 :100.. : mg. 1 : 10 :..100.1:0 1 : 10
319 R f leb inh liv hpc 52w52 ekr .> no dre
320 R f Lob inh Liv hpc 78w78 ekr .> no dre
321 R f Leb inh Liv hpc 93w93 ekr .> no dre
322 R f Leb inh Liv hpc 52w93 ekr .> no dre
323 R m Leb inh Liv hpc 52w52 ekr .> no dre
324 R m Lob inh Liv hpc 78w78 ekr .> no dre
325 R m Leb inh Liv hpc 93w93 ekr .> no dre
326 R m Leb inh Liv hpc 52w93 ekr .> no dre
1-NITROSO05,6-DIHYDROTHYMINE 1O0ng..:. .1ug. :10 :.100.... :Ig. : 10 : .100...:.Ig .10
327 R f mrw wat Liv mix 12.29 e . 31.2mg
a R f mrw wat tba mix 12.29 e no dre
328 R m mrw wat liv tur 12m29 e .> no dre
a R mrw wat tba mix 12.29 o no dre
N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE.:. .10. 100. : 1.mg.: 10. 100...:Ig . 10
329 H f syg gav for mix 41w75 e . + . 1.59mg
a H f syg gav for sqp 41w75 * 1.59mg
b H f syg gav liv cad 41w75 a 32.6mg
c H f syg gav Lun tur 41w75 e no dre
330 R f f34 wat eso mix 37w85 . + . 53.5ug
a R f f34 wat ton mix 37w85 88.8ug
b R f f34 wat eso car 37w85 .117mg
c R f f34 wat for mix 37w85 .178mg
d R f f34 wat ton sqc 37w85 .241mg
a R f f34 wat Liv hpc 37w85 2.40mg
f R f f34 wat Liv mix 37w85 no dre
NITROSO.2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE .... .:10 :..100. 1 : mg. 1 :10 :..100..1 :0 . :10
331 H f syg gav for mix 35w55 a . + . .754mg
a H f syg gav for sqp 35w55 e .868mg
b H f syg gav pdu c/a 35w55 e 3.63mg
c H f syg gav liv hpa 35w55 e 9.92mg
d H f syg gav liv mix 35w55 e 9.92mg
a H f syg gav lun car 35w55 e 20.4mg
f H f syg gav Liv hpc 35w55 e 20.4mg
332 R f f34 wat mso mix 31w55 . + . 35.2ug
a R f f34 wat for mix 31w55 48.2ug
b R f f34 wat ton mix 31w55 55.5ug
c R f f34 wat mso car 31w55 63.7ug
d R f f34 wat ton car 31w55 96.4ug
a R f f34 wat for car 31w55 .155mg
f R f f34 wat liv hpc 31w55 1.30mg
N-NITROSO.2,3-DIHYDROXYPROPYLETHANOLAMINE .. lug. 1 : 10 :..100. 1 : mg. : 100....: 19 g :.10
333 H f syg gav trh ado 12m24 o . 52.7mg
a H f syg gav Lun tum 12m24 e no dre
b H f syg gav Liv tum 12m24 a no dra
334 R f f34 wat liv mix 17m28 . 5.98mg
a R f f34 wat Liv nnd 17m28 8.69mg
b R f f34 wat Liv hpc 17m28 11.5mg
N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMIMNE..: ..10 :.100. : 1.mg.: 10 :.100. : 1g :.10
335 R f f34 wat Liv hpc 50w75 . + . 1.02mg
a R f f34 wat Liv mix 50w75 1.12mg
b R f f34 wat Liv ang 50w75 4.50mg
c R f f34 wat nas olc 50w75 5.44mg
d R f f34 wat eso mix 50w75 6.74mg
e R f f34 wat liv nnd 50w75 no dre
N-NITROSO-3-HYDROXYPYRROLIDINE
336 R b sda wat liv hpc 26m26
a R b ada wat tba mal 26m26
N-NITROSO-N- ISOBUTYLUREA
337 R f don wat dgt mix 76w76 e
a R f don wat duo mix 76w76 e
b R f don wat stg mix 76w76 e
c R f don wat Liv mix 76w76 e
d R f don wat tba mix 76w76 e
1OOng..: ..ug.:10. :100. : .. :10. :100.. :. :10
+ . 8.11mg P<.006
7.65mg P<.03 +
1OOng. .. : .10. :100.: g :10. :100..:. :10





N-NITROSO-N-METHYL-N-DODECYLAMIN ...: .:10. : 100. 1. : 1. :10 :100.. : .19 :10
338 R f f34 gav ubl tum 30w65 . + . .656mg P<.0005+
a R f f34 gav Lun tum 30w65 1.32mg P<.0005
b R f f34 gav liv tum 30w65 no dre P-I.

















































P-I.SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
1-NITROPROPANE 108-03-2
319 1670. 16.4mg n.s.s.
320 1670n 36.9mg n.s.s.
321 16700 147.mg n.s.s.
322 1670r 23.4mg n.s.s.
323 1670. 11.5mg n.s.s.
324 1670n 25.8mg n.s.s.
325 16700 99.1mg n.s.s.



















327 1607 7.66mg n.s.s. 0/20 3.21mg 2/20
a 1607 2.67mg n.s.s. 15/20 3.21mg 14/20
328 1607 13.1mg n.s.s. 0/23 2.25mg 0/19
a 1607 7.43mg n.s.s. 9/23 2.25mg 3/19
N-NITROSO-2,3*DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE
329 1682 .804mg 3.67mg 0/20 4.69mg 13/20
a 1682 .804mg 3.67mg 0/20 4.69mg 13/20
b 1682 5.30mg n.s.s. 0/20 4.69mg 1/20
c 1682 10.0mg n.s.s. 0/20 4.69mg 0/20
330 1612 25.4ug .117mg 0/20 .269mg 18/20
a 1612 45.5ug .196mg 0/20 .269mg 15/20
b 1612 59.3ug .271mg 0/20 .269mg 13/20
c 1612 84.8ug .464mg 0/20 .269mg 10/20
d 1612 .108mg .762mg 0/20 .269mg 8/20
e 1612 .391mg n.s.s. 0/20 .269mg 1/20





Lij insky; jnci ,74,923-926;1985
Lij insky;carc,5,167-170;1984
NITROSO-2,3-DIHYDROXYPROPYL -2-OXOPROPYLAMINE 92177-50-9
331 1682 .386mg 1.66mg 0/20 5.45mg 15/20
a 1682 .443mg 1.95mg 0/20 5.45mg 14/20
b 1682 1.37mg 41.9mg 0/20 5.45mg 5/20
c 1682 2.44mg n.s.s. 0/20 5.45mg 2/20
d 1682 2.44mg n.s.s. 0/20 5.45mg 2/20
1682 3.32mg n.s.s. 0/20 5.45mg 1/20
f 1682 3.32mg n.s.s. 0/20 5.45mg 1/20
332 1639 17.6ug 76.3ug 0/20 .349mg 17/20
a 1639 24.7ug .106mg 0/20 .349mg 15/20
b 1639 28.3ug .125mg 0/20 .349mg 14/20
c 1639 32.2ug .147mg 0/20 .349mg 13/20
d 1639 46.Oug .252mg 0/20 .349mg 10/20
a 1639 66.4ug .588mg 0/20 .349mg 7/20




333 1682 15.9mg n.s.s. 0/20 12.5mg
a 1682 51.5mg n.s.s. 0/20 12.5mg
b 1682 51.5mg n.s.s. 0/20 12.5mg
334 1612 2.75mg n.s.s. 3/20 1.87mg
a 1612 3.59mg n.s.s. 3/20 1.87mg








Lij insky; jnci ,74,923-926;1985
Lij insky;carc,5, 167-170;1984
N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE 75896-33-2
335 1612 .511mg 2.21mg 0/20 5.44mg 17/20
a 1612 .532mg 2.94mg 3/20 5.44mg 17/20
b 1612 1.93mg 17.0mg 0/20 5.44mg 7/20
c 1612 2.20mg 28.4mg 0/20 5.44mg 6/20
d 1612 2.55mg 77.7mg 0/20 5.44mg 5/20
1612 11.7mg n.s.s. 3/20 5.44mg 0/20
N-NITROSO-3-HYDROXYPYRROLIDINE 56222-35-6
336 1634 3.07mg 85.1mg 0/24 2.50mg 5/23
a 1634 2.80mg n.s.s. 1/24 2.50mg 6/23
N-NITROSO-N-ISOBUTYLUREA (N-isobutyl-N-nitrosourea) 760-60-1
337 1549 3.18mg 7.32mg 0/17 5.71mg 6/25 11.4mg 14/24 22.9mg 25/28
a 1549 4.72mg 11.7mg 0/17 5.71mg 2/25 11.4mg 12/24 22.9mg 21/28
b 1549 12.7mg n.s.s. 0/17 5.71mg 3/25 11.4mg 7/24 22.9mg 5/28
c 1549 30.4mg n.s.s. 1/17 5.71mg 2/25 11.4mg 3/24 22.9mg 2/28
d 1549 2.04mg n.s.s. 12/17 5.71mg 20/25 11.4mg 20/24 22.9mg 27/28
N-NITROSO-N-METHYL -N-DODECYLANINE*** 55090-44-3
338 1561 .323mg 1.50mg 1/20 4.52mg 17/20
a 1561 .658mg 3.15mg 0/20 4.52mg 12/20
b 1561 7.28mg n.s.s. 0/20 4.52mg 0/20






Spe Strain Site Xpo+Xpt




N-NITROSO-N-METHYL-4-FLUOROANILINE . .: ..lug... 10.100...:.Io...:.lug.....10 ....100...I:g ...:.10
339 R m 134 wet eso mix 12.26. + . .255mg
a R m 134 wet Liv hnd 12.26 10.3mg
b R m 134 wet tba mix 12.26 no dre
N-NITROSO-N-METHYL-4-NITROANILINE lOOng. .: ..lug.....10 ...:.100... lu.g.....10 ....100...:.Ig ...:.10
340 R m f34 wat Liv hnd 12m26 .> 5.87mg
a R m f34 wet tba mix 12m26 no dre
N-NITROSO-1,3-OXAZOLIDINE
341 H m syg gay Liv cLc 35w65
a H m syg gay Liv hpa 35w65
b H m syg gay Liv hpc 35w65
c H m syg gay Lun car 35w65







NITROSO-2-OXOPROPYLETHANOLAMINE bOOng. .:. .lug... .10 ...:.100.. 1 :.mg... .10 ...:.100... .Ig ...:.10
342 H f syg gay Liv mix 50w65 a + ..997mg
a H f syg gay pdu c/a 50w65 a 2.31mg
b H f syg gay Liv caa 50w65 a 2.68mg
c H f syg gay pdu car 50w65 e 3.72mg
d H f syg gay Liv hca 50w65 e 3.72mg
e H f syg gay Liv hpa 50w65 e 5.58mg
f H f syg gay Liv cLc 50w65 e 5.58mg
g H f syg gay Lun ada 50w65 a 31.3mg
343 R f 134 wet Liv mix 12m28 . + .1.80mg
a R f 134 wet Liv hpc 12m28 2.70mg

















DI(N-NITROSO)-PERHYDROPYRIMIDINE lOOng..: .. lug.....10 ....100. 1. : mg.....10 ...:.100...: g ...:.10
344 R m ada ipj pnL sqc 24m24 rs. + .166mg * P<.003 +
N.NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLANINE . .lug...:.10 ...:.100. 1.:mg...:.10 ...:.100...:.Ig ...:.10
345 R m ada gay eso p.c 88w88 . + . 2.52mg * P<.0005+
a R m ada gay nas mix 88w88 7.34mg Z P<.007 +
b R m ada gav Liv has 88w88 no dre P-1.
I -NITROSO-3,4,5-TRIMETHYLPIPERAZINE
346 H m ayg gay for pam 46w69
a N m syg gay Lun ada 46w69
b N m syg gay Lun car 46w69
c N m syg gay Liv ang 46w69
d N m ayg gay tba mix 46w69
347 R f f34 wet nas oLc 30w85
a R f 134 wet Liv nnd 30w85
b R f 134 wet tba mix 30w85






. + . ~~~~~~~~~~~.151mg
no dre
no dre
N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE.. . .Iug...:.10 ...:.100.. 1 : mg.....10 ...:.100...: g ...:.10
348 R f 134 wet eso mix 5Ow55 . + . .825mg
a R f f34 wet nec mix SOw5S .972mg
b R f f34 wet eso car SOw55 1.13mg














349 R f f34 -it nes mix 50w65
a R f f34 .dt Liv hpc 50w65
b R f f34 wet eso mix 50w65
N -NITROSOALLYL -2-OXOPROPYLAMINE
350 N f syg gay nec mix 40w55 a
a H f syg gay nec car 40w55 a
b H f ayg gay Liv mix 40w55 a
c N f syg gay Liv hpa 40w55 e
d N f syg gay Liv cLc 40w55 e
e H 1 syg gay Lun tum 40w55 e
351 R f 134 wet Liv hpc 50w85
a R f 134 wet eao mix 50w85
N -NITROSOALLYLETHANOLAMINE
352 R f 134 wet nec mix 50w65
a R f 134 wet Liv hpc 50w65
N-NITROSOAZETIDINE
353 N m syg gay Liv mix 50w85
a N m syg gay Liv hpa 50w85
b H m syg gay Lun tum 50w85
c H m syg gav tba mix 50w85
...lug...:.o...10.10.1o ..:.mg... 10. 100...:.Io...:.Ig. 10.:.l
+ . .877mg P<.0005+
1.38mg P<.0005+
4.67mg P<.003 +









lOOng. .: ..lug...:.10...:.100. 1. :mg... 10. 100...:.oo..:.Ig.10.:.l
+ ..491mg
4.12mg























P<.08SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or Pathology
BrkLy Code
N-NITROSO-N-METHYL-4-FLUOROANILINE 937-25-7
339 1544 .121mg .558mg 0/20 .714mg 18/20
a 1544 1.29mg n.s.s. 2/20 .714mg 3/20
b 1544 .234mg n.s.s. 19/20 .714mg 18/20
N-NITROSO-N-METHYL-4-NITROANILINE 943-41-9
340 1544 1.22mg n.s.s. 2/20 .840mg 4/20
a 1544 .149mg n.s.s. 19/20 .840mg 19/20
N-NITROSO- 1,3-OXAZOLIDINE
341 1608 .240mg 1.02mg
a 1608 .464mg 2.35mg
b 1608 .995mg 30.4mg
c 1608 2.40mg n.s.s.











342 1682 .508mg 2.17mg 0/20 5.99mg 16/20
a 1682 1.10mg 6.05mg 0/20 5.99mg 10/20
b 1682 1.24mg 7.57mg 0/20 5.99mg 9/20
c 1682 1.59mg 14.1mg 0/20 5.99mg 7/20
d 1682 1.59mg 14.1mg 0/20 5.99mg 7/20
e 1682 2.11mg 64.3mg 0/20 5.99mg 5/20
f 1682 2.11mg 64.3mg 0/20 5.99mg 5/20
9 1682 5.09mg n.s.s. 0/20 5.99mg 1/20
343 1639 .770mg 6.82mg 0/20 .850mg 7/20
a 1639 1.02mg 31.1mg 0/20 .850mg 5/20




344 1538 67.8ug .778mg 0/40 10.Oug 0/40 28.6ug 6/40
N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE 82018-90-4
345 1554 1.73mg 4.45mg 0/20 2.14mg 9/20 4.29mg 18/20 8.57mg 14/20 17.1mg 17/20
a 1554 4.14mg 120.mg 0/20 2.14mg 4/20 4.29mg 8/20 8.57mg 5/20 (17.1mg 3/20)
b 1554 65.7mg n.s.s. 0/20 2.14mg 1/20 4.29mg 0/20 8.57mg 0/20 17.1mg 0/20
1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE 75881-18-4
346 1570 .623mg 4.85mg 3/20 4.57mg 14/20
a 1570 .844mg 4.28mg 0/20 4.57mg 11/20
b 1570 1.37mg 12.1mg 0/20 4.57mg 7/20
c 1570 2.13mg n.s.s. 0/20 4.57mg 4/20
d 1570 n.s.s. .813mg 3/20 4.57mg 20/20
347 1570 88.2ug .270mg 0/20 .259mg 13/20 .980mg 18/20
a 1570 .564mg n.s.s. 2/20 .259mg 0/20 .980mg 0/20
b 1570 .184mg n.s.s. 19/20 .259mg 17/20 .980mg 18/20
N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE 88208-16-6
348 1613 .412mg 1.78mg 0/20 8.16mg 17/20
a 1613 .495mg 2.11mg 0/20 8.16mg 16/20
b 1613 .578mg 2.49mg 0/20 8.16mg 15/20
c 1613 9.41mg n.s.s. 2/20 8.16mg 0/20
N-NITROSOALLYL-2-HYDROXYPROPYLAMINE 91308-70-2
349 1613 .438mg 1.90mg 0/20 6.22mg 17/20
a 1613 .705mg 3.11mg 0/20 6.22mg 14/20
b 1613 1.89mg 24.4mg 0/20 6.22mg 6/20
N-NITROSOALLYL-2-OXOPROPYLAMINE 91308-71-3
350 1682 .591mg 2.83mg 0/20 5.67mg 12/20
a 1682 .665mg 3.37mg 0/20 5.67mg 11/20
b 1682 1.43mg 43.5mg 0/20 5.67mg 5/20
c 1682 1.68mg n.s.s. 0/20 5.67mg 4/20
d 1682 3.45mg n.s.s. 0/20 5.67mg 1/20
e 1682 6.53mg n.s.s. 0/20 5.67mg 0/20
351 1613 .170mg .728mg 0/20 1.18mg 16/20
a 1613 .535mg 4.73mg 0/20 1.18mg 7/20
N -NITROSOALLYLETHANOLAMINE 91308-69-9
352 1613 .202mg 1.12mg 0/20 5.49mg 19/20
a 1613 1.67mg 21.5mg 0/20 5.49mg 6/20
N-NITROSOAZETIDINE 15216-10-1
353 1608 3.06mg 27.1mg 0/20 6.72mg 7/20
a 1608 4.04mg 123.mg 0/20 6.72mg 5/20
b 1608 18.5mg n.s.s. 0/20 6.72mg 0/20











Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2TaiLpvL
DR AuOp
N.NITROSOBIS(2-HYDROXYPROPYL)AMINE*** .:. .lug... .10 ....100... .lug... .10 ....100...I:.g .... 10
354 R f 134 wat eso mix 42w55. + .813mg P<.0005+
a R f f34 wat eso car 42w55 1.25mg P<.0005
b R f f34 wet nas oLc 42w55 3.04mg P<.002 +
c R f f34 wat Liv nnd 42w55 no dre P-1.
355 R m mrw gay pro car 74w74 er 437.mg* P<.7 +
N.NITROSOBIS(2.OXOPROPYL)AMINE*** bOOng. .: ..lug... .10 ....100... lu.Ig... .10 ....100...I:.g ....10
356 R f 134 gay Liv hpc 30w95 + ..684mg P<.002 +
a R f 34 gay tba mix 30w95 noTD5O P<.6
357 R f 134 wat Liv mix 50w75 .+ ..232mg P<.0005+
a R f 34 wet Lun mix 50w75 .399mg P<.0005+
b R f f34 wat Liv hpc 50w75 .582mg P<.0005+
c R f f 34 wat Liv has 50w75 .892mg P<.0005+
358 R m mrw gay pro car 74w74 er .+ 1.53mg* P<.003 +
N-NITROSOCIMETIDINE
359 R f f34 wat thy tum 25m30
a R f f34 wat pit tum 25m30
b R f 134 wat Liv nnd 25m30
360 R m f34 wat Liv nnd 25.30
361 R f sda gay tba mix 12m24
a R f ada gay tba maL 12m24
362 R m ada gay tba mix 12.24
a R m ada gay tba mat 12m24
NITROSODIBUTYLAMINE***
363 R m 134 gay Liv hpc 7.25
a R m 34 gay for car 7m25
b R m f34 gay Lun car 7m25
c R m 134 gay ubL tcc 7.25
d R m 134 gay tba mix 7.25




.> ~~~~~~no dre P-I.
.> ~~~no dre P-I.
no dre P-I.
.> ~~~no dre P-1.
4.82gm * P<.9-











N.NITROSODIETHANOLAMINE*** lOOng. .:. .lug...:.10 ....100 1. :mg...:.10 ...:.100...:g ...:.10
364 R f f34 wat Liv hpc 13.24 a + 3.27mg * P<.0005+
a R f 134 wat nias adc 13m24 a
b R f f34 wat nasa oLc 13.24 a
c R f f34 wat Liv cLc 13m24 a
d R f f34 wat kid tum 13m24 a
R f 134 wat maso pam 13m24 a
f R f 134 wet nasa sqc 13m24 a
365 R f 134 wet Liv mix 17m30 a
a R f f34 wet Liv nnd 17m30 a
b R f f34 wet Liv hpc 17m30 a
c R f 134 wet kid mix 17m30 a
d R f 134 wet Liv caa 17m30 a
366 R 134 wet Liv hpc 48w95 a
a R 134 wet nas adc 48w95 a
b R m 134 wet Liv cLc 48w95 a
c R m 134 wet nas oLc 48w95 a
d R m 134 wet kid tum 48w95 a
R 134 wet eso pam 48w95 a
f R m 134 wet nas sqc 48w95 a
g R 134 wet eso car 48w95 a
367 R m 134 wet Liv mix 17m29 a
a R m 134 wet Liv nnd 17m29 a
b R m 134 wet Liv hpc 17m29 a
c R m 134 wet kid mix 17m29 a
d R m 134 wet Liv caa 17m29 a
N .NITROSODIETHYLAMINE***
368 R 134 wet eso tum 30w65
a R f 134 wet Liv tum 30w65
b R f 134 wet tba tum 30w65
44.1mg Z P<.0005+
128.mg Z P<.005 +
197.mg * P<.007 +
327.mg * P<.009 +
2.05gm * P<.2 +








23.9mg Z P<.002 +
50.4mg Z P<.003 +
99.7mg * P<.002 +
207.mg * P<.003 +
280.mg * P<.009 +
432.mg * P<.2 +
2.84mg Z P<.0005+
3.93mg * P<.002 +
9.03mg * P<.0005+
19.0mg * P<.07 +
38.6mg * P<.06





369 R m buf eat Liv hpc 26w52 ekr
370 R f 134 wet Liv mix 7m26
a R f 134 wet Liv hpc 7m26
b R f 134 wet Liv hes 7m26
c R f 134 wet Liv nnd 7m26
N -NITROSODIPROPYLAMINE
371 R f 134 gay Liv hpc 30w60
a R 134 gay nas car 30w60
b R 134 gay eso mix 30w60
c R f 134 gav tba mix 30w60


















ncSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE*** (N-bis(2-hydroxypropyL )nitrosamine) 53609-64-6
354 1612 .414mg 1.77mg
a 1612 .630mg 2.88mg
b 1612 1.30mg 11.5mg
c 1612 7.87mg n.s.s.







356 1551 .254mg 3.08mg 0/20
a 1551 n.s.s. n.s.s. 18/20
357 1639 .110mg .506mg 0/20
a 1639 .200mg .967mg 1/20
b 1639 .290mg 1.39mg 0/20
c 1639 .413mg 2.52mg 0/20




















.714mg 2/12 1.43mg 5/15 Pour;carc,4,49-55;1983
N-NITROSOCIMETIDINE 73785-40-7
359 1611 7.11mg 217.mg 0/20
a 1611 1.32mg n.s.s. 11/20
b 1611 8.56mg n.s.s. 3/20
360 1611 7.07mg n.s.s. 5/20
361 1699 142.mg n.s.s. 10/50
a 1699 232.mg n.s.s. 7/50
362 1699 136.mg n.s.s. 9/50
a 1699 149.mg n.s.s. 5/50
NITROSODIBUTYLAMINE*** 924- 16-3
363 1551 .345mg 1.65mg 0/20
a 1551 .436mg 2.39mg 0/20
b 1551 .508mg 6.79mg 1/20
c 1551 .629mg 5.57mg 0/20


































364 1610 1.86mg 5.75mg
a 1610 23.1mg 106.mg
b 1610 48.4mg 1.12gm
c 1610 81.3mg 3.82gm
d 1610 133.mg 13.1gm
* 1610 333.mg n.s.s.
f 1610 190.mg n.s.s.
365 1707 1.32mg 2.92mg
a 1707 1.96mg 5.05mg
b 1707 2.65mg 6.65mg
c 1707 14.6mg n.s.s.
d 1707 17.2mg n.s.s.
366 1610 1.72mg 4.60mg
a 1610 10.1mg 32.1mg
b 1610 12.3mg 89.9mg
c 1610 20.5mg 265.mg
d 1610 45.1mg 409.mg
e 1610 71.3mg 1.32gm
f 1610 84.7mg 9.40gm
9 1610 106.mg n.s.s.
367 1707 1.72mg 6.81mg
a 1707 2.19mg 15.1mg
b 1707 4.65mg 24.9mg
c 1707 7.77mg n.s.s.











































































































































































































368 1561 11.2ug 47.7ug 0/20 .132mg 16/20
a 1561 .127mg n.s.s. 1/20 .132mg 1/20
b 1561 16.1ug n.s.s. 20/20 .132mg 18/20
N-NITROSODIMETHYLAMINE*** (DKN) 62-75-9
369 1664 .286mg n.s.s. 0/14 .500mg
370 1609 33.8ug .123mg 2/20 63.1ug
a 1609 77.5ug .316mg 0/20 63.1ug
b 1609 .188mg 1.56mg 0/20 63.1ug







Angsubhakorn; i jcn,28,621 -626;1981





371 1551 79.3ug .564mg 0/20 .898mg 8/12
a 1551 79.3ug .564mg 0/20 .898mg 8/12
b 1551 .172mg 3.75mg 0/20 .898mg 4/12
c 1551 n.s.s. n.s.s. 18/20 .898mg 12/12
Lij insky;cLet, 19,207-213;1983
287288 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Not
NITROSODODECAMETHYLENEIMINE
372 R f nzd gav Liv hct 12.40 e
a R f nzd gav Lun mix 12a40 e
373 R m nzd gav hea tum 12m35 e
a R m nzd gav Lun aix 12.35 a
b R m nzd gav Liv hct 12m35 a
NITROSOETHYLMETHYLAMINE**
374 R f f34 wat --- tum 7.27
a R f f34 wat Liv tum 7.27
b R f f34 wat tba tur 7r27
N-NITROSOHEXAMETHYLENEIMINE
375 M f nzb wat ssq aix 32w74
a M f nzb wat eso mix 32w74
b M f nzb wat Liv hpc 32w74
c M f nzb wat stg rix 32w74
d M f nzb wat opx mnix 32w74
e M f nzb wat Lun mnix 32w74
376 N m nzb wat eso mix 32w60
a M m nzb wat ssq mix 32w60
b M m nzb wat opx mix 32w60
c M m nzb wat stg mix 32w60
d M m nzb wat Lun mix 32w60
e M m nzb wat Liv hpc 32w60
TD50 2TailpvL
DR AuOp tes























N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE .: ..lug.. : 10. :100.. :lamg.. : 10. :100.. :Ig. : 10
377 H f syg gav nac mix 41w81 . + . .940mg
a H f syg gav nac car 41w81 1.51mg
b H f syg gav Liv h/2 41w81 12.7mg
c H f syg gav tba mix 41w81 .509mg
378 R f f34 wat lun mix 9m26 . + . .646mg
a R f f34 wat Liv mix 9a26 .670mg
b R f f34 wat Liv nnd 9n26 1.01mg
c R f f34 wat eso mix 9r26 1.48mg
d R f f34 wat nas mix 9m26 1.48mg
e R f f34 wat Liv hpc 9m26 3.13mg
N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE .. : .lug.. : 10 :..100. 1g 0: 1.. : 10 :100.. : g. 10 : 10
379 R f f34 wat nas mix 30H75 . + . 48.6ug
a R f f34 wat eso mix 30H75 .105mg
b R f f34 wat eso car 30H75 .408mg
c R f f34 wat Lun mix 30H75 .408mg
d R f f34 wat Liv hpc 30H75 .895mg
e R f f34 wat Liv mix 30H75 .798mg
f R f f34 wat Liv nnd 30H75 2.54mg
380 R m f134 wat nas mix 30H75 . + . 44.2ug
a R m f34 wat eso mix 30H75 .170mg
b R a f34 wat Liv mix 30H75 no dre









































381 R f f34 wat eso car
a R f f34 wat liv car
b R f f34 wat tba mix
382 R m f134 wat eso mix
a R m f34 wat Liv car







N - NITROSOMORPHOL INE
383 H f syg wat res mix 24m24 e
a H f syg wat Liv mix 24m24 a
b H f syg wat tba mix 24m24 a
384 H a syg wat res mix 24m24 a
a H m syg wat Liv mix 24m24 a
b H a syg wat tba mix 24m24 a
N' -NITROSONORNICOTINE
385 H f syg wat res pam 31w96
a H f syg wat Liv tur 31w96
386 H a syg wat res pam 31w96
a H m syg wat Liv ang 31M96
N' -NITROSONORNICOTINE-1-N-OXIDE
387 H f syg wat Liv ang 31w96
388 H m syg wat Liv tur 31w96
389 R f f34 wat nas mix 8m24
a R f f34 wat mso mix 8m24
lOOng .:. .:ug. :10. :100.1m :g.:10. :100.:Ig.:10












1O0ng. .. : 1 .ug . 10.:100. : g...:10. :100.. : . :10
. + . 1.35mg Z P<.0005+
51.6mg * P<.0005+
1.48mg Z P<.0005
.+ . 5.98mg * P<.0005+
9.14mg * P<.0005+
5.56mg * P<.0005


















* + @SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
NITROSODODECAMETHYLENEIMINE 40580-89-0
372 1603 2.67mg 255.mg 0/109 .619mg
a 1603 2.20mg n.s.s. 2/109 .619mg
373 1603 .730mg n.s.s. 18/108 .495mg
a 1603 1.88mg n.s.s. 6/108 .495mg










374 1561 13.4ug n.s.s. 12/20 63.9ug 18/20
a 1561 .322mg n.s.s. 1/20 63.9ug 0/20
b 1561 13.5ug n.s.s. 20/20 63.9ug 19/20
N-NITROSOHEXAMETHYLENEIMIINE 932-83-2
375 1738 .156mg 1.13mg 0/113 3.07mg
a 1738 .320mg 1.96mg 0/113 3.07mg
b 1738 1.02mg 40.6mg 4/113 3.07mg
c 1738 1.22mg 29.1mg 0/113 3.07mg
d 1738 1.56mg 88.1mg 0/113 3.07mg
1738 1.58mg n.s.s. 39/113 3.07mg
376 1738 .110mg .974mg 0/194 3.16mg
a 1738 .176mg 1.40mg 0/194 3.16mg
b 1738 .477mg 7.31mg 0/194 3.16mg
c 1738 .789mg 43.0mg 0/194 3.16mg
d 1738 .4589mg n.s.s. 53/194 3.16mg
1738 1.14mg n.s.s. 3/194 3.16mg
Lij insky;fctx,21,601-605;1983













377 1715 .449mg 2.46mg 0/20 1.57mg 10/20
a 1715 .647mg 5.73mg 0/20 1.57mg 7/20
b 1715 2.07mg n.s.s. 0/20 1.57mg 1/20
c 1715 .250mg 1.38mg 2/20 1.57mg 15/20
378 1609 .289mg 2.04mg 0/20 .430mg 8/20
a 1609 .275mg n.s.s. 2/20 .430mg 9/20
b 1609 .358mg n.s.s. 2/20 .430mg 7/20
c 1609 .509mg n.s.s. 0/20 .430mg 4/20
d 1609 .509mg n.s.s. 0/20 .430mg 4/20
1609 .769mg n.s.s. 0/20 .430mg 2/20
N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE 75411-83-5
379 1609 20.Oug .111mg 0/20 .408mg 19/20
a 1609 53.7ug .231mg 0/20 .408mg 15/20
b 1609 .165mg 2.13mg 0/20 .408mg 6/20
c 1609 .165mg 2.13mg 0/20 .408mg 6/20
d 1609 .270mg n.s.s. 0/20 .408mg 3/20
1609 .215mg n.s.s. 2/20 .408mg 5/20
f 1609 .318mg n.s.s. 2/20 .408mg 3/20
380 1609 21.Oug 96.7ug 0/20 .286mg 18/20
a 1609 78.9ug .480mg 0/20 .286mg 9/20
b 1609 .291mg n.s.s. 2/20 .286mg 2/20





381 1544 .233mg .996mg 0/20
a 1544 3.30mg n.s.s. 4/20
b 1544 .258mg n.s.s. 18/20
382 1544 .136mg .588mg 0/20
a 1544 2.20mg n.s.s. 3/20















383 1543 .714mg 2.97mg 0/50
a 1543 23.4mg 156.mg 0/50
b 1543 .746mg 4.02mg 3/50
384 1543 4.03mg 9.71mg 0/50
a 1543 5.87mg 15.4mg 0/50







14/28 (6.82mg 16/30 13.6mg 22/30)
0/28 6.82mg 2/30 13.6mg 6/30
14/28 (6.82mg 17/30 13.6mg 23/30)
8/29 6.00mg 13/29 12.0mg 21/30
4/29 6.00mg 9/29 12.0mg 18/30
12/29 6.00mg 14/29 12.0mg 26/30
Ketkar;clet,17,333-338;1983/pers.comm.
N'-NITROSONORNICOTINE 16543-55-8
385 1539 3.45mg n.s.s. 0/10
a 1539 12.4mg n.s.s. 0/10
386 1539 3.03mg n.s.s. 0/10







387 1539n 6.34mg n.s.s. 0/10 7.05mg 1/10
388 1539n 10.9mg n.s.s. 0/10 6.20mg 0/10
389 1539m .769mg 6.48mg 0/12 2.37mg 7/12





Spe Strain Site Xpo+Xpt
Sex Route Hist Not
390 R m f34 wat nas mix 8m24
a R m f34 wat eso mix 8m24
b R m f34 wat nas mat 8m24
c R m f34 wat eso pam 8m24
d R m f34 wat nas pam 8m24
N-NITROSOPIPERIDINE***
391 H f syg wat res mix 24m24
a H f syg wat dgt mix 24m24
b H f syg wat Liv mix 24.24
c H f syg wat tbe mix 24m24
392 H m syg wat res mix 24m24
a H m syg wat dgt mix 24.24
b H m syg wat Liv mix 24m24
c H a syg wat tba mix 24.24
393 R b sda wat Liv mix 27m33 a
a R b sda wat mix mix 27m33 a
b R b sda wat tba mal 27m33 a
PENTACHLOROETHANE
394 M f b6c gav liv MXA 24m24 as
a N f b6c gav Liv hpc 24.24 as
b N f b6c gav Liv hpa 24.24 as
c N f b6c gav TBA MXB 24a24 as
d M f b6c gav Liv MXB 24m24 as
e M f b6c gav Lun MXB 24m24 as
395 N m b6c gav Liv hpc 24.24 as
a M m b6c gav Liv MXA 24.24 as
b N m b6c gav TBA MXB 24m24 as
c M m b6c gav Liv MXB 24m24 as
d N m b6c gav Lun MXB 24.24 as
396 R f f34 gav TBA MXB 24m24 s
a R f f34 gav Liv MXB 24.24 s
397 R m f34 gav kid tLa 24m24 s
a R m f34 gav kid MXA 24m24 s
b R m f34 gav TBA MXB 24a24 s








lOOng .. : lug.:10. :100. . : 1g.:10. : 100..:. :10
+ . 96.7mg * P<.0005+
132.mg * P<.002 +
307.mg * P<.005 +
9.89mg Z P<.0005




+ . .963mg Z P<.0005
2.32mg * P<.0005
1.57mg * P<.0005+
lOOng . . .:ug.:10. :100. g : . 1g :10. :100.. : . :10











:> 1.66gm * P<.9 -
no dre P-1.
+ +historical * P<.009 a
+historical * P<.07 a
no dre P-1.
no dre P-1.
2,3,4,5,6-PENTACHLOROPHENOL*** 1 0Ong..:. .ug. 1 :10. :100..:1mg.:10 :..100.1 :0 1 :10
398 N f cdl eat lun ade 52w69 a .> 448.mg P<.3
a M f cdl eat Liv tum 52w69 a no dre P-1.
PHENACETIN*** bO0ng..: ..ug.:10. :100. g :. . :10. :100. . : . :10
399 R f wis eat unt tue 69w69 or .> no dre P-1. 1
PHENOBARBITAL***
400 M f cdl wat Liv hpt 78w78
a N f cdl wat Lun ade 78w78
401 R m fis eat Liv tue 39w78 e
a R m fis eat tba tue 39w78 a
p-PHENYLENEDIAMINE
402 R f f34 eat adr phe 80w80 a
a R f f34 eat Liv tue 80w80 e
403 R m f34 eat idr phe 80w80 e
a R m f34 eat Liv tue 80w80 a










PHENYLGLYCIDYL ETHER lOOng..:. .ug.:10. 1g : .10.. 100..:Ig. :10
404 R f cdr inh nas epc 24.24 r . + . 90.2mg * P<.005 +
405 R m cdr inh nas mix 24m24 r . + . 29.1mg * P<.0005+
beta-PHENYLISOPROPYLHYDRAZINE.HC lOng..:. .ug. :10. :100. g : .. :10. :100.. : . :10
406 N f swe wat liv hpt 28e29 aes .> no dre P-1. -
a N f swa wat Lun tue 28.29 aes no dre P-1. -
407 N m swa wat liv hpt 23.26 aes .> no dre P-1. -
a N e swa wat lun tum 23.26 aes no dre P-1. -
o-PHENYLPHENATE, SODIUM***
408 N f b6c eat Liv hpc 22.24 a
a N f b6c eat Lun ade 22.24 a
b N f b6c eat Liv hnd 22.24 e
409 N a b6c eat Liv hpc 22.24 a
a M a b6c eat liv hes 22.24 a
b M a b6c eat Liv fbs 22.24 a
c N a b6c eat Liv he. 22.24 a
d N m b6c eat Liv hnd 22.24 a
a N m b6c eat Lun adc 22.24 a
f N a b6c eat Lun ado 22.24 a
lOOng..:. .lug. :10. :100. g :. 1g :10. :100.:1g. :10
13.0gm Z P<.4 -
143.9m * P<.3 -
no dre P-1.
+ 5.42gm * P<.009 -






* + -SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrt IDoso lInc 2Dose 2Inc
390 1539. .211mg 1.62mg
a 1539. .673mg 5.67mg
b 1539. .673mg 5.67mg
c 1539. .983mg 21.2mg


















391 1541 56.9mg 240.mg 0/50 8.18mg
a 1541 70.6mg 624.mg 0/50 8.18mg
b 1541 133.mg 3.08gm 0/50 8.18mg
c 1541 4.97mg 27.9mg 3/50 8.18mg
392 1541 32.6mg 90.0mg 0/50 7.20mg
a 1541 55.5mg 198.mg 0/50 7.20mg
b 1541 71.2mg 312.mg 0/50 7.20mg
c 1541 29.6mg 142.mg 8/50 7.20mg
393 1634 .590mg 1.96mg 0/40 17.1ug
a 1634 1.51mg 3.80mg 0/40 17.1ug
b 1634 .998mg 2.69mg 4/40 17.1ug
PENTACHLOROETHANE (pentaL in) 76-01-7
394 c53894 24.0mg 68.0mg 3/50 177.mg
a c53894 38.3mg 118.mg 1/50 177.mg
b c53894 69.1mg 367.mg 2/50 177.mg
c c53894 24.1mg 69.1mg 22/50 177.mg
d c53894 24.0mg 68.0mg 3/50 177.mg
c53894 193.mg n.s.s. 4/50 177.mg
395 c53894 59.1mg 234.mg 4/50 177.mg
a c53894 58.4mg 304.mg 14/50 177.mg
b c53894 46.5mg 278.mg 20/50 177.mg
c c53894 58.4mg 304.mg 14/50 177.mg
d c53894 389.mg n.s.s. 6/50 177.mg
396 c53894 79.4mg n.s.s. 37/50 53.1mg
a c53894 409.mg n.s.s. 1/50 53.1mg
397 c53894 240.mg 14.6gm 0/50 53.1mg
a c53894 229.mg n.s.s. 1/50 53.1mg
b c53894 107.mg n.s.s. 36/50 53.1mg






























































2,3,4,5,6-PENTACHLOROPHENOL*** (Dowicide-7, PCP) 87-86-5
398 1581 73.0mg n.s.s. 0/32 48.8mg 1/31
a 1581 137.mg n.s.s. 0/32 48.8mg 0/31
PHENACETIN*** 62-44-2
399 1740 1.86gm n.s.s. 0/30 500.mg 0/41
PHENOBARBITAL*** (phenobarbitone) 50-06-6
400 1582 137.mg n.s.s. 0/30 100.mg
a 1582 210.mg n.s.s. 1/30 100.mg
401 1653 6.96mg n.s.s. 0/12 10.0mg










402 1542 146.mg n.s.s. 1/21 25.0mg 1/37 50.0mg 2/42
a 1542 78.3mg n.s.s. 0/21 25.0mg 0/37 50.0mg 0/42
403 1542 42.8mg n.s.s. 6/19 20.0mg 8/35 40.0mg 10/36
a 1542 57.4mg n.s.s. 0/19 20.0mg 0/35 40.0mg 0/36
PHENYLGLYCIDYL ETHER 122-60-1
404 1737 31.2mg 812.mg 0/90 .460mg 0/90 5.52mg 4/90
405 1737 13.2mg 108.mg 1/90 .322mg 0/90 3.86mg 9/90
beta-PHENYLISOPROPYLHYDRAZINE.HCL 66-05-7
406 1675 23.0mg n.s.s. 1/15 31.2mg 0/4 62.4mg 0/3
a 1675 145.mg n.s.s. 25/99 31.2mg 10/49 (62.4mg 2/45)
407 1675 65.2mg n.s.s. 0/99 26.0mg 0/42 52.0mg 0/7





408 1647 3.28gm n.s.s.
a 1647 23.29m n.s.s.
b 1647 9.85gm n.s.s.
409 1647 2.689m 188.gm
a 1647 5.84gm n.s.s.
b 1647 21.69m n.s.s.
c 1647 13.3gm n.s.s.
d 1647 5.009m n.s.s.
1647 14.4gm n.s.s.












































Brkly Cod.292 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
o-PHENYLPHENOL***
410 R m f3d eat ubl mix 91w91 eri
a R m f3d eat ubl tcc 91w91 eri
b R m f3d eat ubl nvt 91w91 eri
c R m f3d eat ubl ivt 91w91 eri
PILDRALAZINE
411 N f b6c wat
a M f b6c wat
412 N a b6c wat
a M b6c wat
413 N f bLd wat
a M f bLd wat
b M f bLd wat
Liv mix 19.29 a
Lun mix 19.29 a
Liv mix 19m29 e
Lun mix 19m29 e
--- Lym 19m29 e
Liv hpa 19m29 e
Lun mix 19m29 e
POLYBROMINATED BIPHENYL MIXTURE
414 M f b6c gav liv hpc 6.30
a M f b6c gav TBA MXB 6m30
b M f b6c gav liv MXB 6m30
c M f b6c gav lun MXB 6m30
415 M m b6c gav Liv hpc 6.30
a M m b6c gav TBA MXB 6m30
b M m b6c gav Liv MXB 6m30
c M m b6c gav Lun MXB 6m30
416 R f f34 gav Liv MXA 6m29 y
a R f f34 gav liv nnd 6m29 y
b R f f34 gav Liv hpc 6m29 y
c R f f34 gav Liv ctc 6m29 y
d R f34 gav TBA MXB 6m29 y
417 R m f34 gav Liv MXA 6m27 y
a R m f34 gav liv nnd 6m27 y
b R m f34 gav liv hpc 6m27 y
c R m f34 gav liv cLc 6m27 y
d R m f34 gav TBA MXB 6m27 y
PRIMIDOLOL . HCL
418 N f cdl eat
a M f cdl eat
b M f cdl eat
c M f cdl eat
419 M m cdl eat
a M m cdl eat
b M m cdl eat
c M m cdl eat
d M cdl eat
a M m cdl eat
lun ada 78w78 a
Lun adc 78w78 a
Liv hpc 78w78 e
tba mix 78w78 e
liv hpc 78w78 e
Liv cho 78w78 a
liv ada 78w78 a
lun adc 78w78 e
Lun ade 78w78 e
tba mix 78w78 e
PROPRANOLOL . HC L
420 M f cdl eat Lun ada 78w92 a
a M f cdl eat liv tum 78w92 a
b M f cdl eat tba ben 78w92 a
c M f cdl eat tba maL 78w92 a
d M f cdl eat tba mix 78w92 e
421 M m cdl eat Liv car 78w92 a
a M m cdl eat Liv ado 78w92 e
b M m cdl eat Lun ade 78w92 e
c M m cdl eat Lun car 78w92 e
d M m cdl eat tba maL 78w92 e
e M m cdl eat tba ben 78w92 e
f M m cdl eat tba mix 78w92 e
422 R f Lev eat Liv tum 18m24 a
a R f Lev eat tba mix 18.24 a
b R f Lev eat tba ben 18m24 a
c R f Lev eat tba maL 18m24 a
423 R m Lev eat Liv hpa 18m24 a
a R m Lev eat tba mix 18m24 a
b R m Lev eat tba ben 18m24 e
c R a Lev eat tba maL 18m24 a
PROPYLENE
424 M f b6c inh TBA MXB
a M f b6c inh Liv MXB
b M f b6c inh lun MXB
425 M m b6c inh TBA MXB
a M a b6c inh Liv MXB
b M a b6c inh lun MXB
426 R f f34 inh TBA MXB
a R f f34 inh Liv MXB
427 R a f34 inh TBA MXB













lOOng..:. .ug.:10. :100.. : mg.:10. :100.. : g. :10
s . + . 232.mg Z P<.0005+
s 296.mg Z P<.0005+
s 451.mg Z P<.0005+
s 1.65gm Z P<.008 +
lOOng .. : lug.:10. :100.. : mg.:10. :100.:Ig. :10
503.mg * P<.2 -
no dre P-1. -
922.mg Z P<.6 -
no dre P-1. -
408.mg * P<.6 -
no dre P-1. -
no dre P-1. -
lOOng.. :. .lug.:10. :100. a :mg.:10. : 100..:g. :10













: (+) : .148mg * P<.0005c
.168mg * P<.0005c
1.30mg * P<.0005c
14.4mg * P<.006 c
64.5ug * P<.0005



























































:> no dre P-1.
20.5gm * P<.2
:> 15.5gm * P<1.
4.61gm * P<.06SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
o-PHENYLPHENOL*** (orthoxenol, Dowicide-1) 90-43-7
410 1646 137.mg 430.mg 0/24 250.mg 0/20 500.mg 23/24 (1.00gm 4/23)
a 1646 171.mg 568.mg 0/24 250.mg 0/20 500.mg 20/24 (1.00gm 2/23)
b 1646 245.mg 960.mg 0/24 250.mg 0/20 500.mg 15/24 (1.00gm 2/23)
c 1646 625.mg 26.3g. 0/24 250.mg 0/20 500.mg 5/24 (1.00gm 0/23)
Brkly Code
PILDRALAZINE 56393-22-7
411 1567 160.mg n.s.s.
a 1567 475.mg n.s.s.
412 1567 171.mg n.s.s.
a 1567 232.mg n.s.s.
413 1567 72.9mg n.s.s.
a 1567 765.mg n.s.s.








13.0mg 5/48 25.9mg 5/49 51.8mg
13.0mg 4/48 25.9mg 2/49 51.8mg
10.8mg 0/48 21.6mg 8/50 43.2mg
10.8mg 10/48 21.6mg 5/50 43.2mg
13.0mg 31/49 25.9mg 23/50 51.8mg
13.0mg 1/49 25.9mg 0/50 51.8mg









POLYBROMINATED BIPHENYL MIXTURE (Firemaster FF-1) 67774-32-1
414 c53635 .250mg 1.66mg 0/13 14.2ug 0/19 42.5ug 2/15 .142mg
a c53635 .141mg 2.97mg 12/13 14.2ug 13/19 42.5ug 12/15 .142mg
b c53635 .180mg 1.22mg 0/13 14.2ug 2/19 42.5ug 2/15 .142mg
c c53635 .285mg n.s.s. 0/13 14.2ug 1/19 42.5ug 1/15 .142mg
415 c53635 .200mg .899mg 12/25 14.2ug 8/27 42.5ug 8/24 .142mg
a c53635 .190mg 1.87mg 20/25 14.2ug 23/27 42.5ug 22/24 .142mg
b c53635 .147mg .685mg 14/25 14.2ug 9/27 42.5ug 12/24 .142mg
c c53635 .471mg n.s.s. 1/25 14.2ug 1/27 42.5ug 3/24 .142mg
416 c53635 .323mg 1.22mg 0/20 14.4ug 2/21 43.2ug 0/21 .144mg
a c53635 .505mg 3.47mg 0/20 14.4ug 2/21 43.2ug 0/21 .144mg
b c53635 .619mg 4.21mg 0/20 14.4ug 0/21 43.2ug 0/21 .144mg
c c53635 .800mg 6.40mg 0/20 14.4ug 0/21 43.2ug 0/21 .144mg
d c53635 .136mg 13.7mg 18/20 14.4ug 18/21 43.2ug 17/21 .144mg
417 c53635 45.7ug .491mg 0/33 15.1ug 2/39 46.2ug 1/40 .151mg
a c53635 47.2ug .608mg 0/33 15.1ug 0/39 46.2ug 1/40 .151mg
b c53635 .484mg 3.70mg 0/33 15.1ug 2/39 46.2ug 0/40 .151mg
c c53635 3.45mg 286.mg 0/33 15.1ug 0/39 46.2ug 0/40 .151mg
















































































418 1669 95.9mg n.s.s. 8/100
a 1669 272.mg n.s.s. 0/100
b 1669 271.mg n.s.s. 0/100
c 1669 25.5mg 595.mg 24/100
419 1669 130.mg n.s.s. 2/100
a 1669 290.mg n.s.s. 1/100
b 1669 290.mg n.s.s. 8/100
c 1669 290.mg n.s.s. 1/100
d 1669 121.mg n.s.s. 22/100































420 1635 267.mg n.s.s.
a 1635 779.mg n.s.s.
b 1635 243.mg n.s.s.
c 1635 323.mg n.s.s.
d 1635 211.mg n.s.s.
421 1635 371.mg n.s.s.
a 1635 672.mg n.s.s.
b 1635 228.mg n.s.s.
c 1635 512.mg n.s.s.
d 1635 171.mg n.s.s.
1635 314.mg n.s.s.
f 1635 203.mg n.s.s.
422 1635 347.mg n.s.s.
a 1635 19.4mg n.s.s.
b 1635 33.5mg n.s.s.
c 1635 78.0mg n.s.s.
423 1635 347.mg n.s.s.
a 1635 39.0mg n.s.s.
b 1635 59.6mg n.s.s.
c 1635 76.7mg n.s.s.
PROPYLENE 115-07-1
424 c50077 7.47gm n.s.s.
a c50077 15.3gm n.s.s.
b c50077 17.1gm n.s.s.
425 c50077 12.7gm n.s.s.
a c50077 13.2gm n.s.s.
b c50077 25.7gm n.s.s.
426 c50077 915.mg n.s.s.
a c50077 5.059m n.s.s.
427 c50077 704.mg n.s.s.













































































































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
1,2-PROPYLENE OXIDE***
428 N f b6c inh --- MXA 24m24
a N f b6c inh nas MXA 24m24
b N f b6c inh mgl MXA 24m24
c M f b6c inh Lun a/a 24m24
d M f b6c inh --- hes 24m24
e a f b6c inh --- hem 24m24
f N f b6c inh nas hem 24m24
g M f b6c inh mgl adq 24m24
h M f b6c inh TBA NXB 24m24
i N f b6c inh liv MXB 24m24
j M f b6c inh Lun MXB 24m24
429 N m b6c inh nas NXA 24m24
a M m b6c inh --- MXA 24m24
b M m b6c inh nas hem 24m24
c N m b6c inh nas hes 24m24
d N m b6c inh TBA MXB 24m24
e N m b6c inh liv MXB 24m24
f N m b6c inh lun MXB 24m24
430 R f f34 inh NXA MXA 24m24
a R f f34 inh nas ppa 24m24
b R f f34 inh TBA MXB 24m24
c R f f34 inh Liv NXB 24m24
431 R a f34 inh nas ppa 24m24
a R a f34 inh TBA MXB 24m24
b R a f34 inh Liv NXB 24m24
432 R a f3h inh adr phe 23m24 ei
a R a f3h inh Liv hpc 23m24 ei
b R a f3h inh Liv nnd 23m24 ei
PROQUAZONE
433 N f cdl eat Liv hem 86w86
a M f cdl eat Liv has 86w86
b M f cdl eat liv hpc 86w86
c M f cdl eat Lun a/a 86w86
d M f cdl eat Lun a/c 86w86
434 N m cdl eat Liv hpc 86w86
a M a cdl eat Lun a/a 86w86
b M m cdl eat liv hem 86w86
c M m cdl eat Lun a/c 86w86
PYRILAMINE MALEATE
435 R f f34 eat Liv mix 26m31
a R f f34 eat Liv nnd 26m31
b R f f34 eat Liv hpc 26m31
436 R f f34 wat Liv nnd 26m31
437 R m f34 eat Liv hpc 26m31
a R m f34 eat Liv mix 26.31
b R a f34 eat Liv nnd 26.31




lOOng . . .:ug.:10. :100. g :. 1g :10. :100.. : . :10
+ 863.mg / P<.003


















732.mg * P<.04 a
124.mg * P<.4
no dre P-1.
:+ 826.mg * P<.1 a
220.mg * P<.8
528.mg * P<.4
s pooL . (+) . 35.1mg \ P<.002 +
a 2.96gm * P<.3
s no dre P-1.
bO0ng.. :. .ug.:10. :100. g :. 1g :10. :100.:Ig. :10





4.35gm * P<.6 -
5.45gm * P<.7 -
14.0gm * P<.2 -
no dre P-1. -

















QUERCETIN*** lOOng... . lug.:10. :100.:1mg.:10. :100..:g. :10
439 R f f34 eat tba mix 64w64 fg .> no dre P-1.
440 R m f34 eat tba mix 64w64 .> no dre P-1.
QUERCETIN DIHYDRATE*** 1 O0ng.. :. ..1ug.1:0.100..:1mg.:10 :..100.1 :0 1 :10
441 R f f34 eat adr coa 77w77 a .> 118.mg P<.3
442 R m f34 eat tba mix 77w77 e noTD50 P<.6
D £ C RED NO. 5***
443 R f waL eat Liv mix 52w91 er
a R f waL eat liv hpc 52w91 or
444 R f wat eat Liv mix 91w91 or
a R f waL eat Liv hpc 91w91 or
NC RED NO. 3*
445 M f b6c gav for sqp 24.24 s
a M f b6c gav TBA MXB 24m24 s
b N f b6c gav Liv MXB 24m24 s
c N f b6c gav Lun MXB 24m24 s
446 M a b6c gav Liv MXA 24m24
a N a b6c gav TBA MXB 24m24
b N m b6c gav Liv MXB 24m24
c M m b6c gav Lun MXB 24.24
447 R f f34 gav TBA MXB 24m25
a R f f34 gav Liv MXB 24m25
448 R m f34 gav TBA MXB 24m25
a R m f34 gav Liv MXB 24m25


















eSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl IDose 1Inc 2Dose 2Inc
1,2-PROPYLENE OXIDE*** (1,2-epoxypropane)
428 c50099 360.mg 5.439m 1/50 148.mg
a c50099 451.mg 4.639m 0/50 148.mg
b c50099 475.mg 80.3gm 0/50 148.mg
c c50099 243.ag n.s.s. 4/50 148.mg
d c50099 522.mg n.s.s. 0/50 148.mg
c50099 554.mg n.s.s. 1/50 148.mg
f c50099 606.mg n.s.s. 0/50 148.mg
g c50099 732.mg n.s.s. 0/50 148.mg
h c50099 107.mg 15.0gm 28/50 148.mg
i c50099 320.mg n.s.s. 3/50 148.mg
j c50099 243.mg n.s.s. 4/50 148.mg
429 c50099 355.mg 1.95gm 0/50 123.mg
a c50099 342.mg 8.20gm 2/50 123.mg
b c50099 558.mg 12.1gm 0/50 123.mg
c c50099 604.mg 15.1gm 0/50 123.mg
d c50099 173.mg n.s.s. 29/50 123.mg
c50099 425.mg n.s.s. 14/50 123.mg
f c50099 469.mg n.s.s. 15/50 123.mg
430 c50099 71.3mg n.s.s. 3/50 35.2mg
a c50099 221.mg n.s.s. 0/50 35.2mg
b c50099 32.8mg n.s.s. 38/50 35.2mg
c c50099 1.01gm n.s.s. 1/50 35.2mg
431 c50099 202.mg n.s.s. 0/50 24.7mg
a c50099 27.8mg n.s.s. 40/50 24.7mg
b c50099 133.mg n.s.s. 1/50 24.7mg
432 1624 18.4mg 144.mg 8/78p 14.2mg
a 1624 482.mg n.s.s. 0/78p 14.2mg




























































433 1667 2.50gm n.s.s. 1/50 60.0mg 0/50 180.mg 0/50 360.mg 1/50
a 1667 2.88gm n.s.s. 1/50 60.0mg 0/50 180.mg 1/50 360.mg 0/50
b 1667 1.65gm n.s.s. 0/50 60.0mg 3/50 180.mg 0/50 360.mg 1/50
c 1667 866.mg n.s.s. 4/50 60.0mg 6/50 180.mg 10/50 360.mg 3/50
d 1667 284.mg n.s.s. 12/50 60.0mg 3/50 (180.mg 2/50 360.mg 1/50)
434 1667 762.mg n.s.s. 4/50 60.0mg 2/50 180.mg 8/50 360.mg 4/50
a 1667 666.mg n.s.s. 5/50 6040mg 6/50 180.mg 9/50 360.mg 6/50
b 1667 2.28gm n.s.s. 0/50 60.0mg 0/50 180.mg 0/50 360.mg 1/50
c 1667 861.mg n.s.s. 12/50 60.0mg 11/50 180.mg 7/50 360.mg 10/50
PYRILANINE MALEATE 59-33-6
435 1644 70.5mg n.s.s. 3/20
a 1644 91.9mg n.s.s. 3/20
b 1644 216.mg n.s.s. 0/20
436 1644m 145.mg n.s.s. 3/20
437 1644 173.mg n.s.s. 0/20
a 1644 95.7mg n.s.s. 5/20
b 1644 138.mg n.s.s. 5/20









































439 1648 69.1mg n.s.s. 0/10 50.0mg
440 1648 59.8mg n.s.s. 1/10 40.0mg
QUERCETIN DIHYDRATE*** 6151-25-3
441 1662 27.2mg n.s.a. 1/16 50.0mg
442 1662 n.s.s. n.s.s. 15/16 40.0mg
D & C RED NO. 5*** (ponceau MX) 3761-53-3
443 1730m 107.mg 641.mg 0/6 714.mg
a 1730m 643.mg n.s.s. 0/6 714.mg
444 1730n n.s.s. 488.mg 0/6 1.25gm
a 1730n 800.mg n.s.s. 0/6 1.25gm
NC RED NO. 3* 2871-01-4
445 c54922 208.mg n.s.s. 0/50
a c54922 67.0mg n.s.s. 16/50
b c54922 273.mg n.s.s. 4/50
c c54922 241.mg n.s.s. 1/50
446 c54922 141.mg n.s.s. 25/50
a c54922 142.mg n.s.s. 44/50
b c54922 141.mg n.s.s. 25/50
c c54922 251.mg n.s.s. 11/50
447 c54922 238.mg n.s.s. 45/50
a c54922 n.s.s. n.s.s. 0/50
448 c54922 154.mg n.s.s. 44/50











88.4mg 0/50 177.mg 3/50
88.4mg 15/50 177.mg 18/50
88.4mg 1/50 177.mg 2/50
88.4mg 2/50 177.mg 1/50
88.4mg 15/50 177.mg 35/50
88.4mg 36/50 177.mg 42/50
88.4mg 15/50 177.mg 35/50
88.4mg 13/50 177.mg 13/50
177.mg 44/50 354.mg 41/50
177.mg 0/50 354.mg 0/50
177.mg 38/50 356.mg 38/50










Spe Strain Site Xpo+Xpt
Sex Route Hist No
RIPAZEPAM
449 N f cdl eat Liv hpa 78w78 a
a M f cdl eat Lun car 78w78 o
b N f cdl eat lun ada 78w78 a
c N f cdl eat tba ben 78w78 a
d N f cdl eat tba maL 78w78 e
e M f cdl eat tba mix 78w78 e
450 N m cdl eat liv hpa 78w78 e
a M a cdl eat Liv hpc 78w78 e
b M e cdl eat Lun car 78w78 e
c N m cdl eat tba mix 78w78 a
d N m cdl eat tba ben 78w78 a
a N m cdl eat tba maL 78w78 a
451 R f cdr eat Liv hpc 24.24 a
a R f cdr eat Liv hpa 24.24 o
b R f cdr eat tba mal 24.24 a
c R f cdr eat tba ben 24.24 a
d R f cdr eat tba mix 24.24 a
452 R m cdr eat pit ada 24m24 a
a R e cdr eat Liv hpa 24.24 a
b R m cdr eat tba mix 24.24 a
c R e cdr eat tba ben 24e24 a
d R m cdr eat tba maL 24.24 o
p-ROSANILINE.HCL***
453 M f b6c eat Liv MXA 24m24
a M f b6c eat MXB MXB 24m24
b N f b6c eat Liv hpc 24.24
c N f b6c eat Liv hpa 24.24
d M f b6c eat --- MXA 24m24
a M f b6c eat adr NXA 24.24
f M f b6c eat --- mLp 24m24
g N f b6c eat Lun MXA 24.24
h N f b6c eat hag MXA 24.24
i M f b6c eat Lun a/a 24,24
j M f b6c eat --- mLh 24.24
k M f b6c eat hag ada 24,24
l N f b6c eat hag MXA 24.24
m M f b6c eat TBA MXB 24.24
n N f b6c eat Liv MXB 24m24
o M f b6c eat Lun MXB 24.24
454 N m b6c eat Liv hpc 24,24
a M m b6c eat Liv MXA 24.24
b M m b6c eat --- mLm 24.24
c M m b6c eat TBA MXB 24m24
d N m b6c eat Liv MXB 24,24
a N m b6c eat Lun MXB 24.24
455 R f f34 eat mgL MXA 24m24
a R f f34 eat mgL fba 24.24
b R f f34 eat MXB MXB 24.24
c R f f34 eat sub MXA 24.24
d Rf f 134 eat sub MXA 24.24
a R f f34 eat sub fib 24m24
f R f f34 eat ute ess 24.24
g R f f34 eat thy MXA 24.24
h R f f34 eat zym can 24.24
i R f f34 eat thy fca 24m24
j R f f34 eat mgL MXA 24.24
k R f f34 eat Liv MXA 24.24
l R f f34 eat mgL acn 24.24
* ft f 134 eat TBA MXB 24.24
n R f f34 eat Liv MXB 24.24
456 R m f34 eat tes ict 24,24
a R m f34 eat MXB MXB 24.24
b R m f34 eat sub MXA 24m24
c R m f34 eat sub MXA 24.24
d R m f34 eat sub fib 24.24
a R f f34 eat Liv MXA 24,24
f R m f34 eat thy MXA 24.24
g R f f34 eat Liv nnd 24.24
h R m f34 eat thy fcc 24.24
i R m f34 eat ski MXA 24,24
j R m f34 eat zym can 24.24
k R m f34 eat ski sqc 24m24
l R m f34 eat Liv hpc 24,24
. R f f34 eat pni MXA 24,24




lOOng.. :. .lug.:10. :100. g :.lg :10. :100.:Ig. :10












* 2.77g * P<.05 -
3.67gm * P<.7 -
1.44g. * P<.5 -
no dre P-1. -
no dre P-1. -
+ . 147.mg * P<.004 -
988.mg * P<.2 -
89.7mg * P<.04 -
106.mg * P<.03 -
2.25gm * P<.7 -
bO0ng .:. .:ug.:10. :100..:lg.:10. :100.. : g. :10






























190.mg * P<.002 c
318.mg I P<.007
156.mg * P<.03 e
189.mg * P<.04
232.mg * P<.06 o
17.8mg * P<.0005
189.mg * P<.04














176.mg I P<.OOOScSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or PathoLogy
RIPAZEPAM (pyrazapon) 26308-28-1
449 1602 142.mg n.s.s. 5/50
a 1602 252.mg n.s.s. 0/50
b 1602 633.mg n.s.s. 3/50
c 1602 111.mg n.s.s. 10/50
d 1602 214.mg n.s.s. 2/50
1602 17.8mg n.s.s. 13/50
450 1602 38.9mg 157.mg 10/50
a 1602 513.mg n.s.s. 0/50
b 1602 496.mg n.s.s. 3/50
c 1602 33.7mg 618.mg 24/50
d 1602 39.2mg 394.mg 21/50
e 1602 13.5mg n.s.s. 4/50
451 1602 683.mg n.s.s. 0/50
a 1602 429.mg n.s.s. 4/50
b 1602 301.mg n.s.s. 9/50
c 1602 74.0mg n.s.s. 45/50
d 1602 68.2mg n.s.s. 48/50
452 1602 69.5mg 1.14gm 20/50
a 1602 304.mg n.s.s. 5/50
b 1602 31.6mg n.s.s. 40/50
c 1602 41.3mg n.s.s. 36/50














































p-ROSANILINE.HCL*** (p-magenta, C.I. Basic Red 9.HCL) 569-61-9
453 c54739 13.5mg 32.3mg 5/50 63.8mg 35/50 128.mg 41/50
a c54739 18.9mg 46.5mg 4/50 63.8mg 25/50 128.mg 37/50
b c54739 20.9mg 52.5mg 3/50 63.8mg 19/50 128.mg 37/50
c c54739 18.6mg 85.9mg 2/50 63.8mg 18/50 (128.mg 4/50)
d c54739 33.7mg 179.mg 17/50 63.8mg 24/50 128.mg 25/50
c54739 45.0mg 245.mg 1/50 63.8mg 8/50 128.mg 8/50
f c54739 51.6mg 810.mg 0/50 63.8mg 5/50 (128.mg 1/50)
g c54739 108.mg 1.35gm 0/50 63.8mg 2/50 128.mg 5/50
h c54739 106.mg 1.58gm 0/50 63.8mg 0/50 128.mg 5/50
c54739 111.mg 1.95gm 0/50 63.8mg 2/50 128.mg 4/50
c54739 163.mg 2.64gm 1/50 63.8mg 3/50 128.mg 8/50
k c54739 147.mg 45.2gm 0/50 63.8mg 0/50 128.mg 3/50
c54739 121.mg n.s.s. 1/50 63.8mg 0/50 128.mg 5/50
c54739 14.7mg 44.0mg 31/50 63.8mg 50/50 128.mg 49/50
n c54739 13.5mg 32.3mg 5/50 63.8mg 35/50 128.mg 41/50
o c54739 108.mg 1.35gm 0/50 63.8mg 2/50 128.mg 5/50
454 c54739 69.0mg 582.mg 10/50 58.9mg 20/50 118.mg 27/50
a c54739 50.1mg n.s.s. 29/50 58.9mg 37/50 118.mg 41/50
b c54739 263.mg n.s.s. 0/50 58.9mg 3/50 118.mg 4/50
c c54739 56.8mg n.s.s. 44/50 58.9mg 43/50 118.mg 46/50
d c54739 50.1mg n.s.s. 29/50 58.9mg 37/50 118.mg 41/50
c54739 284.mg n.s.s. 11/50 58.9mg 7/50 118.mg 8/50
455 c54739 14.1mg 83.6mg 23/50 24.6mg 32/50 49.3mg 32/50
a c54739 15.0mg 108.mg 22/50 24.6mg 31/50 49.3mg 29/50
b c54739 21.2mg 51.7mg 0/50 24.6mg 16/50 49.3mg 21/50
c c54739 25.1mg 82.0mg 1/50 24.6mg 17/50 49.3mg 12/50
d c54739 26.5mg 76.6mg 0/50 24.6mg 16/50 49.3mg 10/50
c54739 27.2mg 80.7mg 0/50 24.6mg 15/50 49.3mg 10/50
f c54739 60.0mg 1.50gm 1/50 24.6mg 5/50 49.3mg 6/50
g c54739 68.8mg 534.mg 0/50 24.6mg 2/50 49.3mg 6/50
h c54739 86.5mg 651.mg 0/50 24.6mg 2/50 49.3mg 7/50
c54739 108.mg 5.07gm 0/50 24.6mg 0/50 49.3mg 4/50
c54739 63.2mg n.s.s. 2/50 24.6mg 4/50 49.3mg 6/50
k c54739 73.0mg n.s.s. 1/50 24.6mg 4/50 49.3mg 4/50
c54739 79.3mg n.s.s. 2/50 24.6mg 2/50 49.3mg 5/50
c54739 10.1mg 57.5mg 41/50 24.6mg 50/50 49.3mg 48/50
n c54739 73.0mg n.s.s. 1/50 24.6mg 4/50 49.3mg 4/50
456 c54739 9.57mg 33.0mg 43/50 39.2mg 46/50 79.2mg 37/50
a c54739 14.8mg 32.0mg 3/50 39.2mg 26/50 79.2mg 40/50
b c54739 20.6mg 59.7mg 3/50 39.2mg 22/50 79.2mg 16/50
c c54739 20.8mg 62.6mg 6/50 39.2mg 24/50 79.2mg 19/50
d c54739 22.2mg 62.9mg 2/50 39.2mg 20/50 79.2mg 16/50
c54739 24.0mg 89.4mg 5/50 39.2mg 15/50 79.2mg 14/50
c54739 34.9mg 97.5mg 0/50 39.2mg 5/50 79.2mg 25/50
g c54739 31.0mg 246.mg 5/50 39.2mg 14/50 79.2mg 6/50
h c54739 42.1mg 137.mg 0/50 39.2mg 5/50 79.2mg 18/50
c54739 47.9mg 235.mg 2/50 39.2mg 2/50 79.2mg 14/50
j c54739 61.6mg 314.mg 1/50 39.2mg 1/50 79.2mg 13/50
k c54739 61.7mg 317.mg 0/50 39.2mg 1/50 79.2mg 10/50
l c54739 65.7mg 357.mg 0/50 39.2mg 2/50 79.2mg 8/50
c54739 62.5mg 2.26gm 2/50 39.2mg 5/50 79.2mg 4/50






































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
o R m f34 eat
p R m f34 eat
q R m f34 eat
r R m f34 eat
s R m f34 eat
t R m f34 eat
u R m f34 eat
v R m f34 eat
w R m f34 eat

































RUTIN SULFATE lOOng. ... : :10. :100 .. : 1mg : 10. :100 ...: g :10
457 R f sda gav tiv hpc 24.32
e .> 44.8gm * P<1M.
458 R m sda gav liv hpc 24.31
SACCHARIN, SODIUM***
459 R aci eat ubl pam 52w52 r
a R m aci eat ubl tcc 52w52 r
460 R m f34 eat ubL tue 52w52 r
461 R m fis eat Liv tum 24m24
a R m
fis eat ubL tue 24m24
462 R fis eat tes ict 77w98
a R fis eat Liv tum 77w98
b R fis eat ubL tum 77w98
463 R sda eat ubL tue 52w52 r
464 R m wis eat ubl tue 52w52 r
SAFROLE***
465 N f cdl
a f cdl
466 M f cdl
a Nf cdl



















eat emo Ley 24.24 er
no dre P- 1.





















lOOng .. : ..lug.. : 10. :100... :.1g... :10. :100. g. :.1g :10
+ . 59.7mg * P<.0005+
3.50gm * P<1.





lOOng. : : 10 100. : 10. :100. g. :. :10
. + 44.6mg * P<.0005+
SOTALOL.HCL lOOng : lug.:10 :..100. :0 .1g : 10 :100.1 :0 :10
469 f cdl eat Lun ade 78w92 .> 3.50gm * P<.2
a N f cdl eat Lun car 78w92 24.5gm * P-1.
b N f cdl eat Liv tue 78w92 e no dre P-1.
c N f cdl eat tba ben 78w92 1.74gm * P<.05 -
d Nf cdl eat tba mix 78w92 1.91gm * P<.3
N f cdl eat tba eaL 78w92 a no dre P-.1
470 N m cdl eat lun ado 78w92 .> 31.4gm * P<1.
a N m cdl eatliv car 78w92 no dre P-1.
b N m cdl eat Liv ada 78w92 no dre P-1.
c N m cdl eat lun car 78w92 no dre P-1.
d N m cdl eat tba ben 78w92 no dre P-1.
N m cdl eat tba aeL 78w92 no dre P-1.
f N m cdl eat tba mix 78w92 no dre P-1.
471 R f Lev eat Liv cho 18.24 a .> 12.6gm * P<.3
a R f Lev eat tba mix 18.24 477.mg * P<.4
b R flov eattba maL 18.24 1.60gm * P<.2
c R f Lev eat tba ben 18.24 a no dre P-1.
472 R aov eatliv hpc18e24 .> 12.4gm * P<.3
a R mlev eat Liv hpa 18.24 309.gm *P<1.
b R m Lev eat tba mix18.24 a 796.mg * P<.6
c R m Lev eat tba eaL 18.24 a 2.27gm * P<.5
d R Lev eat tba ben 18e24 no dre P-1.
STYRENE OXIDE lOOng .. :. .lug. :10. :100. : g. :10. :100. :Ig :10
473 R fsda gav for mix 12.36 or . + . 96.5mg * P<.0005+
a R fsda gav forsqc 12.36 er 102.mg * P<.0005+
b R fsda gay forsqn 12.36 er 129.mg * P<.0005+
c R fsda gav forsqi 12.36 er 301.mg * P<.0005+
d R f ada gav for ben 12e36 er 503.mg * P<.009 +
474 R m ada gav forsqc 12.36 er + . 63.0mg\ P<.0005+
a R
a sda gav for mix 12.36 er 99.6mg* P<.0005+
b R sda gav for sqn 12.36 or 140.mg* P<.0005+
c R m ada gav for sqi 12m36 or 267.mg* P<.004 +
d R msda gav for ben 12e36 er 354.mg * P<.003 +
298SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc Citation or Pathology
o c54739 90.5mg 711.mg
p c54739 98.7mg 2.799m
q c54739 157.mg 2.299m
r c54739 70.1mg 42.6gm
s c54739 85.2mg n.s.s.
t c54739 90.9mg n.s.s.
u c54739 116.mg n.s.s.
v c54739 162.mg n.sa.s.
w c54739 9.99mg 29.7mg












457 1604 480.mg n.s.s. 0/12
458 1604 8.95mg n.s.s. 1/12
SACCHARIN, SODIUM*** 128-44-9
459 1537 523.mg 3.41gm 0/30
a 1537 1.129m n.s.s. 0/30
460 1537 2.589m n.s.s. 0/25
461 1574 8.24gm n.s.s. 0/30
a 1574 8.24gm n.s.s. 0/30
462 1657 232.mg 4.71gm 22/42
a 1657 5.759m n.s.s. 0/42
b 1657 5.75gm n.s.s. 0/42
463 1537 2.58gm n.s.s. 0/25




























0/12 23.0mg 1/12 65.4mg 1/12 162.mg 0/12 Habs;clet,23,103-108;
1984


























465 1581 39.3mg 95.8mg
a 1581 571.mg n.s.s.
466 1582m 32.3mg 108.mg
a 1582m 370.mg n.s.s.
467 1582n 30.2mg 58.5mg
a 1582n 130.mg 389.mg
b 1582n 1.09gm n.s.s.
SALBUTAMOL 18559-94-9









































































473 1702 60.6mg 167.mg
a 1702 63.7mg 180.mg
b 1702 78.0mg 264.mg
c 1702 151.mg 755.mg
d 1702 217.mg 19.7gm
474 1702 29.6mg 184.mg
a 1702 63.2mg 194.mg
b 1702 84.3mg 284.mg
c 1702 141.mg 2.30gm




































































































































Brkly Code300 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sax Route Hist No
TELONE II*
475 M f b6c gav NXB MXB 24.25
a M f b6c gav ubt tcc 24.25
b M f b6c gav lun a/a 24.25
c N f b6c gav liv NXA 24.25
d M f b6c gav lun NXA 24.25
* M f b6c gav liv hpa 24.25
f M f b6c gav sto MXA 24.25
g N f b6c gav TBA MXB 24.25
h M f b6c gav liv NXB 24.25
i N f b6c gav Lun NXB 24.25
476 M m b6c gav TBA NXB 24.24 s
a M m b6c gav Liv MXB 24.24 s
b M m b6c gav lun MXB 24.24 s
477 R f f34 gav thy MXA 24a25
a R f f34 gav sto sqp 24.25
b R f f34 gav TBA NXB 24.25
c R f f34 gav liv MXB 24a25
478 R m f34 gav MXB MXB 24.25
a R m f34 gav MXA MXA 24m25
b R m f34 gav liv MXA 24m25
c R a f34 gav MXA MXA 24m25
d R m f34 gav Liv nnd 24m25
a R a f34 gav sto sqc 24a25
f R m f34 gav TBA MXB 24.25
g R a f34 gav Liv MXB 24.25
TDSO 2Tailpvl
DR AuOp tes
lOOng . . .Iug.. : 10. :100.. : lag.. : 10. :100.. : g. :.10














176.mg * P<.05 a
no dre P-1.
168.mg * P<.5
:+ : 33.2mg * P<.0005
64.1mg I P<.0005c
68.Omg * P<.01
97.0mg * P<.006 c
76.0mg * P<.02 c
213.mg * P<.02 c
no dre P-1.
68.0mg * P<.01
TERBUTALINE lOOng..:. .:ug. : 10. :100. la : 1 ng .:10. :100.. :Ig. :10
479 R f cdr aat mao lay 24.24 erv . + . 410.mg * P<.0005+
1,1,1,2-TETRACHLOROETHANE lOOng .. :. .lug.. :10. :100.. :1mg. : 10. :100.. :Ig. : 10
480 N f b6c gav Liv MXA 24m24 as + 175.mg / P<.0005c
a N f b6c gav Liv hpa 24m24 as 254.mg / P<.0005c
b N f b6c gav Liv hpc 24.24 as 640.mg * P<.0005c
c M f b6c gav TBA MXB 24.24 as 110.mg / P<.0005
d N f b6c gav Liv MXB 24.24 as 175.mg I P<.0005
a M f b6c gav Lun MXB 24m24 as 1.82gm * P<.07
481 M b6c gav Liv MXA 24.24 as + 124.mg /P<.0005
a M m b6c gav Liv hpa 24.24 as 190.mg I P<.0005c
b M m b6c gav TBA MXB 24.24 as 97.9mg / P<.0005
c M m b6c gav liv MXB 24.24 as 124.mg I P<.0005
d N m b6c gav Lun MXB 24.24 as 1.33gm P<.3
482 R f f34 gav mgL fba 24m24 s #170.mg \ P<.04 -
a R f f34 gav TBA MXB 24m24 s no dre P-1.
b R f f34 gav Liv MXB 24m24 s 3.989m * P<.5
483 R m f34 gav MXA MXA 24m24 s A #842.mg * P<.03 -
a R a f34 gav Liv MXA 24m24 s 1.13gm * P<.04
b R m f34 gav TBA MXB 24a24 s 464.mg * P<.4
c R a f34 gav Liv MXB 24m24 s 1.13gm * P<.04
TETRACHLOROETHYLENE*** O0ng .. :. .lug.. : 10. :100.. :1.mg.. : 10. :100.. : Ig. :10
484 N f b6c inh Liv MXA 24m24 :+ : 188.mg / P<.0005
a M f b6c inh Liv hpc 24m24 200.mg / P<.0005c
b M f b6c inh TBA MXB 24m24 211.mg * P<.0005
c M f b6c inh Liv MXB 24m24 188.mg I P<.0005
d M f b6c inh Lun MXB 24m24 no dre P-I.
485 M a b6c inh Liv hpc 24m24 + : 162.mg \ P<.0005
a M m b6c inh Liv MXA 24m24 190.mg * P<.0005c
b N a b6c inh Liv hpa 24m24 668.mg * P<.04
c M a b6c inh MXA MXA 24m24 681 .mg \ P<.05
d M a b6c inh TBA MXB 24m24 225.mg * P<.003
a M a b6c inh Liv MXB 24m24 190.mg * P<.0005
f M m b6c inh Lun MXB 24m24 6.05gm * P<.8
486 R f f34 inh MXA MXA 24m24 :> 287.mg * P<.2 a
a R f f34 inh TBA MXB 24m24 869.mg * P<.8
b R f f34 inh Liv MXB 24m24 no dre P-1.
487 R a f34 inh MXB MXB 24m24 : + : 90.8mg * P<.007
a R m f34 inh tes ict 24,24 68.6mg * P<.02
b R m f34 inh MXA MXA 24m24 101.mg * P<.02 c
c R m f34 inh kid MXA 24m24 504.mg * P<.07 c
d R a f34 inh TBA MXB 24m24 77.7mg * P<.04
a R a f34 inh Liv MXB 24.24 368.mg * P<.2
TETRAMETHYLTHIURAM DISULFIDE*** lOOng .. : ..ug.. : 10. :100.. :1.mg.. : 10. :100.. :I1g. :10
488 R f f34 eat Liv nnd 24m30 av .> 97.3mg P<.2
489 R a f34 eat liv nnd 24m30 av .> 374.mg P<.7
a R a f34 eat liv mix 24m30 ev no dre P-1.
b R a f34 eat Liv car 24m30 ev no dre P-1.SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
TELONE II* (1,3-dichtoropropene) 542-75-6
475 c03985 24.5mg 57.1mg 0/50 20.8mg
a c03985 31.8mg 83.7mg 0/50 20.8mg
b c03985 74.7mg 446.mg 0/50 20.8mg
c c03985 37.3mg n.s.s. 1/50 20.8mg
d c03985 77.8mg n.s.s. 2/50 20.8mg
c03985 97.3mg n.s.s. 0/50 20.8mg
f c03985 130.mg n.s.s. 0/50 20.8mg
g c03985 19.3mg 140.mg 16/50 20.8mg
h c03985 37.3mg n.s.s. 1/50 20.8mg
i c03985 77.8mg n.s.s. 2/50 20.8mg
476 c03985 26.7mg n.s.s. 8/50 21.2mg
a c03985 63.6mg n.s.s. 5/50 21.2mg
b c03985 37.2mg n.s.s. 1/50 21.2mg
477 c03985 55.8mg n.s.s. 0/52 10.4mg
a c03985 66.3mg n.s.s. 0/52 10.4mg
b c03985 17.6mg n.s.s. 45/52 10.4mg
c c03985 39.0mg n.s.s. 6/52 10.4mg
478 c03985 19.3mg 85.7mg 2/52 10.5mg
a c03985 32.9mg 217.mg 1/52 10.5mg
b c03985 32.9mg 4.91gm 1/52 10.5mg
c c03985 43.9mg 1.16gm 1/52 10.5mg
d c03985 35.1mg n.s.s. 1/52 10.5mg
c03985 73.6mg n.s.s. 0/52 10.5mg
f c03985 17.1mg n.s.s. 44/52 10.5mg






































































479 1734 186.mg 1.33gm
1,1,1,2-TETRACHLOROETHANE
480 c52459 108.mg 316.mg
a c52459 145.mg 517.mg
b c52459 275.mg 2.68gm
c c52459 66.5mg 225.mg
d c52459 108.mg 316.mg
c52459 447.mg n.s.s.
481 c52459 75.3mg 255.mg
a c52459 112.mg 391.mg
b c52459 58.4mg 215.mg
c c52459 75.3mg 255.mg
d c52459 334.mg n.s.s.
482 c52459 68.8mg n.s.s.
a c52459 194.mg n.s.s.
b c52459 601.mg n.s.s.
483 c52459 337.mg n.s.s.
a c52459 385.mg n.s.s.
b c52459 115.mg n.s.s.
c c52459 385.mg n.s.s.





































































484 c04580 127.mg 314.mg 4/50 211.mg 17/50 422.mg
a c04580 137.mg 313.mg 1/50 211.mg 13/50 422.mg
b c04580 119.mg 712.mg 27/50 211.mg 35/50 422.mg
c c04580 127.mg 314.mg 4/50 211.mg 17/50 422.mg
d c04580 1.20gm n.s.s. 6/50 211.mg 3/50 422.mg
485 c04580 90.4mg 407.mg 7/50 176.mg 25/50 (352.mg
a c04580 115.mg 459.mg 17/50 176.mg 31/50 352.mg
b c04580 283.mg n.s.s. 12/50 176.mg 8/50 352.mg
c c04580 234.mg n.s.s. 3/50 176.mg 7/50 (352.mg
d c04580 119.mg 1.30gm 29/50 176.mg 38/50 352.mg
a c04580 115.mg 459.mg 17/50 176.mg 31/50 352.mg
f c04580 706.mg n.s.s. 6/50 176.mg 6/50 352.mg
486 c04580 110.mg n.s.s. 18/50 101.mg 30/50 201.mg
a c04580 101.mg n.s.s. 42/50 101.mg 45/50 201.mg
b c04580 706.mg n.s.s. 2/50 101.mg 0/50 201.mg
487 c04580 44.4mg 1.34gm 28/50 70.4mg 37/50 141.mg
a c04580 31.7mg n.s.s. 35/50 70.4mg 39/50 141.mg
b c04580 47.4mg n.s.s. 28/50 70.4mg 37/50 141.mg
c c04580 173.mg n.s.s. 1/50 70.4mg 3/50 141.mg
d c04580 33.7mg n.s.s. 46/50 70.4mg 48/50 141.mg






















TETRAMETHYLTHIURAM DISULFIDE*** (TMTD, thiram) 137-26-8
488 1645 28.8mg n.s.s. 4/24 20.3mg 8/24
489 1645 46.3mg n.s.s. 2/24 16.2mg 3/24
a 1645 51.1mg n.s.s. 3/24 16.2mg 3/24



















Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
THIOSENICARBAZIDE***
490 N f ewe wet Liv hpt
a N f swa wat Lun tum
491 N m ews wat liv hpt






492 R f cdr eat Liv tur 52w52 ek
493 R f cdr eat liv tum 24.24 e
a R f cdr eat tba mix 24.24 e
b R f cdr eat tba mal 24.24 e
494 R e cdr eat liv tum 52w52 ek
495 R m cdr eat liv tue 24.24 e
a R e cdr eat tbe mix 24.24 e
b R m cdr eat tba mae 24m24 e
TD50 2TeiLpvL
DR AuOp
lOOng.. : .ug.. : 10. :100.. :l1ug.. : 10..:100.. :.1g. :10
s .> no dre
s no dre
B .> no dre
s no dre





















TOLUENE lOOng.. : .ug.:10. :100. : ng.:10. :100..:Ig. :10
496 R f f34 inh Liv mix 25m25 e .> 1.76gm P<.2
497 R m f34 inh Liv mix 25m25 e .> 1.219m P<.4
TRICHLOROETHYLENE***
498 N f ic. inh lun .ix
a N f icm lnh lun adc
b N f ic. inh Liv ade
c N f ic. inh tba mix
499 R f cdr inh mgl fba
a R f cdr inh Liv mix









500 R m f34 gav col pla 52w52 ekr
a R m f34 gav kid adc 52w52 ekr
b R m f34 gav Liv tum 52w52 ekr
TRIS(2-ETHYLHEXYL)PHOSPHATE
501 N f b6c gav liv hpc 24,24
a N f b6c gav liv MXA 24.24
b N f b6c gav TBA MXB 24.24
c N f b6c gav liv NXB 24.24
d N f b6c gav tun MXB 24.24
502 N o b6c gav TSA MXB 24.24
a N m b6c gav Liv MXB 24m24
b N . b6c gav lun MXB 24.24
503 R f f34 gav TBA MXB 24.24
a R f f34 gav Liv MXB 24m24
504 R m f34 gev adr phe 24m24
a R m f34 gav adr MXA 24.24
b R m f34 gav NXA NXA 24m24
c R m f34 gav NXA MXA 24.24
d R m f34 gav TBA MXB 24m24
* R m f34 gav Liv MXB 24m24
DL-TRYPTOPHAN
505 R fies eat liv tum 98w98
a R m fis eat ubl tum 98w98
L -TRYPTOPHAN***
506 R m fissat Liv tum 24.24
a R m fis eat ubl tum 24m24
VINYL ACETATE
507 R f f34 wat thy cca 23m30
a R f f34 wat Liv nnd 23m30
b R f f34 wat ute adc 23m30
c R f f34 wat thy ccr 23.30
d R f f34 wat tba mix 23m30
508 R . f34 wet Liv nnd 23.30
a R m f34 wat thy ccr 23.30
b R m f34 wat tba mix 23m30
VINYL CHLORIDE***
509 H f syg inh mgt car 6.24 es
a H f syg inh sto ad. 6.24 es
b H f syg inh --- hes 6.24 es
510 H f syg inh mgL car 12m24 es
a H f syg inh ski car 12m24 es
b H f syg inh -- hes 12m24 es
c H f syg inh sto ado 12.24 es
lOOng .. : lug.:10. :100. g :. . :10. :100..:19 :10
3.379m * P<.07






..l:.1ug.:10. :100.:1mg.:10. :100. g.10
+ . 13.4mg P<.006 +
54.8mg P<.2 +
no dre P-1.
lOOng.. : .ug.:10. :100. 1g :1g :10. :100..: g. :10





:> no dre P-I1.
9.00gm * P<.9
no dre P-1.
:> 230.gm * P<1. -
no dre P-1.
+ 5.29gm * P<.002 a





bO0ng . . .Iug.:10. :100. m : g.:10. :100.:Ig..:10
.> no dre P-1.
no dre P-1.
100ng. . .. :1ug . 10. :100. . : 1g . :10. :100.:Ig..:10
.> no dre P-1.
no dre P-1.
lOOng. . .. : lug . 10. :100.:1.g.:10. :100..: ..:10
+ . 420.mg * P<.006 +
488.mg * P<.003 +
494.mg * P<.006 +
25.5gm * P<l. +
no dre P-1.
132.g \ P<.02 +
no dre PaI. +
57.7mg * P<.3
bO0ng. . .. :1ug. 10. :100.1. : g.:10. :100. I :g. :10
I . + . 32.3mg
47.2mg
I 78.6.g










P<.5 +SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
RefMum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
THIOSEMICARBAZIDE*** (thiocarba.ylhydrazins) 79-19-6
490 1675 38.4mg n.s.s. 1/15 31.2mg 0/14 62.4mg
a 1675 469.mg n.s.s. 24/98 31.2mg 9/49 62.4mg
491 1675 204.mg n.s.s. 0/100 26.0mg 0/49 52.0mg








DL-aLpha-TOCOPHERYL ACETATE (vitamin E) 59-02-9
492 1558m 147.mg n.s.s. 0/10 500.mg 0/10 1.009g
493 1558n 24.49m n.s.s. 2/50 500.mg 1/49 1.009m
a 1558n 911.ag n.s.s. 46/50 2.00gm 45/50
b 1558n 8.01gm n.s.s. 9/50 2.00gm 6/50
494 1558m 147.mg n.s.s. 0/10 500.mg 0/10 1.00gm
495 1558n 21.4gm n.s.s. 2/49 500.mg 1/50 1.00gm
a 1558n 2.12gm n.s.s. 28/49 2.009m 29/50
b 1558n 5.23gm n.s.s. 7/49 2.00gm 8/50
TOLUENE 108-88-3
496 1578 490.mg n.s.s. 1/90 84.6mg 4/90
497 1578 297.mg n.s.s. 3/89 59.2mg 6/90
0/10 2.009m 0/10
1/50 2.009m 0/50





498 1626 1.26gm n.s.s. 6/49
a 1626 1.46gm n.s.s. 1/49
b 1626 6.909m n.s.s. 0/49
c 1626 704.mg n.s.s. 18/49
499 1626 320.mg n.s.s. 6/50
a 1626 1.409m n.s.s. 0/50
b 1626 288.mg n.s.s. 32/50
95.8mg 5/50 287.mg 13/50 862.mg 11/46
95.8mg 3/50 287.mg 8/50 862.mg 7/46
95.8mg 0/50 287.mg 0/50 862.mg 1/46
95.8mg 18/50 287.mg 27/50 862.mg 24/46
22.8mg 12/50 68.4mg 10/47 205.mg 14/51
22.8mg 1/50 68.4mg 0/47 205.mg 1/51
22.8mg 39/50 68.4mg 31/47 205.mg 32/51
Fukuda; indh,21,243-254; 1983
TRIS(2,3-DIBRO4OPROPYL)PHOSPHATE*** (TRIS) 126-72-7
500 1729 3.72mg 189.mg 0/9 71.4mg 3/5
a 1729 8.84mg n.s.s. 0/9 71.4mg 1/5
b 1729 18.4mg n.s.s. 0/9 71.4mg 0/5
Reznik; l ivt,44,74-83;1981
TRIS(2-ETHYLHEXYL)PHOSPHATE 78-42-2
501 c54751 1.28gm 17.6gm 0/50 352.mg
a c54751 995.mg n.s.s. 2/50 352.mg
b c54751 1.01gm n.s.s. 24/50 352.mg
c c54751 995.mg n.s.s. 2/50 352.mg
d c54751 2.449m n.s.s. 2/50 352.mg
502 c54751 1.09gm n.s.s. 33/50 352.mg
a c54751 785.mg n.s.s. 15/50 352.mg
b c54751 1.99gm n.s.s. 7/50 352.mg
503 c54751 1.04gm n.s.s. 37/50 704.mg
a c54751 13.9gm n.s.s. 1/50 704.mg
504 c54751 2.86gm 24.9gm 2/50 1.41gm
a c54751 2.869m 24.9gm 2/50 1.41gm
b c54751 6.54gm n.s.s. 1/50 1.41ga
c c54751 9.66gm n.s.s. 0/50 1.41gm
d c54751 2.04gm n.s.s. 32/50 1.41gm
c54751 n.s.s. n.s.s. 0/50 1.41gm
DL-TRYPTOPHAN 54-12-6
505 1657 2.93gm n.s.s.
a 1657 2.93ga n.s,s.
L -TRYPTOPHAN*** 73-22-3
506 1574 3.30gm n.s.s.
a 1574 3.30gm n.s.s.
VINYL ACETATE 108-05-4
507 1546 181.mg 4.68gm
a 1546 198.mg 2.31gm
b 1546 201.mg 4.70gm
c 1546 590.mg n.s.s.
d 1546 37.7mg n.s.s.
508 1546 45.4mg n.s.s.
a 1546 254.mg n.s.s.
b 1546 14.8mg n.s.s.
VINYL CHLORIDE*** 75-01-4
509 1536m 20.5mg 55.1mg
a 1536m 27.1mg 105.mg
b 1536m 41.4mg 177.mg
510 1536n 17.7mg 46.4mg
a 1836n 56.9mg 330.mg
b 1536n 108.mg 1.73gm










































































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2TaiLpvL
DR AuOp
511 H f syg inh mgL car 18m24 es
a H f syg inh sto ada 18.24 as
b H f syg inh --- hes 18.24 as
512 N f swi inh mgL car 6.24 es
a N f swi inh --- hes 6m24 es
b N f swi inh Lun car 6.24 es
513 N f swi inh --- hes 12.24 as
a N f swi inh mgL car 12.24 as
b N f swi inh Lun car 12.24 es
514 N f swi inh mgL car 18m24 es
a M f swi inh --- hes 18m24 es
b M f swi inh lun car 18,24 es
515 R f f34 inh Liv nnd 6a24 e
a R f f34 inh mgL fba 6m24 e
b R f f34 inh --- hes 6a24 e
c R f f34 inh Liv hpc 6.24 a
516 R f f34 inh mgL fba 12.24 a
a R f f34 inh Liv nnd 12,24 a
b R f f34 inh --- hes 12.24 e
c R f f34 inh mgL adc 12.24 a
d R f f34 inh Liv hpc 12m24 e
517 R f f34 inh mgL fba 18.24 a
a R f f34 inh --- hes 18.24 a
b R f f34 inh Liv hpc 18a24 a
c R f f34 inh mgL adc 18a24 a
d R f f34 inh Liv nnd 18a24 e
518 R f f34 inh --- hes 24,24 a
a R f f34 inh mgL fba 24,24 a
b R f f34 inh Liv hpc 24.24 a
c R f f34 inh Liv nnd 24.24 a





































































519 R f sss wat Liv nnd 24m24 a
a R f sss wat Liv hpc 24.24 a
b R f sss wat mgL aff 24m24 a
c R f sss wat pit ada 24m24 a
520 R m sss wat Liv hpc 24m24 e
a R m sss wat Liv nnd 24m24 a
lOOng.. :. .lug.:10. :100.. : g.:10. :100.:Ig. :10




.> 22.9gm * P<1.
no dre P-1.
FD & C VIOLET NO. 1*** iOOng..:..lug.:10. :100. 1m : g.:10. :100.:Ig. :10
521 R f sda eat .gl car 51w52 erv . + . 573.mg P<.0005+
a R f sda eat ski sqc 51w52 arv 1.109g P<.0005+
b R f sda eat tba mix 51w52 arv 418.mg P<.0005+
ZINC DINETHYLDITHIOCARBANATE*** lOOng...:1u9 : 10 .1:0.100.. g : . . :10. :100.:Ig. :10
522 N f b6c eat lun a/a 24m24 : 561.mg * P<.04 a
a H f b6c eat --- mlp 24.24 947.mg * P<.05
b N f b6c eat TBA MXB 24m24 no dre P-1.
c M f b6c eat liv NXB 24m24 no dre P-1.
d N f b6c eat lun NXB 24m24 710.mg * P<.2
523 N m b6c eat TBA MXB 24a24 :> no dre P-1.
a M m b6c eat Liv MXB 24m24 no dre P-1.
b M a b6c eat lun MXB 24.24 765.mg * P<.3
524 R f f34 eat TBA NXB 24m24 :> no dre P-I.
a R f f34 eat liv MXB 24m24 no dre P-1.
525 R m f34 eat thy ccr 24.24 + 95.8mg * P<.004 c
a R m f34 eat TBA NXB 24m24 no dre P-1.
b R a f34 eat liv MXB 24.24 no dre P-1.
+ gSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE































































































519 1655 74.1mg n.s.s. 1/80
a 1655 106.mg n.s.s. 0/80
b 1655 8.69mg n.s.s. 53/75
c 1655 19.3mg n.s.s. 25/76
520 1655 86.2mg n.s.s. 2/80






































































































VIOLET NO. 1*** (benzyl vioLet 4B)
1643 325.mg 1.14gm 0/35 2.419m
1643 547.mg 2.72gm 0/35 2.41gm






ZINC DINETHYLDITHIOCARBAMATE*** (methyl zimate, milbam, ziram) 137-30-4
522 c50442 245.mg n.s.s. 2/50 76.5mg 5/50 154.mg 10/50
a c50442 373.mg n.s.s. 1/50 76.5mg 1/50 154.mg 7/50
b c50442 338.mg n.s.s. 28/50 76.5mg 19/50 154.mg 23/50
c c50442 341.mg n.s.s. 9/50 76.5mg 4/50 (154.mg 1/50)
d c50442 254.mg n.s.s. 4/50 76.5mg 6/50 154.mg 11/50
523 c50442 192.mg n.s.s. 31/50 70.6mg 24/50 143.mg 25/49
a c50442 209.mg n.s.s. 19/50 70.6mg 9/50 (143.mg 9/49)
b c50442 215.mg n.s.s. 8/50 70.6mg 8/50 143.mg 12/49
524 c50442 39.5mg n.s.s. 43/50 14.6mg 42/50 29.6mg 39/50
a c50442 n.s.s. n.s.s. 0/50 14.6mg 0/50 29.6mg 0/50
525 c50442 45.1mg 602.mg 0/50 11.8mg 2/50 23.8mg 7/50
a c50442 21.8mg n.s.s. 37/50 11.8mg 42/50 23.8mg 39/50












APPENDIX 1: CHEMICAL NAMES AND SYNONYMS IN THIS PLOT
CAS
NUMBER CHEMICAL NAME














61-82-5 AMITROL (see 3-AMINOTRIAZOLE)
104-46-1 ANETHOLE











50-32-8 BENZPYRENE (see BENZO(a)PYRENE)
50-32-8 3,4-BENZPYRENE (see BENZO(a)PYRENE)
1694-09-3 BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)
25013-16-5 BHA (see BUTYLATED HYDROXYANISOLE)
53609-64-6 N-BIS(2-HYDROXYPROPYL)NITROSAMINE (see N-NITROSOBIS(2-
HYDROXYPROPYL)AMINE)
54143-56-5 2,5-BIS(2,2,2-TRIFLUORETHOXYL)-N-(2-PIPERIDYLMETHYL)
BENZAMIDE ACETATE (see FLECAINIDE ACETATE)
2475-45-8 C.I. DISPERSE BLUE 1
2784-94-3 HC BLUE NO. 1
33229-34-4 HC BLUE NO. 2
7758-01-2 BROMATE, POTASSIUM
106-99-0 1,3-BUTADIENE
3817-11-6 BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-
HYDROXYBUTYL) NITROSAMINE)
109-69-3 N-BUTYL CHLORIDE









63449-39-8 CHLORINATED PARAFFINS (C23, 43% CHLORINE)
63449-39-8 CHLORINATED PARAFFINS (C12, 60% CHLORINE)




593-70-4 CHLOROFLUOROMETHANE (see FLUOROCARBON 31)
63449-39-8 CHLOROWAX 40 (se CHLORINATED PARAFFINS
(C23, 43% CHLORINE))





55600-34-5 CLOPHEN A 30
11096-82-5 CLOPHEN A 60 (see AROCLOR 1260)
60391-92-6 CMNU (see CARBOXYMETHYLNITROSOUREA)
65765-07-3 COMPOUND 50-892
51630-58-1 CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-alpha-







55-18-5 DEN (see N-NITROSODIETHYLAMINE)
9004-54-0 DEXTRAN
9011-18-1 DEXTRAN SULFATE SODIUM (DS-M-1)
9011-18-1 DEXTRAN SULFATE SODIUM (DST-H)




124-48-1 DIBROMOCHLOROMETHANE (see CHLORODIBROMOMETHANE)
3296-90-0 DIBROMONEOPENTYL GLYCOL
924-16-3 DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)
7572-29-4 DICHLOROACETYLENE
95-50-1 1,2-DICHLOROBENZENE
95-50-1 o-DICHLOROBENZENE (see 1,2-DICHLOROBENZENE)
75-09-2 DICHLOROMETHANE (see METHYLENE CHLORIDE)
542-75-6 1,3-DICHLOROPROPENE (see TELONE U)
21498-08-8 2I1-(2,6-DICHLORPHENOXY)-ETHYLI-2-IMIDAZOLINE.HCl (see
LOFEXIDINE.HCI)
55-18-5 DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)





868-85-9 DIMETHYL HYDROGEN PHOSPHITE
597-25-1 DIMETHYL MORPHOLINOPHOSPHORAMIDATE
1643-20-5 N,N-DIMETHYLDODECYLAMINE-N-OXIDE
62-75-9 DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)




621-64-7 DIPROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
68-89-3 DIPYRONE
868-85-9 DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
62-75-9 DMN (see N-NITROSODIMETHYLAMINE)
90-43-7 DOWICIDE-1 (see o-PHENYLPHENOL)
87-86-5 DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
9011-18-1 DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
9011-18-1 DST-H (see DEXTRAN SULFATE SODIUM (DST-H))
50-18-0 ENDOXAN (see CYCLOPHOSPHAMIDE)
13838-16-9 ENFLURANE
759-73-9 ENU (see 1-ETHYL-1-NITROSOUREA)
134-72-5 EPHEDRINE SULPHATE
6381-77-7 ERYTHORBATE, SODIUM





759-73-9 N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
75-21-8 ETHYLENE OXIDE
759-73-9 ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
97-53-0 EUGENOL
24554-26-5 FANFT (see NJ4-(5-NITRO-2-FURYL)-2-THIAZOLYLFORMAMIDE)
51630-58-1 FENVALERATE
67774-32-1 FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL MIXTURE)
54143-56-5 FLECAINIDE ACETATE
53-96-3 FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)





75-09-2 FREON 30 (see METHYLENE CHLORIDE)
23255-69-8 FUSARENON-X
67730-11-4 GLU-P-1 (see2-AMINO-6-METHYLDIPYRIDOj1,2-a3',2'-dJMIDAZOLE)




53-95-2 N-HYDROXY-N-ACETYL-2-AMINOFLUORENE (see N-HYDROXY-2-
ACETYLAMINOFLUORENE)
53-95-2 N-HYDROXY-2-ACETYLAMINOFLUORENE
53-95-2 HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-
ACETYLAMINOFLUORENE)
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NUMBER CHEMICAL NAME




54-85-3 INH (see ISONIAZID)
76180-96-6 IQ (see 2-AMINO-3-METHYLIMIDAZO[4,5-fQUINOLINE)
6381-77-7 ISOASCORBATE (see ERYTHORBATE, SODIUM)
760-60-1 N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-ISOBUTYLUREA)
54-85-3 ISONIAZID
1453-82-3 ISONICOTINAMIDE
54-85-3 ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
78-59-1 ISOPHORONE
65765-07-3 1-ISOPROPYL-4-(m-METHOXYPHENYL)-7-METHYL-2(1H)-




9011-18-1 KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
21498-08-8 LOFEXIDINEHC1
67-20-9 MACRODANTIN (see 1-1(5-NITROFURFURYLIDENE)AMINOI
HYDANTOIN)
569-61-9 p-MAGENTA (see p-ROSANILINE.HCI)




25843-45-2 Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
70-25-7 N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
21308-79-2 METHYL 12-OXO-trans-10-OCTADECENOATE
614-00-6 METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)





137-30-4 MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
70-25-7 MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
1068-57-1 MONOACETYL HYDRAZINE






















































90-43-7 ORTHOXENOL (see o-PHENYLPHENOL)
103-90-2 PARACETAMOL (see ACETAMINOPHEN)
11096-82-5 PCB (see AROCLOR 1260)
87-86-5 PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)
76-01-7 PENTACHLOROETHANE
87-86-5 2,3,4,5,6-PENTACHLOROPHENOL
76-01-7 PENTALIN (see PENTACHLOROETHANE)
127-18-4 PERCHLOROETHYLENE (see TETRACHLOROETHYLENE)
62-44-2 PHENACETIN
50-06-6 PHENOBARBITAL
50-06-6 PHENOBARBITONE (see PHENOBARBITAL)
106-50-3 p-PHENYLENEDIAMINE






100-75-4 PIP (see N-NITROSOPIPERIDINE)
67774-32-1 POLYBROMINATED BIPHENYL MIXTURE
3761-53-3 PONCEAU MX (see D & C RED NO. 5)
7758-01-2 POTASSIUM BROMATE (see BROMATE, POTASSIUM)
40778-40-3 PRIMIDOLOL.HCI




621-64-7 DI-N-PROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
22760-18-5 PROQUAZONE




148-24-3 8-QUINOLINOL (see 8-HYDROXYQUINOLINE)
569-61-9 C.L BASIC RED 9.HC1 (see p-ROSANILINE.HCI)
3761-53-3 D & C RED NO. 5







7681-49-4 SODIUM FLUORIDE (soe FLUORIDE, SODIUM)
959-24-0 SOTALOL.HCl
28754-68-9 SQ 18506 (see trans-5-AMINO-3{2-(5-NITRO-2-FURYL)VINYL-1,2,4-
OXADIAZOLE)
96-09-3 STYRENE OXIDE
68-89-3 SULPYRIN (see DIPYRONE)






79-19-6 THIOCARBAMYLHYDRAZINE (see THIOSEMICARBAZIDE)
79-19-6 THIOSEMICARBAZIDE
137-26-8 THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)



















FD & C VIOLET NO. 1
VITAMIN C (see L-ASCORBIC ACID)
VITAMIN E (see DL-alpha-TOCOPHERYL ACETATE)
ZINC DIMETHYLDITHIOCARBAMATE
ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
CAS NUMBER = Chemical Abstracts Service registry number
APPENDIX 2: CHEMICAL NAMES IN THIS PLOT





























































































































































TETRAMETHYLTHIURAM DISULFIDE (TMTD, thiram)



































FD & C VIOLET NO. 1 (benzyl violet 4B)
CAPTAFOL
C.I. DISPERSE BLUE 1
HC BLUE NO. 1
ALLYL ISOVALERATE
HC RED NO. 3
DIACETYL HYDRAZINE
DIBROMONEOPENTYL GLYCOL
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CHEMICAL NAME
DEXTRAN SULFATE SODIUM (DST-H) (Mol. Wt. -9500)
DEXTRAN SULFATE SODIUM (KMDS-H) (Mol. Wt. 520,000)
HYDRAZINE SULFATE
NITROSOETHYLMETHYLAMINE















































CHLORINATED PARAFFINS (C12, 60% CHLORINE) (Chlorowax 500c,
Avg. Mol. Wt. 411)
CHLORINATED PARAFFINS (C23, 43% CHLORINE) (Chlorowax 40,





























b6b (B6C3F1 X B6C3 background, brachymorphic)
inter se = B6C3F2
brachymorphic
b6c B6C3F1
b6n (B6C3F1 X B6C3 background, brachymorphic)









cbn C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr inter se
cdl Charles River CD1
cdf CDF1
cdr Charles River CD
cff C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr
cfi C3H/FIB









fmf Fischer 344/Mai fBR
icm ICR
ifm IF
























































































APPENDIX 4: ROUTE OF ADMINISTRATION Code Site
CODES AND DEFINITIONS pdu pancreatic duct




eat diet pit pituitary gland
gav gavage pIs palate, soft
inh inhalation pni pancreatic islets
ipi intraperitoneal injection pnl paranasal sinus
ivj intravenous injection pns peripheral nervous system




APPENDIX 5: SITE CODES AND DEFINITIONS
res respiratory system APPENDIX 5:SITE CODES AND ~~~~~~~ski skin
Code Site slg salivary gland
smi small intestine
spl spleen
--- all target sites ssq stomach, squamous
adr adrenal gland stg stomach, glandular
amd adrenal medulla sto stomach
blv blood vessels sub subcutaneous tissue
bod body cavities TBA all tumor bearing animals, NCI/NTP
bom bone marrow tba all tumor bearing animals
bra brain tes testis
cec cecum thm thymus gland
cli clitoral gland thx thorax
clr colorectum thy thyroid gland
col colon tnv tunica vaginalis
cst cardiac stomach ton tongue
cvu cervix uteri trh trachea
dgt digestive tract tyf thyroid follicle
duo duodenum ubl urinary bladder
edu ear duct unt urinary tract
eso esophagus ute uterus
for forestomach utm uterus/endometrium
gam gastric mucosa vag vagina
git gastrointestinal tract vse vascular epithelium














mix more than one site; sites specified in published paper
mln mesenteric lymph node
mls multiple sites
mul multiple organs
MXA more than one site, combined by NCI/NTP




























bda bile duct adenoma































































more than one tumor type; tumor types specified
in published paper
monocytic leukemia
malignant lymphoma, histiocytic type
malignant lymphoma, mixed type
malignant lymphoma, lymphocytic type







mtb mixed tumor, benign
mtm mixed tumor, malignant
MXA more than one tumor type, combined by NCI/NTP























sqi squamous-cell carcinoma, invasive
sqn squamous-cell carcinoma, in situ
sqp squamous-cell papilloma
squ squamous-cell carcinoma, unclassified
srn sarcoma, NOS
ssc squamous-cell carcinoma, sebaceous
tcc transitional-cell carcinoma





tum tumor or more than one tumor type; tumor types




NOS = not otherwise specified.
APPENDIX 7: NOTECODES AND DEFINITIONS
Code Definition
a The exposure time reported on the plot is an average of
the different exposure times of the individual dose
groups in the experiment. For NCI/NTP bioassays,
both exposure and experiment times have been averaged
because of differential survival among the dose groups.
(In the TD50 calculation for the NCI/NTP bioassays,
full lifetable data have been used.)
b Diet was specially prepared to be deficient in one or
more vitamins.
c Diet was specially prepared to be low in lipotropes.






































































number of animals in a group whenever possible. This
effective number is either: (1) the number of animals
examined, or (2) the number of animals alive at the
time of appearance of the first tumor.
f Diet was specially prepared to have a lower than aver-
age protein level.
g Some or all of the animals were used as breeders during
the course of the experiment.
i Dosing in this test was intermittent; it was stopped for
more than one week at some point in the experiment.
j The data for this test have been previously published in
the database. The experimental results have been
revised and re-published by the authors. In the data-
base, we give the same reference number to the test in
both publications.
k For interim and serial sacrifice experiments, we have
reported, as a separate experiment, each sacrifice time
that otherwise met the inclusion rules of the database.
The k notecode identifies these sacrificed groups.
Wherever possible, we have included unscheduled
deaths with the terminal sacrifice data, and when this
has been done, there is no k notecode for that experi-
ment.
r Restricted site analysis; the authors either examined or
chose to report data for only a few selected tissues.
s Authors noted that survival was decreased due to toxi-
city or disease.
v Variable or irregular dosing schedules have been used,
e.g., dose level changed during the experiment.
y Animals were dosed for only 25 weeks; one week short
of the standard criterion. Due to rounding, 6 months is
reported as the exposure time on the plot.
APPENDIX 8: DOSE-RESPONSE CURVE
SYMBOLS AND DEFINITIONS
Code Dose-Response Curve
* consistent with linearity
/ significant departure from linearity, upward curvature
significant departure from linearity, downward curvature
Z significant departure from linearity, more than three dose
groups including controls
blank either no dose-related effect, or only two dose groups
including controls, so not enough information to
determine a curve shape
APPENDIX 9:
REFERENCE CODES AND DEFINITIONS
Code Reference
acnr Anticancer Research
ajpa American Journal of Pathology
ajsu American Journal of Surgery
amet Advances in Modern Environmental Toxicology
anes Anesthesiology






ciit A Chronic Inhalation Toxicology Study in Rats and
Mice Exposed to Formaldehyde. (K.L. Pavkov, W.D.
Kerns, R.I. Mitchell, M.M. Connell, D.J. Donofrio, H.H.
Harroff, A.D. Barker, G.L. Fisher, R.L. Joiner, D.C.
Thake) Final Report, CIIT Docket #10922. Chemical
Industry Institute of Toxicology, Research Triangle
Park, NC, 1981.
clet Cancer Letters
ctfr A Twenty-Four Month Inhalation Toxicology Study in
Fischer-344 Rats Exposed to Atmospheric Toluene.
(E.J. Gralla) Final Report, CIIT Docket #22000. Chem-
ical Industry Institute of Toxicology, Research Triangle
Park, NC, 1980.
dact Drug and Chemical Toxicology
eaes Ecotoxicology and Environmental Safety
eamp Experimental and Molecular Pathology
enhp Environmental Health Perspectives
faat Fundamental and Applied Toxicology
fctx Food and Chemical Toxicology (formerly Food and
Cosmetics Toxicology, until 1982)
gann Gann
hepg Hepato-gastroenterology
hijm Hiroshima Journal of Medical Sciences
iarc IARC Scientific Publication #31. (E.A. Walker, L.
Griciute, M. Castegnaro, and M. Borzsonyi, Eds.),
World Health Organization, International Agency for
Research on Cancer, Lyon, France, 1980.
ijcn International Journal of Cancer (formerly International
Union Against Cancer. Acta. Vol 1-20, 1936-64)
ijmr Indian Journal of Medical Research
ijvn International Journal for Vitamin and Nutrition
Research
indh Industrial Health
jcph Journal of Clinical Pharmacology
jctx Journal of Combustion Toxicology
jfds Journal of Food Safety
jjem Japanese Journal of Experimental Medicine
jnci Journal of the National Cancer Institute (U.S. National
Cancer Institute. Journal)
jsac Journal of Studies on Alcohol
jtxe Journal of Toxicology and Environmental Health
livt Laboratory Investigation
onco Oncology
pffm Plant Foods for Man
pjpa Proceedings of the Japan Academy
pseb Proceedings of the Society for Experimental Biology
and Medicine (New York)
sjge Scandinavian Journal of Gastroenterology
txap Toxicology and Applied Pharmacology
txcy Toxicology
txlt Toxicology Letters
zkko Journal of Cancer Research and Clinical Oncology
(formerly Zeitschrift fur Krebsforschung und Klinische
Onkologie through Vol 9, 1979)
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APPENDIX 10: NCI/NTP BIOASSAYS
EVALUATED AS INADEQUATE IN
TECHNICAL REPORTS
Experiments Evaluated
Chemical Name as Inadequate
CHLORODIBROMOMETHANE male mice (low dose)
HC RED NO. 3 female mice
TELONE II male mice
APPENDIX 11:
AUTHOR'S OPINION CODES AND DEFINITIONS
Code Author's Opinion for Each Site
a NTP evaluation is "some evidence of carcinoge-
nicity".
c NTP evaluation is "clear evidence of carcinoge-
nicity".
e NTP evaluation is "equivocal evidence of carcinoge-
nicity".
+ Author in general literature evaluated site as posi-
tive.
- NTP evaluation of experiment is "no evidence of
carcinogenicity" ("-" is given for most potent site in
the experiment); or author in general literature
evaluated site as negative.
blank For NTP and general literature: all other sites.
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APPENDIX 13:
Bibliography: National Cancer Institute/
National Toxicology Program Technical Reports
TECHNICAL PUBLICATION
CHEMICAL NAME REPORT NUMBER DATE
ALLYL ISOVALERATE 253 1983
L-ASCORBIC ACID (VITAMIN C) 247 1983
BENZENE 289 1986
C.I. DISPERSE BLUE 1 299 1986
HC BLUE NO. 1 271 1985
HC BLUE NO. 2 293 1985
1,3-BUTADIENE 288 1984
N-BUTYL CHLORIDE 312 1986
CHLORINATED PARAFFINS (C23, 43% CHLORINE) 305 1986
CHLORINATED PARAFFINS (C12, 60% CHLORINE) 308 1986
CHLOROBENZENE 261 1985
CHLORODIBROMOMETHANE 282 1985
DECABROMODIPHENYL OXIDE 309 1986
DIALLYL PHTHALATE (mice) 242 1983
DIALLYL PHTHALATE (rats) 284 1985
1,2-DICHLOROBENZENE 255 1985
DICHLOROMETHANE (METHYLENE CHLORIDE) 306 1986
DIMETHYL HYDROGEN PHOSPHITE 287 1985
DIMETHYL MORPHOLINOPHOSPHORAMIDATE 298 1986





4,4'-METHYLENEDIANILINE DIHYDROCHLORIDE 248 1983
PENTACHLOROETHANE 232 1983
POLYBROMINATED BIPHENYL MIXTURE 244 1983
PROPYLENE 272 1985
1,2-PROPYLENE OXIDE 267 1985
HC RED NO. 3 281 1986
C.I. BASIC RED 9 MONOHYDROCHLORIDE 285 1986
TELONE II 269 1985
1,1,1,2-TETRACHLOROETHANE 237 1983
TETRACHLOROETHYLENE (PERCHLOROETHYLENE) 311 1986
TRIS(2-ETHYLHEXYL)PHOSPHATE 274 1984
ZIRAM 238 1983SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
APPENDIX 14: INDEX TO CHEMICAL NAMES IN ALL PLOTS
CAS
PLOT NUMBER CHEMICAL NAME
3 26148-68-5 A-alpha-C (we 2-AMINO-9H-PYRIDO(2,3-b)INDOLE)
















I --- ACETYLATED DIAMYLOPECTIN PHOSPHATE
1 --- ACETYLATED DISTARCH ADIPATE
1 --- ACEIYLATED DISTARCH GLYCEROL
1 --- ACETYLATED DISTARCH PHOSPHATE
1,2 3567-69-9 C.I. ACID RED 14, DISODIUM SAT (e Cl. FD RED 3)
1 7008-42-6 ACRONYCINE
1 107-13-1 ACRYLONITRILE
1 50-76-0 ACTINOMYCIN D




1,3 1162-65-8 AFLATOXIN BI
1 --- AFLATOXIN, CRUDE
2 9002-18-0 AGAR
2 2757-90-6 AGARITINE (see beta-N-fgLmma-L(+)-GLUTAMYLJ-4-
HYDROXYMETHYLPHENYLHYDRAZINE)
1 101-73-5 AGERrT 150 (se p-ISOPROPOXYDIPHENYLAMINE)
1 103-16-2 AGERITE ALBA (see HYDROQUINONE MONOBENZYL
ETHER)
1 74-31-7 AGERITE DPPD (see DIPHENYL-p-
PHENYLENEDIAMINE)
1,2 135-88-6 AGERITE POWDER (see PHENYL-beta-
NAPHTHYLAMINE)
1 93-46-9 AGERITE WHITE (see sym.-dileta-NAPHTHYL-p-
PHENYLENEDLAMINE)
1 544M-8 ALDERLIN (see PRONETHALOL)
1 51-02-5 ALDERLIN.HCI (see PRONETHALOL.HCI)
1 116-06-3 ALDICARB
1 309-00-2 ALDRIN
I --- ALKYLBENZENESULFONATE, LINEAR
3 97-59-6 ALLANTOIN
1 107-05-1 ALLYL CHLORIDE
2 57-06-7 ALLYL ISOTHIOCYANATE
3 2835-39-4 ALLYL ISOVALERATE
3 97-53-0 1-ALLYL-3-METHOXY-4-HYDROXYBENZENE (see
EUGENOL)
1 52207-83-7 ALLYLHYDRAZINE.HCI
1 120-78-5 ALTAX (see BENZOTHIAZYL DISULFIDE)
I --- ALUMINUM POTASSIUM SULFATE
1 915-67-3 AMARANTH (see FD & C RED NO. 2)
1 102-77-2 AMAX (se N-OXYDIETHYLENEBENZOTHIAZOLE-2-
SULFENAMIDE)
1 97-56-3 2-AMINO-5-AZOTOLUENE (see o-AMINOAZOTOLUENE)
1 75104-43-7 3-AMINO-1,4-DIMETHYL-5H-PYRIDO(4,3-bIDOLE
ACETATE




1 mixture 3-AMINO-9-ETHYLCARBAZOLE MIXTURE
1 4363-03-5 4-AMINO-3-HYDROXYBIPHENYL (see 3-HYDROXY-4-
AMINOBIPHENYL)










































































































































































PLOT NUMBER CHEMICAL NAME
1 319-84-6 alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-
HEXACHLOROCYCLOHEXANE)
2 369-57-3 BENZENEDIAZONIUM TETRAFLUOROBORATE
1 5351-65-5 BENZENESULPHONOHYDRAZIDE










1 120-78-5 BENZOTHIAZYL DISULFIDE
1 95-14-7 1H-BENZOTRIAZOLE
1 613-94-5 BENZOYL HYDRAZINE
1,2,3 50-32-8 BENZPYRENE (see BENZO(a)PYRENE)
1,2,3 50-32-8 3,4-BENZPYRENE (see BENZO(a)PYRENE)
1,3 1694-09-3 BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)
1 20570-96-1 BENZYLHYDRAZINE.2HCl
1 13510-49-1 BERYLLIUM SULFATE
2,3 25013-16-5 BHA (see BUTYLATED HYDROXYANISOLE)
1,2 128-37-0 BHT (see BUTYLATED HYDROXYTOLUENE)
1 92-52-4 BIPHENYL
2 2185-92-4 2-BIPHENYLAMINE.HCl











1 23746-34-1 BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID,
POTASSIUM





1 21260-46-8 BISMATE (see BISMUTH
DIMETHYLDITHIOCARBAMATE)
1 21260-46-8 BISMUTH DIMETHYLDITHIOCARBAMATE
1 7787-59-9 BISMUTH OXYCHLORIDE
2 80-05-7 BISPHENOL A
1 2519-30-4 BLACK PN
1 1937-37-7 C.I. DIRECT BLACK 38
1 3844-45-9 FD & C BLUE NO. 1
1 860-22-0 FD & C BLUE NO. 2
3 2784-94-3 HC BLUE NO. 1
3 33229-34-4 HC BLUE NO. 2
3 2475-45-8 C.I. DISPERSE BLUE 1
1 2602-46-2 C.I. DIRECT BLUE 6
1 109-84-2 BOH (see 2-HYDROXYETHYLHYDRAZINE)
1 99-30-9 BOTRAN (see 2,6-DICHLORO-4-NITROANILINE)
1 2519-30-4 BRILLIANT BLACK BN (see BLACK PN)
1 3844-45-9 BRILLIANT BLUE FCF (see FD & C BLUE NO. 1)
1,2 5160-02-1 BRILLIANT RED (see D & C RED NO.9)
1,3 7758-01-2 BROMATE, POTASSIUM
1 77-65-6 BROMODIETHYLACETYLUREA (see CARBROMAL)
1 16071-86-6C.I . DIRECT BROWN 95
1 5351-65-5 BSH (see BENZENESULPHONOHYDRAZIDE)
1 55-98-1 BUSULFAN (see MYLERAN)
1 --- BUTACIDE (see PIPERONYL BUTOXIDE IN SOLVENT)
3 106-99-0 1,3-BUTADIENE
2 85-68-7 BUTYL BENZYL PHTHALATE
1,3 3817-11-6 BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-
HYDROXYBUTYL)NITROSAMINE)
3 109-69-3 N-BUTYL CHLORIDE
1 88-85-7 2-sec-BUTYL-4,6-DINITROPHENOL
1 --- N-N-BUTYL-N-FORMYLHYDRAZINE
2,3 25013-16-5 2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED
HYDROXYANISOLE)
CAS
PLOT NUMBER CHEMICAL NAME
1,3 3817-11-6 N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE
1 --- DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL
1 13010-08-7 N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE
3 869-01-2 N-N-BUTYL-N-NITROSOUREA
1 136-23-2 BUTYL ZIMATE (see ZINC
DIBUTYLDITHIOCARBAMATE)
2,3 25013-16-5 BUTYLATED HYDROXYANISOLE






1 75-60-5 CACODYLIC ACID (see DIMETHYLARSINIC ACID)
1 543-90-8 CADMIUM ACETATE
1 35658-65-2 CADMIUM CHLORIDE MONOHYDRATE
1 14239-68-0 CADMIUM DIETHYLDITHIOCARBAMATE
1 7790-84-3 CADMIUM SULPHATE
1,2,3 58-08-2 CAFFEINE
1 8003-03-0 CAFFEINE, ASPIRIN, AND PHENACETIN (see ASPIRIN,
PHENACETIN, AND CAFFEINE)




1 149-30-4 CAPTAX (see 2-MERCAPTOBENZOTHIAZOLE)





1,3 56-23-5 CARBON TETRACHLORIDE
1,3 60391-92-6 CARBOXYMETHYLNITROSOUREA
1 77-65-6 CARBROMAL
1,2 3567-69-9 CARMOISINE (see C.I. FOOD RED 3)
2 9000-40-2 CAROB SEED GUM (see LOCUST BEAN GUM)
1,2 --- CARRAGEENAN, ACID-DEGRADED
1 9000-07-1 CARRAGEENAN, NATIVE
1 999-81-5 CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM
CHLORIDE)
1 122-34-9 CDT (see SIMAZINE)
1 9004-32-4 CELLULOSE CARBOXYMETHYL ETHER, SODIUM
(see EDIFAS B)
1 474-25-9 CHENODEOXYCHOLIC ACID





1 106-47-8 4-CHLORANILIC (see p-CHLOROANILINE)
1,2 57-74-9 CHLORDANE
1 143-50-0 CHLORDECONE (see KEPONE)
1 80-33-1 CHLORFENSON (see p-CHLOROPHENYL-p-
CHLOROBENZENE SULFONATE)
3 63449-39-8 CHLORINATED PARAFFINS (C23, 43% CHLORINE)
3 63449-39-8 CHLORINATED PARAFFINS (C12, 60% CHLORINE)
1 7782-50-5 CHLORINE



















1 107-20-0 CHLOROACETALDEHYDESUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
CAS








1 999-81-5 (2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
3 593-70-4 CHLOROFLUOROMETHANE (see FLUOROCARBON 31)
1 67-66-3 CHLOROFORM
1 107-30-2 CHLOROMETHYL METHYL ETHER
1 6959-47-3 2-(CHLOROMETHYL)PYRIDINE.HCI
1 6959-48-4 3-(CHLOROMETHYL)PYRIDINE.HCI
1 56-75-7 CHLOROMYCETIN (see CHLORAMPHENICOL)
1 100-00-5 p-CHLORONITROBENZENE (see 1-CHLORO-4-
NITROBENZENE)









1 107-05-1 CHLOROPROPENE (see ALLYL CHLORIDE)
1 590-21-6 1-CHLOROPROPENE
1 1897-45-6 CHLOROTHALONIL
3 63449-39-8 CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23,
43% CHLORINE))
3 63449-39-8 CHLOROWAX 500c (see CHLORINATED PARAFFINS
(C12, 60% CHLORINE))
1 54749-90-5 CHLOROZOTOCIN
3 113-92-8 CHLORPHENIRAMINE MALEATE
1 94-20-2 CHLORPROPAMIDE
1 101-21-3 CHLORPROPHAM (see ISOPROPYL-N-(3-
CHLOROPHENYL)CARBAMATE)
1 2921-88-2 CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-TRICHLORO-
2-PYRIDYL)PHOSPHOROTHIOATE)
1 12236-46-3 CHOCOLATE BROWN FB
1 4553-89-3 CHOCOLATE BROWN HT
1 1308-38-9 CHROMIC OXIDE PIGMENT
1 1066-30-4 CHROMIUM (III) ACETATE
2 87-29-6 CINNAMYL ANTHRANILATE






1 43054-45-1 CLOMIPHENE CITRATE
1 1420-04-8 CLONITRALID
1,3 11096-82-5 CLOPHEN A 60 (see AROCLOR 1260)
3 55600-34-5 CLOPHEN A 30
1 107-30-2 CMME (see CHLOROMETHYL METHYL ETHER)
1,3 60391-92-6 CMNU (see CARBOXYMETHYLNITROSOUREA)
1 477-30-5 COLCEMID
3 65765-07-3 COMPOUND 50-892
1 --- CONJUGATED EQUINE ESTROGENS (see PREMARIN)
1 137-29-1 COPPER DIMETHYLDITHIOCARBAMATE
1 10380-28-6 COPPER-8-HYDROXYQUINOLINE
1 56-72-4 COUMAPHOS
1 91-64-5 COUMARIN (see 1,2-BENZOPYRONE)
1 120-71-8 p-CRESIDINE
1 102-50-1 m-CRESIDINE
1 137-29-1 CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
1 135-20-6 CUPFERRON









1 95-33-0 N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE
CAS
PLOT NUMBER CHEMICAL NAME
1 4998-76-9 CYCLOHEXYLAMINE.HCI
1 19834-02-7 CYCLOHEXYLAMINE SULFATE
1,3 50-18-0 CYCLOPHOSPHAMIDE
2 16170-75-5 CYTEMBENA
2 538-41-0 DAAB (see 4,4'-DIAMINOAZOBENZENE)
1 60-11-7 DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
2 785-30-8 DABA (see 4,4'-DIAMINOBENZANILIDE)
1 4342-03-4 DACARBAZINE
1 1897-45-6 DACONIL (see CHLOROTHALONIL)
1 1596-84-5 DAMINOZIDE
1 80-08-0 DAPSONE
1 58-14-0 DARAPRIN (see PYRIMETHAMINE)
1 96-12-8 DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE)
1 488-41-5 DBM (see DIBROMOMANNITOL)
1 91-94-1 DCB (see 3,3'-DICHLOROBENZIDINE)





1 62-73-7 DDVP (see DICHLORVOS)
3 1163-19-5 DECABROMODIPHENYL OXIDE
1 576-68-1 DEGRANOL (see MANNITOL NITROGEN MUSTARD)
1 520-45-6 DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,4-
PYRANDIONE)
1,3 55-18-5 DEN (see N-NITROSODIETHYLAMINE)
1 625-89-8 6-F-DEN (see N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)
AMINE)
1 64039-27-6 beta-2'-DEOXY-6-THIOGUANOSINE MONOHYDRATE
(see beta-THIOGUANINE DEOXYRIBOSIDE)
1 56-53-1 DES (see DIETHYLSTILBESTROL)
1 131-01-1 DESERPIDINE
3 9004-54-0 DEXTRAN
2,3 9011-18-1 DEXTRAN SULFATE SODIUM (DS-M-1)
3 9011-18-1 DEXTRAN SULFATE SODIUM (DST-H)
3 9011-18-1 DEXTRAN SULFATE SODIUM (KMDS-H)
1 --- N-1-DIACETAMIDOFLUORENE
3 3148-73-0 DIACETYL HYDRAZINE
1 2303-16-4 DIALLATE




1 39156-41-7 2,4-DIAMINOANISOLE SULFATE
2 538-41-0 4,4'-DIAMINOAZOBENZENE
2 785-30-8 4,4'-DIAMINOBENZANILIDE
1 7411-49-6 3,3'-DIAMINOBENZIDINE.4HCI (see 3,3',4,4'-
TETRAAMINOBIPHENYL.4HCI)





1 6369-59-1 2,5-DIAMINOTOLUENE SULFATE












3 3296-90-0 DIBROMONEOPENTYL GLYCOL
2 34522-69-5 5,7-DIBROMOQUINOLINE
1 56654-52-5 1,3-DIBUTYL-1-NITROSOUREA
1,3 924-16-3 DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)
1 1067-33-0 DIBUTYLTIN DIACETATE
1 4342-03-4 DIC (see DACARBAZINE)
1 117-80-6 DICHLONE (see 2,3-DICHLORO-1,4-NAPHTHOQUINONE)
1 51-75-2 DICHLOREN (see NITROGEN MUSTARD)
1 8001-50-1 DICHLORICIDE MOTHPROOFER (see STROBANE)























































































DICHLOROMETHANE (see METHYLENE CHLORIDE)
alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID
alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID

























































PLOT NUMBER CHEMICAL NAME
1 60-11-7 N,N-DIMETHYL-4-AMINOAZOBENZENE
1 57-97-6 9,10-DIMETHYL-1,2-BENZANTHRACENE (see 7,12-
DIMETHYLBENZ(a) ANTHRACENE)
1 3851-16-9 N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE
3 868-85-9 DIMETHYL HYDROGEN PHOSPHITE









1 75-60-5 DIMETHYLARSINIC ACID
1 57-97-6 7,12-DIMETHYLBENZ(a)ANTHRACENE
1 79-44-7 DIM[ETHYLCARBAMOYL CHLORIDE (see
DIMETHYLCARBAMYL CHLORIDE)
1 79-44-7 DIMETHYLCARBAMYL CHLORIDE







1,2,3 62-75-9 DIMETHYLNITROSAMINE (see N-
NITROSODIMETHYLAMINE)
1,2,3 62-75-9 N,N-DIMETHYLNITROSAMINE (see N-
NITROSODIMETHYLAMINE)
1 6119-92-2 DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE
1 51-28-6 2,4-DINITROPHENOL






1 123-91-1 p-DIOXANE (see 1,4-DIOXANE)
1 123-91-1 1,4-DIOXANE
1 78-34-2 DIOXATHION
1 1746-01-6 DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)






1 86-30-6 DIPHENYLNITROSAMINE (see N-
NITROSODIPHENYLAMINE)
1 --- N,N-DIPROPYL-4-(4'-[PYRIDYL-l'-OXIDE]AZO)ANILINE
3 621-64-7 DIPROPYLNITROSAMINE (see N-
NITROSODIPROPYLAMINE)
3 68-89-3 DIPYRONE
1 142-59-6 DISODIUM ETHYLENEBISDITHIOCARBAMATE (see
ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
1 7757-82-6 DISODIUM SULFATE (soe SULFATE, SODIUM)
1 97-77-8 DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)




1 330-54-1 DIURON (see 3-(3,4-DICHLOROPHENYL)-1,1-
DIMETHYLUREA)
1 1596-84-5 DMASA (see DAMINOZIDE)
1 57-97-6 DMBA (see 7,12-DIMEIHYLBENZ(a)ANTHRACENE)
3 868-85-9 DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
1,2,3 62-75-9 DMN (seeN-NITROSODIETHYLAMINE)
1 120-61-6 DMT (se DIMErHYL TEREPHTHALATE)
1 2439-10-3 N-DODECYLGUANEDINE ACETATE
1 2439-10-3 DODINE (see n-DODECYLGUANIDINE ACETATE)
1 88-06-2 DOWICIDE,2S (see2,4,6-TRICHLOROPHENOL)
1,3 87-86-5 DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
1,3 90-43-7 DOWICIDE-1 (see o-PHENYLPHENOL)
2,3 9011-18-1 D8-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
a 9011-18-1 DST-H (see DEXTRAN SULFATE SODIUM (DST-H))SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
CAS
PLOT NUMBER CHEMICAL NAME
1 95-33-0 DURAX (see N-CYCLOHEXYL-2-BENZOTHIAZOLE
SULFENAMIDE)
1 106-93-4 EDB (see 1,2-DIBROMOETHANE)
1 107-06-2 EDC (see 1,2-DICHLOROETHANE)
1 9004-32-4 EDIFAS B
1 9004-59-5 EDIFAS A
1 150-38-9 EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
1 150-38-9 EDTA, TRISODIUM SALT TRIHYDRATE
1 316-42-7 EMETINE.2HCl
1 55965-13-4 EMULSIFIER YN
1 115-29-7 ENDOSULFAN































































1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
ERYTHORBATE, SODIUM

























ETHYL SELENAC (see SELENIUM
DIETHYLDITHIOCARBAMATE)
ETHYL TELLURAC
ETHYL TUADS (see TETRAETHYLTHIURAM
DISULFIDE)
ETHYL ZIMATE (see ZINC
DIETHYLDITHIOCARBAMATE)
ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)















ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL [10:1J
(see OVULEN)





FAST GREEN FCF (see FD & C GREEN NO. 3)
CAS




1 14484-64-1 FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)
1 14484-64-1 FERRIC DIMETHYLDITHIOCARBAMATE
1 mixture FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND
TETRAMETHYLTHIURAM DISULFIDE
(see VANGUARD GF)
3 67774-32-7 FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL
MIXTURE)
3 54143-56-5 FLECAINIDE ACETATE
2 2164-17-2 FLUOMETURON
1 363-17-7 N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE
1 28314-03-6 N-1-FLUORENYLACETAMIDE (see 1-
ACETYLAMINOFLUORENE)
1 28322-02-3 N-4-FLUORENYLACETAMIDE (see 4-
ACETYLAMINOFLUORENE)
1,2,3 53-96-3 FLUORENYLACETAMIDE (see 2-
ACETYLAMINOFLUORENE)
1,2,3 53-96-3 N-2-FLUORENYLACETAMIDE (see 2-
ACETYLAMINOFLUORENE)
1 --- N-1-FLUORENYLDIACETAMIDE (see N-1-
DIACETAMIDOFLUORENE)
1,3 7681-49-4 FLUORIDE, SODIUM
1 324-934 4'-FLUORO-4-AMINODIPHENYL
1 398-32-3 N-(4'-FLUORO-4-BIPHENYLYL)ACETAMIDE (see N-4-(4'-
FLUOROBIPHENYL) ACETAMIDE)
1 398-32-3 N-4-(4'-FLUOROBIPHENYL)ACETAMIDE
3 593-70-4 FLUOROCARBON 31
3 75-88-7 FLUOROCARBON 133a
1 51-21-8 5-FLUOROURACIL
1 3570-75-0 FNT (see FORMIC ACID 2-14-(5-NITRO-2-FURYL)-2-
THIAZOLYLIHYDRAZIDE)
1 133-07-3 FOLPET (see N-(TRICHLOROMETHYLTHIO)
PHTHALIMDE)
2,3 50-00-0 FORMALDEHYDE
1 31873-81-1 FORMIC ACID 2-14-(2-FURYL)-2-THIAZOLYLHYDRAZIDE
1 32852-21-4 FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE
1 3570-75-0 FORMIC ACID 2-4-(5-NITRO-2-FURYL)-2-THIAZOLYLj
HYDRAZIDE




3 75-092 FREON 30 (see METHYLENE CHLORIDE)




1 3688-53-7 FURYLFURAMIDE (see AF-2)
3 23255-69-8 FUSARENON-X
2 25812-30-0 GEMFIBROZIL
1 97-16-5 GENITE-R99 (sm 2,4-DICHLOROPHENYLBENZENE
SULFONATE)
1 --- GERMANATE, SODIUM
1 139-40-2 GESAMIL (see PROPAZINE)
1 77-06-5 GIBBERELLIC ACID
3 67730-10-3 GLU-P-2 (soe 2-AMINODIPYRIDOI1,2-a:3',2'-dIIMIDAZOLE)
3 67730-11-4 GLU-P-1 (se 2-AMINO-6-METHYLDIPYRIDC1,2-a:3',2'-dI
IMIDAZOLE)
3 56-86-0 L-GLUTAMIC ACID
2 2757-90-6 beta-N4gamma-L(+)-GLUTAMYLF4-
HYDROXYMETHYLPHENYLHYDRAZINE
1 96-24-2 GLYCEROL alpha-MONOCHLOROHYDRIN
1 765-34-4 GLYCIDALDEHYDE
1 1072-53-3 GLYCOL SULFATE (see ETHYLENE GLYCOL)
1 3741-38-6 GLYCOL SULFITE
1 2353-45-9 FD & C GREEN NO. 3
1 4680-78-8 FD & C GREEN NO. 1
1 5141-20-8 FD & C GREEN NO. 2
1 126-07-8 GRISEOFULVIN
2 9000-30-0 GUAR GUM
1 4680-78-8 GUINEA GREEN B (se FD & C GREEN NO. 1)
2 9000-01-5 GUM ACACIA (ee GUM ARABIC)
2 9000-01-5 GUM ARABIC
1 86-50-0 GUSATHION (se AZINPHOSMETHYL)
1 118-74-1 HCB (see HEXACHLOROBENZENE)
323324 GOLD ETAL.
CAS
PLOT NUMBER CHEMICAL NAME





1 2163-79-3 HERCULES-7531 (see 3-(HEXAHYDRO-4,7-
METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)

























































































































ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
CAS
PLOT NUMBER CHEMICAL NAME











1 122-42-9 ISOPROPYL-N-PHENYL CARBAMATE
2 80-05-7 4,4'-ISOPROPYLIDENEDIPHENOL (see BISPHENOL A)
1 120-58-1 ISOSAFROLE
3 520-18-3 KAEMPFEROL
1 6119-92-2 KARATHANE (see DINITRO(1-METHYLHEPTYL)
PHENYL CROTONATE)
1 330-54-1 KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-
DIMETHYLUREA)
1 115-32-2 KELTHANE (see DICOFOL)
1 143-50-0 KEPONE
3 9011-18-1 KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
1 303-34-4 LASIOCARPINE
1 301-04-2 LEAD ACETATE
1 1335-32-6 LEAD ACETATE, BASIC
1 19010-66-3 LEAD DIMETHYLDITHIOCARBAMATE
1 1335-32-6 LEAD SUBACETATE (see LEAD ACETATE, BASIC)
1 19010-66-3 LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)
1 24365-47-7 LEUPEPTIN
1 5141-20-8 LIGHT GREEN SF YELLOWISH (see FD & C GREEN
NO. 2)
1 58-89-9 LINDANE (see gamma-1,2,3,4,5,6-
HEXACHLOROCYCLOHEXANE)
1 434-13-9 LITHOCHOLIC ACID




1,3 67-20-9 MACRODANTIN (see 1-1(5-NITROFURFURYLIDENE)
AMINOJHYDANTOIN)
1,2 632-99-5 MAGENTA I (see ROSANILINE.HCI)
1,2,3 569-61-9 p-MAGENTA (see p-ROSANILINE.HCl)




1 1634-78-2 MALATHION-O-ANALOG (see MALAOXON)
1,2 123-33-1 MALEIC HYDRAZIDE
2 24382-04-5 MALONALDEHYDE, SODIUM
1 mixture MAM ACETATE AND CYCASIN MIXTURE (see
METHYLAZOXYMETHANOL ACETATE AND
CYCASIN MIXTURE)
1 12427-38-2 MANEB (see MANGANESE
ETHYLENEBISTHIOCARBAMATE)
1 12427-38-2 MANGANESE ETHYLENEBISTHIOCARBAMATE
2 69-65-8 D-MANNITOL
1 576-68-1 MANNITOL NITROGEN MUSTARD







1 155-04-4 2-MERCAPTOBENZOTHIAZOLE, ZINC
3 19767-45-4 2-MERCAPTOETHANESULFONATE, SODIUM
1 50-44-2 6-MERCAPTOPURINE









1 5834-17-3 2-METHOXY-3-AMINODIBENZOFURANSUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
CAS
PLOT NUMBER CHEMICAL NAME
1 5834-17-3 2-METHOXY-3-DIBENZOFURANAMINE (see 2-
METHOXY-3-AMINODIBENZOFURAN)
1 72-43-5 METHOXYCHLOR
1 1701-77-5 METHOXYPHENYLACETIC ACID
3 25843-45-2 Z-METHYL-O,N,N-AZOXYMETHANE (see
AZOXYMETHANE)
1 6294-89-9 METHYL CARBAZATE





1 9004-59-5 METHYL ETHYL CELLULOSE (see EDIFAS A)
1,2 758-17-8 N-METHYL-N-FORMYLHYDRAZINE
2 27323-65-5 METHYL LINOLEATE HYDROPEROXIDE
2 --- METHYL LINOLEATE, NATIVE










1 684-93-5 N-METHYL-N-NITROSOUREA (see N-NITROSO-N-
METHYLUREA)
1 140-56-7 METHYL ORANGE B (see FENAMINOSULF,
FORMULATED)
3 21308-79-2 METHYL 12-OXO-trans-10-OCTADECENOATE
1 298-00-0 METHYL PARATHION
1,3 614-00-6 METHYL-PHENYL-NITROSAMINE (see
NITROSOMETHYLANILINE)
1 144-34-3 METHYL SELENAC (see SELENIUM
DIMETHYLDITHIOCARBAMATE)




1 mixture METHYLAZOXYMETHANOL ACETATE AND CYCASIN
MIXTURE












1 302-15-8 METHYLHYDRAZINE SULFATE
1 115-09-3 METHYLMERCURIC ACETATE (see
MERCURYMETHYLCHLORIDE)











1 90-94-8 MICHLER'S KETONE
1,3 137-30-4 MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
1 2385-85-5 MIREX
1 39801-14-4 MIREX, PHOTO-
1 126-85-2 MITOMEN (see NITROGEN MUSTARD N-OXIDE)
1 50-07-7 MITOMYCIN-C
1 66-27-3 MMS (see METHYL METHANESULFONATE)
1,2,3 70-25-7 MNNG (see N-METHYL-N'-NITRO-N-
NITROSOGUANIDINE)
CAS
PLOT NUMBER CHEMICAL NAME
1 684-93-5 MNU (see N-NITROSO-N-METHYLUREA)
1 101-14-4 MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))
3 1068-57-1 MONOACETYL HYDRAZINE
1 79-11-8 MONOCHLOROACETIC ACID
3 108-90-7 MONOCHLOROBENZENE (see CHLOROBENZENE)
3 315-22-0 MONOCROTALINE
3 142-47-2 L-MONOSODIUM GLUTAMATE
3 32221-81-1 DL-MONOSODIUM GLUTAMATE
1 32607-00-4 MONOSODIUM IMINODIACETIC ACID (see
IMINODIACETIC ACID, MONOSODIUM)






1 87-56-9 MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-
FORMYLACRYLIC ACID)
1 55-98-1 MYLERAN
1 142-59-6 NABAM (see ETHYLENEBISDITHIOCARBAMATE,
DISODIUM)
1 86-86-2 1-NAPHTHALENE ACETAMIDE





1,2 91-59-8 beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
1,2 91-59-8 2-NAPHTHYLAMINE
2 81-16-3 2-NAPHTHYLAMINO,1-SULFONIC ACID
2 81-16-3 NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)
1 2611-82-7 NEW COCCINE (see SX PURPLE)
1 531-82-8 NFTA (see N-14-(5-NITRO-2-FURYL)-2-THIAZOLYL]
ACETAMIDE)
1 7440-02-0 NICKEL
1 373-02-4 NICKEL (II) ACETATE
1 13927-77-0 NICKEL DIBUTYLDITHIOCARBAMATE




2 59-67-6 NICOTINIC ACID
1 553-53-7 NICOTINIC ACID HYDRAZIDE
1 --- NIGROSINE
1 12034-09-2 NIOBATE, SODIUM
1 139-94-6 NITHLAZIDE
1,2 7631-99-4 NITRATE, SODIUM
1 10102-43-9 NITRIC OXIDE
1 139-13-9 NITRILOTRIACETIC ACID
1 18662-53-8 NITRILOTRIACETIC ACID, TRISODIUM SALT,
MONOHYDRATE
1,2,3 7632-00-0 NITRITE, SODIUM
1 1777-84-0 3-NITRO-p-ACETOPHENETIDE
1 99-59-2 5-NITRO-o-ANISIDINE
1 59-87-0 5-NITRO-2-FURALDEHYDE SEMICARBAZONE
1 772-43-0 5-NITRO-2-FURAMIDOXIME


















1 619-17-0 4-NITROANTHRANILIC ACID
1 94-52-0 6-NITROBENZIMIDAZOLE
1 1836-75-5 NITROFEN
325326 GOLD ET AL.
CAS
PLOT NUMBER CHEMICAL NAME





1 51-75-2 NITROGEN MUSTARD













































































1 25081-31-6 NITROSOIMINODIACETIC ACID
3 86451-37-8 N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE









1 684-93-5 NITROSOMETHYLUREA (seeN-NITROSO-N-
METHYLUREA)




1 4615-18-8 NIROSOPIPECOLIC ACID
1 5632-47-3 NITROSOPIPERAZINE (seeN-NITROSOPIPERAZINE)
1 5632-47-3 N-NITR(OPIPERAZINE
1 5632-47-3 1-NITROSOPIPEILAZINE (see N-NITROSOPIPERAZINE)
1,3 100-75-4 N-NITROSOPIPERIDINE
1 7519-36-0 NITROSOPROINE




1 mixture beta-NITROSTYRENE AND STYRRNE MIXTURE (see
STYRENE AND beta-NITROSTYRENE MIXTURE)
1 68-23-5 NORETHYNDREL
1 --- NORETHYNODREL/MESTRANOL 125:11 (see ENOVID-E)




1 303-47-9 OCHEATOXIN A
1 50-28-2 l7beta-OESTRADIOL (see ESTRADIOL)
1,3 90-43-7 ORTHOXENOL (see o-PHENYLPHENOL)








1,3 103-90-2 PARACETAMOL (see ACETAMINOPHEN)
1 56-38-2 PARATHION
1 92-69-3 PARAXENOL (seep-PHENYLPHENOL)
1 149-29-1 PATULIN
1 27323-18-8 PCB (see AROCLOR 1254)
1,3 11096-82-5 PCB (see AROCLOR 1260)
1 82-68-8 PCNB (see PENTACHLORONITROBENZENE)




3 76-01-7 PENTALIN (see PENTACHLOROETHANE)
1 13010-10-1 N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE
1 1119-68-2 n-PENTYLHYDRAZINE.HCI
1 8006-904 PEPPERMINT OIL
1,3 127-18-4 PERCHLOROETHYLENE (see
TETRACHLOROETHYLENE)
1 72-56-0 PEKRHANE (se p,p'-ETHYL-DDD)
1 60102-374 PETASTENINE
1.2,3 62-44-2 PHENACETIN












































































































































PHOTODIELDRIN (ee DIELDRIN, PHOTO-)
PHOTOMIREX (am MIREX, PHOTO-)
PHTHALAMIDE
PHTHALIC ANHYDRIDE










PIPERONYL BUTOXIDE IN SOLVENT
PIPRNYL SULFOXIDE
PIVALOLACTONE




PONCEAU SX (see FD & C RED NO. 4)
PONCEAU MX (see D & C RED NO. 6)
PONCEAU 3R (see FD & C RED NO. 1)
PONCEAU 4R (see SX PURPLE)
POTASSIUM BROMATE (see BROMATE., POTASSIUM)




































































































































































D & C RED NO. 10
FD & C RED NO. 3
FD & C RED NO. 1
FD & C RED NO. 4
FD & C RED NO. 2
D& C RED NO.9
D & C RED NO. 5
HC RED NO. 3
C.I. FOOD RED 3

















SANAMYCIN (see ACTINOMYCIN C)
L-SARCOLYSIN (see MELPHALAN)









SODIUM ARSENM (see ARSENITE, SODIUM)
SODIUM AZIDE (see AZIDE, SODIUM)
SODIUM BENZOATE (ee BENZOATE, SODIUM)
SODIUM BITHIONOLATE
SODIUM CYCLAMATE (see CYCLAMATE, SODIUM)
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE
SODIUM FLUORIDE (see FLUORIDE, SODIUM)
SODIUM NIOBATE (see NIOBATE, SODIUM)
SODIUM NITRATE (see NITRATE, SODIUM)
SODIUM SULFATE. (see SULFATE, SODIUM)
SODIUM TETRAFLUOROBORATE (see
TETRAFLUOROBORATE, SODIUM)






































































































SQ 18506 (see trans-5-AMINO-312-(5-NITRO-2-FURYL)
VINYL-1,2,4-OXADIAZOLE)
STANNOUS CHLORIDE (see TIN (II) CHLORIDE)
STARCH ACETATE
STERIGMATOCYSTIN





STYRENE AND beta-NITROSTYRENE MIXTURE
STYRENE OXIDE






























































THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
TILLAM-6-E (see PROPYL N-ETHYL-N-
BUTYLTHIOCARBAMATE)
CAS
PLOT NUMBER CHEMICAL NAME
1,2 7772-99-8 TIN (II) CHLORIDE
1 13463-67-7 TITANIUM DIOXIDE
1 --- TITANIUM OXALATE, POTASSIUM
1,3 137-26-8 TMTD (see TETRAMETHYLTHIURAM DISULFIDE)




1 636-23-7 2,4-TOLUENEDIAMINE.2HCl (see 2,4-
DIAMINOTOLUENE.2HC1)
2 15481-70-6 2,6-TOLUENEDIAMINE.2HCI (see 2,6-
DIAMINOTOLUENE.2HC1)

















1 93-72-1 2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
1 93-76-5 2,4,5-TRICHLOROPHENOXYACETIC ACID
1 102-71-6 TRIETHANOLAMINE










1 900-95-8 TRIPHENYLTIN ACETATE
1 76-87-9 TRIPHENYLTIN HYDROXIDE




1 150-38-9 TRISODIUM ETHYLENEDIAMINETETRAACETATE
TRIHYDRATE (see EDTA, TRISODIUM SALT
TRIHYDRATE)
1 72254-58-1 TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-
PYRIDOj4,3-bJINDOLE ACETATE)




1 83-79-4 TUBATOXIN (see ROTENONE)
1 13472-45-2 TUNGSTATE, SODIUM
1,3 103-90-2 TYLENOL (see ACETAMINOPHEN)
1 97-74-5 UNADS (see TETRAMETHYLTHIURAM MONOSULFIDE)
1 57-13-6 UREA
1 51-79-6 URETHANE
1 27774-13-6 VANADYL SULFATE
1 6379-46-0 VANCIDE PB (see 1,2,3-TRICHLORO-4,6-
DINITROBENZENE)
1 6385-58-6 VANCIDE BN (see SODIUM BITHIONOLATE)
1 97-18-7 VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
1 13927-77-0 VANGAURD N (see NICKEL
DIBUTYLDITHIOCARBAMATE)
1 mixture VANGUARD GF
1 62-73-7 VAPONA (see DICHLORVOS)
1 865-21-4 VINBLASTINE
3 108-05-4 VINYL ACETATE
1 593-60-2 VINYL BROMIDE
1,2,3 75-01-4 VINYL CHLORIDE
1,2,3 75-35-4 VINYLIDENE CHLORIDESUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
CAS
PLOT NUMBER CHEMICAL NAME
1,3 1694-09-3 FD & C VIOLET NO. 1
1 50-14-6 VITAMIN D2
3 59-02-9 VITAMIN E (see DL-alpha-TOCOPHERYL ACETATE)
3 50-81-7 VITAMIN C (see L-ASCORBIC ACID)
1 302-79-4 VITAMIN A ACID
1 21436-96-4 2,4-XYLIDINE.HCI
1 51786-53-9 2,5-XYLIDINE.HC1
1 1934-21-0 FD & C YELLOW NO. 5
1 6358-85-6 DIARYLANILIDE YELLOW (see C.I. PIGMENT
YELLOW 12)
1,2 2783-94-0 FD & C YELLOW NO. 6
2 2832-40-8 C.I. DISPERSE YELLOW 3
1 128-66-5 C.I. VAT YELLOW 4
1 6358-85-6 C.I. PIGMENT YELLOW 12
1,2 842-07-9 C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-
NAPHTHOL)
1 5979-28-2 C.I. PIGMENT YELLOW 16
1 5567-15-7 C.I. PIGMENT YELLOW 83
2 17924-92-4 ZEARALENONE
1 315-18-4 ZECTRAN (see MEXACARBATE)
1 155-04-4 ZETAX (see 2-MERCAPTOBENZOTHIAZOLE, ZINC)
1 136-23-2 ZINC DIBUTYLDITHIOCARBAMATE
1 14324-55-1 ZINC DIETHYLDITHIOCARBAMATE
1,3 137-30-4 ZINC DIMETHYLDITHIOCARBAMATE
1 12122-67-7 ZINC ETHYLENEBISTHIOCARBAMATE
1 12122-67-7 ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
1,3 137-30-4 ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
1 14644-61-2 ZIRCONIUM (IV) SULFATE
CAS NUMBER = Chemical Abstracts Service registry number
PLOT 1 = Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., de
Veciana, M., Levinson, R., Hooper, N.K., Havender, W.R., Bernstein, L.,
Peto,, R., Pike, M., and Ames, B.N. A carcinogenic potency database of the
standardized results of animal bioassays. Env. Hlth. Pers. 58: 9-319 (1984).
PLOT 2 = Gold, L., de Veciana, M., Backman, G., Magaw, R., Lopi-
pero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames,
B.N. Chronological supplement to the carcinogenic potency database: stand-
ardized results of animal bioassays published through December 1982. Env.
Hlth. Pers. 67: 161-200 (1986).
PLOT 3 = This publication
329